Unnamed: 0,title,date,stock,sentiment
161523.0,Biogen Reports New Results From NURTURE Study Of SPINRAZA,2020-06-10 07:32:00-04:00,BIIB,positive
161524.0,"Benzinga's Top Upgrades, Downgrades For June 9, 2020",2020-06-09 09:45:00-04:00,BIIB,positive
161525.0,Biogen shares are trading lower after Bernstein downgraded the stock from Outperform to Market Perform and lowered the price target from $360 to $297 per share.,2020-06-09 08:18:00-04:00,BIIB,positive
161526.0,"Bernstein Downgrades Biogen to Market Perform, Lowers Price Target to $297",2020-06-09 08:01:00-04:00,BIIB,negative
161527.0,4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize,2020-06-08 18:26:00-04:00,BIIB,neutral
161528.0,Biogen To Present Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 Jun. 3-6,2020-06-04 07:34:00-04:00,BIIB,neutral
161529.0,Vir Biotechnology And Biogen Execute Agreement To Manufacture SARS-CoV-2 Antibodies For Potential COVID-19 Coronavirus Treatment,2020-05-29 08:27:00-04:00,BIIB,positive
161530.0,Biogen shares are trading higher after the company published data showing that its SPINRAZA demonstrated sustained efficacy and longer-term safety.,2020-05-18 08:44:00-04:00,BIIB,positive
161531.0,Biogen Publishes Data Showing its SPINRAZA Demonstrated Sustained Efficacy and Longer Term Safety,2020-05-18 07:33:00-04:00,BIIB,positive
161532.0,13F From Buffett's Berkshire Shows Cut Stake In Biogen By ~5.4K Shares,2020-05-15 16:27:00-04:00,BIIB,neutral
161533.0,Biogen shares are trading higher. Not currently seeing company-specific news.,2020-05-11 12:41:00-04:00,BIIB,positive
161534.0,"Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.",2020-05-07 11:25:00-04:00,BIIB,positive
161535.0,"Cantor Fitzgerald Reiterates Neutral on Biogen, Lowers Price Target to $308",2020-05-01 09:59:00-04:00,BIIB,negative
161536.0,Biogen Prices $3B In Senior Unsecured Notes,2020-04-27 16:06:00-04:00,BIIB,negative
161537.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,BIIB,negative
161538.0,"Canaccord Genuity Maintains Buy on Biogen, Lowers Price Target to $350",2020-04-24 11:07:00-04:00,BIIB,negative
161539.0,Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay,2020-04-23 15:49:00-04:00,BIIB,negative
161540.0,"SunTrust Robinson Humphrey Maintains Buy on Biogen, Lowers Price Target to $330",2020-04-23 10:45:00-04:00,BIIB,negative
161541.0,"Morgan Stanley Maintains Underweight on Biogen, Lowers Price Target to $301",2020-04-23 09:37:00-04:00,BIIB,negative
161542.0,10 Biggest Price Target Changes For Thursday,2020-04-23 08:29:00-04:00,BIIB,neutral
161543.0,"Credit Suisse Maintains Neutral on Biogen, Lowers Price Target to $310",2020-04-23 08:20:00-04:00,BIIB,positive
161544.0,"Oppenheimer Maintains Outperform on Biogen, Lowers Price Target to $365",2020-04-23 08:04:00-04:00,BIIB,negative
161545.0,"Barclays Maintains Overweight on Biogen, Lowers Price Target to $370",2020-04-23 07:20:00-04:00,BIIB,negative
161546.0,"A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings, Economic Reports",2020-04-23 06:10:00-04:00,BIIB,neutral
161547.0,Citigroup Downgrades Biogen to Sell,2020-04-23 05:31:00-04:00,BIIB,neutral
161548.0,Raymond James Downgrades Biogen to Underperform,2020-04-23 05:28:00-04:00,BIIB,neutral
161549.0,70 Biggest Movers From Yesterday,2020-04-23 04:12:00-04:00,BIIB,neutral
161550.0,Hearing Raymond James Downgrades Biogen To Underperform,2020-04-22 16:26:00-04:00,BIIB,neutral
161551.0,"Jefferies Issues Mid-Day Note On Biogen, Notes 'Partner Biogen's 1Q Spinraza Sales Slightly Higher on Inventory & Ex-US Growth,' Says Remains Cautious On Ionis Pharma",2020-04-22 12:32:00-04:00,BIIB,negative
161552.0,46 Stocks Moving In Wednesday's Mid-Day Session,2020-04-22 12:13:00-04:00,BIIB,neutral
161553.0,Biogen Shares Unaffected; Traders Circulate Word Evercore Analyst Remains Positive On Stock After Speaking To Mgmt. Following Wed. Earnings Call,2020-04-22 10:42:00-04:00,BIIB,positive
161554.0,Morning Market Stats in 5 Minutes,2020-04-22 10:40:00-04:00,BIIB,neutral
161555.0,"Biogen Delays Regulatory Filing For Approval Of Alzheimer's Drug, Shares Slump",2020-04-22 10:23:00-04:00,BIIB,positive
161556.0,Recap: Biogen Q1 Earnings,2020-04-22 09:26:00-04:00,BIIB,neutral
161557.0,Biogen shares are trading lower despite better-than-expected Q1 earnings results.,2020-04-22 08:54:00-04:00,BIIB,neutral
161558.0,From Biogen Earnings Conference Call: CEO Says Had Initial Discussion With Regulators Outside US About Its Alzheimer's Drug Aducanumab,2020-04-22 08:14:00-04:00,BIIB,neutral
161559.0,"The Daily Biotech Pulse: Immunic To Develop COVID Treatment, Gilead Strikes IO Partnership",2020-04-22 07:51:00-04:00,BIIB,negative
161560.0,17 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-04-22 07:38:00-04:00,BIIB,neutral
161561.0,"Biogen Q1 Adj. EPS $9.140 Beats $7.740 Estimate, Sales $3.500B Beat $3.410B Estimate",2020-04-22 07:03:00-04:00,BIIB,neutral
161562.0,"Earnings Scheduled For April 22, 2020",2020-04-22 04:07:00-04:00,BIIB,neutral
161563.0,"The Week Ahead In Biotech (April 19-25): Eli Lilly, Biogen Earnings On Tap, Sanofi Awaits FDA Decision",2020-04-19 17:22:00-04:00,BIIB,positive
161564.0,Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.,2020-04-16 12:38:00-04:00,BIIB,positive
161565.0,"Biogen, Broad Institute Of MIT And Harvard, Partners HealthCare Launch Consortium To Build And Share A COVID-19 Biobank",2020-04-16 07:36:00-04:00,BIIB,positive
161566.0,Every Member Of Trump's 'Great American Economic Revival' Industry Groups,2020-04-15 13:09:00-04:00,BIIB,positive
161567.0,Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic.,2020-04-14 10:59:00-04:00,BIIB,positive
161568.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,BIIB,positive
161570.0,Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.,2020-04-06 09:42:00-04:00,BIIB,positive
161571.0,Shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the US weigh on equities.,2020-04-01 09:20:00-04:00,BIIB,negative
161572.0,Shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus. NOTE: The sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak.,2020-03-30 10:17:00-04:00,BIIB,positive
161573.0,Veeva Systems' CRM Product Is Seeing Ten Times More Usage During Coronavirus Pandemic,2020-03-27 02:59:00-04:00,BIIB,neutral
161574.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,BIIB,positive
161575.0,Vir Biotechnology Says Proceeding With Two Clinical Development Candidates For Coronavirus,2020-03-25 08:08:00-04:00,BIIB,neutral
161576.0,12 Key Medical Meetings Canceled Or Postponed In The Face Of A Pandemic,2020-03-19 10:51:00-04:00,BIIB,negative
161577.0,40 Stocks Moving in Thursday's Pre-Market Session,2020-03-19 07:37:00-04:00,BIIB,neutral
161578.0,Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 09:40:00-04:00,BIIB,negative
161579.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,BIIB,neutral
161580.0,Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.,2020-03-13 09:29:00-04:00,BIIB,positive
161581.0,Shares of several healthcare companies are trading lower as equities sell off amid continued global coronavirus concerns. The virus has caused global economic disruption and negatively impacted stocks across sectors.,2020-03-12 09:26:00-04:00,BIIB,negative
161582.0,Vir Biotechnology Announces It Signed A Letter Of Intent To Collaborate With Biogen To Manufacturing Antibodies To Potentially Treat COVID-19,2020-03-12 08:14:00-04:00,BIIB,positive
161583.0,"Biogen Says, Following Co. Meeting With Employees In Boston Last Week, A Number Of Attendees Have Tested Positive For Coronavirus; Co. Has Directed Boston Meeting Attendees To Work From Home For 2 Weeks",2020-03-06 09:49:00-05:00,BIIB,positive
161584.0,Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.,2020-03-04 07:16:00-05:00,BIIB,positive
161585.0,Shares of several healthcare companies are trading lower in sympathy with the overall market. The Fed cut rates to combat the coronavirus outbreak which caused an initial spike but then continued to trade lower.,2020-03-03 11:55:00-05:00,BIIB,negative
161586.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,BIIB,positive
161587.0,Shares of several healthcare companies are trading higher in sympathy with the overall market as it rebounds from a selloff caused by coronavirus fears.,2020-03-02 11:18:00-05:00,BIIB,positive
161588.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,BIIB,negative
161589.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,BIIB,neutral
161590.0,"Biogen And Sangamo Announce Global Collaboration To Develop Gene Regulation Therapies for Alzheimer's, Parkinson's, Neuromuscular And Other Neurological Diseases; Biogen To Pay Sangamo $350M Upfront, Sangamo Eligible For Up To $2.37B In Milestones",2020-02-27 16:10:00-05:00,BIIB,negative
161591.0,"Benzinga's Top Upgrades, Downgrades For February 27, 2020",2020-02-27 09:37:00-05:00,BIIB,positive
161592.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,BIIB,negative
161593.0,"Barclays Initiates Coverage On Biogen with Overweight Rating, Announces $389 Price Target",2020-02-27 08:00:00-05:00,BIIB,negative
161594.0,"Mizuho Maintains Neutral on Biogen, Raises Price Target to $316",2020-02-25 07:50:00-05:00,BIIB,neutral
161595.0,"Q4 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",2020-02-18 13:00:00-05:00,BIIB,neutral
161596.0,Biogen shares are trading higher after Berkshire Hathaway's 13F filing showed that it paid $192.5 million for roughly a 0.4% stake in the company.,2020-02-18 08:47:00-05:00,BIIB,positive
161597.0,35 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-02-18 08:25:00-05:00,BIIB,neutral
161598.0,"Warren Buffett's Berkshire Hathaway Trims Apple Stake, Buys Into Kroger, Biogen",2020-02-18 06:13:00-05:00,BIIB,neutral
161599.0,"Berkshire Hathaway 13F Shows 648,447 Share Stake In Biogen",2020-02-14 16:24:00-05:00,BIIB,positive
161600.0,Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint,2020-02-10 12:22:00-05:00,BIIB,negative
161601.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-10 07:30:00-05:00,BIIB,neutral
161602.0,"Nomura Maintains Buy on Biogen, Raises Price Target to $392",2020-02-07 07:44:00-05:00,BIIB,neutral
161603.0,Biogen shares are trading higher after the company won a patent decision against Mylan. Biogen will keep exclusive rights to its multiple sclerosis drug Tecfidera until 2028.,2020-02-06 10:46:00-05:00,BIIB,positive
161604.0,"Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $302",2020-02-06 10:02:00-05:00,BIIB,neutral
161605.0,"Twitter Up, Tesla Down: Strong User Numbers Help TWTR, But TSLA Selling Continues",2020-02-06 09:36:00-05:00,BIIB,positive
161606.0,"SVB Leerink Maintains Outperform on Biogen, Raises Price Target to $410",2020-02-06 09:06:00-05:00,BIIB,neutral
161607.0,"Baird Maintains Underperform on Biogen, Raises Price Target to $290",2020-02-06 09:05:00-05:00,BIIB,neutral
161608.0,"Credit Suisse Maintains Neutral on Biogen, Raises Price Target to $330",2020-02-06 08:53:00-05:00,BIIB,positive
161609.0,10 Biggest Price Target Changes For Thursday,2020-02-06 08:42:00-05:00,BIIB,neutral
161610.0,"Wells Fargo Maintains Equal-Weight on Biogen, Raises Price Target to $311",2020-02-06 07:54:00-05:00,BIIB,positive
161611.0,"The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs",2020-02-06 07:47:00-05:00,BIIB,negative
161612.0,"Cantor Fitzgerald Reiterates Neutral on Biogen, Raises Price Target to $361",2020-02-06 07:38:00-05:00,BIIB,neutral
161613.0,90 Biggest Movers From Yesterday,2020-02-06 05:15:00-05:00,BIIB,neutral
161614.0,Hearing Mizuho Says Tecfidera Win Is Worth $15-$30/Share To DCF,2020-02-05 14:43:00-05:00,BIIB,positive
161615.0,"Hearing Guggenheim Out On Biogen Saying With IPR Overhang Removed, ' Aducanumab Becomes The Key Focus Key Message'",2020-02-05 14:34:00-05:00,BIIB,neutral
161616.0,Biogen Rallies On Tecfidera Patent Decision,2020-02-05 14:18:00-05:00,BIIB,neutral
161617.0,"Mylan Says Strongly Disagrees With Decision By US PTAB Upholding Biogen's Patent Covering Tecfidera, Plans To Pursue All Available Options For Appeal",2020-02-05 14:16:00-05:00,BIIB,negative
161618.0,Hearing Goldman Sachs On Biogen Decision Says ' In our view today's decision removes a downside scenario for Tecfidera IP and we expect shares to react favorably' But Notes Ongoing Cases With Expected 2020 Decisions,2020-02-05 14:11:00-05:00,BIIB,positive
161619.0,UPDATE: USPTO's Final Written Decision Doc For Mylan v Biogen,2020-02-05 13:41:00-05:00,BIIB,neutral
161620.0,Biogen shares trading higher following a report of a patent trial challenge by Mylan on '514 Tecfidera. The report suggests the company's patent claims remain valid.,2020-02-05 13:29:00-05:00,BIIB,positive
161621.0,"Biogen Shares Resume Trade, Up 12% For Session",2020-02-05 13:29:00-05:00,BIIB,positive
161622.0,Biogen Shares Expected To Resume Trade At 1:28:36 EST,2020-02-05 13:27:00-05:00,BIIB,positive
161623.0,"Biogen Shares Halted On A Circuit Breaker, Stock Up 11%",2020-02-05 13:26:00-05:00,BIIB,positive
161624.0,'Biogen wins IPR patent trial on '514 Tecfidera patent as patent claims challenged by Mylan remain valid.',2020-02-05 13:23:00-05:00,BIIB,positive
161625.0,Shares of healthcare companies are trading higher amid a rebound in global equities following last week's selloff on coronavirus fears.,2020-02-04 10:08:00-05:00,BIIB,negative
161626.0,10 Biggest Price Target Changes For Monday,2020-02-03 08:23:00-05:00,BIIB,neutral
161627.0,"SunTrust Robinson Humphrey Maintains Buy on Biogen, Raises Price Target to $360",2020-02-03 07:33:00-05:00,BIIB,neutral
161628.0,Biogen shares are trading lower after Morgan Stanley analysts maintained an underweight rating on the stock and lowered the price target from $270 to $261.,2020-01-31 11:37:00-05:00,BIIB,negative
161629.0,"Morgan Stanley Maintains Underweight on Biogen, Lowers Price Target to $261",2020-01-31 10:48:00-05:00,BIIB,negative
161630.0,"The Daily Biotech Pulse: Sanofi Reports Positive Readout, Tonix Vaccine Candidate Aces Animal Study, Hologix's Weak Guidance",2020-01-30 09:26:00-05:00,BIIB,positive
161631.0,Biogen shares are trading higher after the company reported better-than-expected Q4 EPS and sales results. UPDATE: Shares are trading slightly lower as of 9:52 a.m.,2020-01-30 08:51:00-05:00,BIIB,positive
161632.0,Biogen Reports Q4 Earnings Beat,2020-01-30 07:14:00-05:00,BIIB,neutral
161633.0,"Biogen Q4 Adj. EPS $8.34 Beats $7.92 Estimate, Sales $3.67B Beat $3.52B Estimate; Sees FY20 Adj. EPS $31.50-$33.50, Sales $14B-$14.3B",2020-01-30 06:55:00-05:00,BIIB,neutral
161634.0,"Earnings Scheduled For January 30, 2020",2020-01-30 04:59:00-05:00,BIIB,neutral
161635.0,"Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says",2020-01-27 11:18:00-05:00,BIIB,positive
161636.0,"Canaccord Genuity Upgrades Biogen to Buy, Announces $360 Price Target",2020-01-27 06:00:00-05:00,BIIB,neutral
161637.0,"The Week Ahead In Biotech: Amgen, Eli Lilly, Pfizer In Earnings Mix, IPO Flow Resumes",2020-01-26 10:23:00-05:00,BIIB,neutral
161638.0,9 Takeaways From The JPMorgan Healthcare Conference,2020-01-17 14:47:00-05:00,BIIB,neutral
161639.0,"Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $270",2020-01-17 08:20:00-05:00,BIIB,neutral
161640.0,"Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB",2020-01-13 08:46:00-05:00,BIIB,positive
161641.0,"Biogen To Acquire PF-05251749, A Novel Clinical Stage Asset With Application in Alzheimer's And Parkinson's From Pfizer; Pfizer To Receive $75M Upfront And Up To $635M In Milestones",2020-01-13 07:32:00-05:00,BIIB,positive
161642.0,"'California Gov. Gavin Newsom wants the state to become the first to create its own generic drug label, an attempt to create more competition and bring down prices.' -Axios, From Earlier",2020-01-10 12:55:00-05:00,BIIB,positive
161643.0,"A Preview Of JPMorgan's Healthcare Conference: Focus On Value-Creating Themes, 2020 Expectations",2020-01-10 08:52:00-05:00,BIIB,neutral
161644.0,"CAMP4 Therapeutics Reports Collaboration With Biogen For Addressing Neurodegenerative, Neurological Disease; Co. To Receive $15M Upfront Payment, Development, Milestone Payments Of Up To $96M Plus Future Royalties For Up To $173M",2020-01-10 07:03:00-05:00,BIIB,neutral
161645.0,Banner Life Sciences Receives Favorable Ruling Against Biogen in Patent Infringement Challenge,2020-01-09 12:24:00-05:00,BIIB,positive
161646.0,Drugmakers Kick Off 2020 With Margin-Expanding Price Hikes,2020-01-02 10:41:00-05:00,BIIB,neutral
161647.0,"Bristol-Myers Squibb, Gilead Sciences, Biogen Raised U.S. List Prices on 50+ Drugs on Wednesday an Average of 5%",2020-01-01 11:58:00-05:00,BIIB,neutral
161648.0,"Barron's Picks And Pans: Alibaba, Biogen, China Mobile, Peter Lynch Picks And More",2019-12-21 11:24:00-05:00,BIIB,neutral
161649.0,Biogen 8-K Shows $5B Buyback,2019-12-19 16:18:00-05:00,BIIB,neutral
161650.0,"Benzinga Pro's Top 5 Stocks To Watch For Thurs., Dec. 19, 2019: NKE, TIVO, CBIO, APOG, RAD",2019-12-19 08:42:00-05:00,BIIB,positive
161651.0,"UPDATE: Catalyst To Receive $15M Upfront Payment, Is Eligible For Up To $340M In Milestone Payments Plus Tiered Royalties Based On Net Sales",2019-12-19 08:09:00-05:00,BIIB,neutral
161652.0,"Catalyst Biosciences Reports Global License, Collab Deal With Biogen To Develop Pegylated CB 2782 For Treatment Of Dry Age-Related Macular Degeneration",2019-12-19 08:08:00-05:00,BIIB,neutral
161653.0,"Ionis Pharma Reports License Of IONIS-MAPT Therapy; Earned $45M License Fee From Biogen, Is Eligible To Earn Up To $155M In Added Milestone Payments",2019-12-19 07:09:00-05:00,BIIB,neutral
161654.0,Biogen Reports Topline Results From Phase 2 Study Of Progressive Supranuclear Palsy: Primary Endpoint Was Not Met,2019-12-13 07:31:00-05:00,BIIB,neutral
161655.0,"Credit Suisse Upgrades Biogen to Neutral, Raises Price Target to $300",2019-12-13 06:43:00-05:00,BIIB,positive
161656.0,"Bulls And Bears Of The Week: Facebook, Intel, Netflix, Tesla And More",2019-12-08 09:27:00-05:00,BIIB,neutral
161657.0,Biogen Analysts Divided Over Alzheimer's Drug Following CTAD Presentation,2019-12-06 09:55:00-05:00,BIIB,neutral
161658.0,Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response,2019-12-05 14:01:00-05:00,BIIB,neutral
161659.0,Biogen shares are trading higher after the company presented data for its Aducanumab.,2019-12-05 12:15:00-05:00,BIIB,positive
161660.0,"Morgan Stanley Concludes By Saying 'From a stock prospective, we see the final point as incrementally negative but ultimately do not expect much movement in BIIB today'",2019-12-05 12:10:00-05:00,BIIB,negative
161661.0,"Morgan Stanley Says 'The effect size of the drug is small. In EMERGE, the change in CDR-SB was 0.40 well below what has been noted as a clinically meaningful effect of 1'",2019-12-05 12:10:00-05:00,BIIB,positive
161662.0,Morgan Stanley On Biogen Alzheimer's Presentation Says 'The cumulative data presented today is not significantly different from the data previously presented.' And Notes 'there were no significant baseline imbalances which could have influenced results',2019-12-05 12:09:00-05:00,BIIB,negative
161663.0,"Boston Business Journal Biotech Reporter Allison DeAngelis, On Results From Biogen Alzheimer's Trials, Tweets, 'the drug appears to make a difference in amyloid plaque levels, but shows marginal effect in cognition, memory, etc'",2019-12-05 11:54:00-05:00,BIIB,neutral
161664.0,"Panel From Alzheimer's Conference, Stephen Salloway, Says Sees Data From Biogen's EMERGE Trial On Alzheimer's Treatment Was 'Positive'",2019-12-05 11:51:00-05:00,BIIB,neutral
161665.0,"Biogen Shares Now Positive For Session, Have Rebounded 7% From Low",2019-12-05 11:49:00-05:00,BIIB,positive
161666.0,UPDATE: Biogen Shares Now Down ~4% For Session,2019-12-05 11:36:00-05:00,BIIB,positive
161667.0,"Biogen Shares Resume Trade, Move Lower, Now Down ~1.6%",2019-12-05 11:35:00-05:00,BIIB,neutral
161668.0,"From Biogen Call On Aducanumab: EMERGE Trial Showed Low-Dose Treatment With 50.5% Completion, High-Dose Treatment With 52.1% Completion, Placebo Showed 50.2%",2019-12-05 11:22:00-05:00,BIIB,neutral
161669.0,Mike Khouw Highlights Unusual Options Activity In Biogen,2019-12-05 11:18:00-05:00,BIIB,neutral
161670.0,Biogen Shares To Resume Trade At 11:35 a.m. EST,2019-12-05 11:18:00-05:00,BIIB,positive
161671.0,"From Biogen Call On Aducanumab: Futility Data Set Showed EMERGE Trial By Mar. 20, 2019 Of 49% Opportunity To Complete, ENGAGE Trial 66%; ENGAGE Futility Data Did Not Reduce Clinical Decline",2019-12-05 11:18:00-05:00,BIIB,positive
161672.0,"From Biogen Call On Aducanumab: High-Dose Regimen Showed 29% Of Patients In EMERGE, 22% Of Patients In ENGAGE Received Full Possible 14 Doses Of 10mg/kg Doses",2019-12-05 11:14:00-05:00,BIIB,positive
161673.0,Biogen Shares Halted Ahead Of Scheduled 11 a.m. EST Release/Conference Call For Phase 3 Topline Results Of Aducanumab,2019-12-05 10:59:00-05:00,BIIB,positive
161674.0,"Biogen Shares Halted, News Pending",2019-12-05 10:56:00-05:00,BIIB,positive
161675.0,"The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission",2019-12-05 07:14:00-05:00,BIIB,positive
161676.0,"Cramer Weighs In On Biogen, Caterpillar And More",2019-12-03 11:22:00-05:00,BIIB,neutral
161677.0,Biogen Announces Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE); Study Met Primary Endpoint,2019-12-03 07:33:00-05:00,BIIB,neutral
161678.0,"Biogen's Alzheimer's Drug 'Falls Far Short Of Compelling Argument For Approval,' Baird Says In Downgrade",2019-12-02 13:55:00-05:00,BIIB,negative
161679.0,"Benzinga's Top Upgrades, Downgrades For December 2, 2019",2019-12-02 09:53:00-05:00,BIIB,positive
161680.0,10 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-02 07:24:00-05:00,BIIB,neutral
161681.0,Biogen shares are trading lower after the company's stock was downgraded from Neutral to Underperform by analysts at Baird.,2019-12-02 06:45:00-05:00,BIIB,neutral
161682.0,"Baird Downgrades Biogen to Underperform, Announces $250 Price Target",2019-12-02 06:39:00-05:00,BIIB,neutral
161683.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,BIIB,neutral
161684.0,"Morgan Stanley On Biogen Notes 'We see BIIB up 5-10% on clean sub-group analysis, flat to down 5-10% on incrementally mixed data, and down 10%+ on marginal supportive evidence'",2019-11-27 10:57:00-05:00,BIIB,positive
161685.0,"Morgan Stanley Maintains Underweight, $262 Target On Biogen Notes 'We expect additional EMERGE/ENGAGE PhIII data at CTAD on December 5 with an 85% probability BIIB is pressured on the data'",2019-11-27 10:56:00-05:00,BIIB,negative
161686.0,"RBC Out Positive On Biogen Hearing Developments, Noting One Of The Judges Is Being Replaced Due To Unavailability; Says Views This As Positive, As This Judge 'eemed most vocal around the potential obviousness of the 480mg dose in BIIB's '514 patent'",2019-11-26 10:02:00-05:00,BIIB,positive
161687.0,Biogen Reaches Generic Tecfidera Settlement/Dismissal With Aurobindo Pharma,2019-11-26 09:51:00-05:00,BIIB,positive
161688.0,﻿Biogen shares are trading higher on continued momentum after the company presented data showing improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA.,2019-11-25 10:54:00-05:00,BIIB,positive
161689.0,Biogen shares are trading higher after the company presented data showing improved gastrointestinal tolerability with VUMERITY compared to TECFIDERA.,2019-11-22 14:41:00-05:00,BIIB,positive
161690.0,"Trump Says he Will Release a Plan to Let States Import Prescription Drugs Which are ""MUCH CHEAPER""",2019-11-22 14:08:00-05:00,BIIB,neutral
161691.0,Biogen Highlights Data Showing Improved Gastrointestinal Tolerability With VUMERITY Compared To TECFIDERA,2019-11-22 07:31:00-05:00,BIIB,positive
161692.0,Biogen Reports Completion Of Enrollment Of Global Phase 3 Therapy Study For Inherited Retinal Disorder,2019-11-21 07:31:00-05:00,BIIB,negative
161693.0,Biogen shares are trading higher. Not seeing any news to justify the price action.,2019-11-19 10:28:00-05:00,BIIB,positive
161694.0,Biogen shares are trading lower as a potential sell-off after the stock increased roughly 38% on October 22nd following the company reporting better-than-expected Q3 EPS and sales results.,2019-11-14 10:35:00-05:00,BIIB,positive
161695.0,Biogen shares are trading lower on seemingly no company-specific news.,2019-11-13 14:28:00-05:00,BIIB,negative
161696.0,"Benzinga's Top Upgrades, Downgrades For November 12, 2019",2019-11-12 09:37:00-05:00,BIIB,positive
161697.0,Alkermes Receives $150M Milestone Payment From Biogen Related To FDA Approval Of VUMERITY,2019-11-12 07:17:00-05:00,BIIB,positive
161698.0,"SunTrust Robinson Humphrey Initiates Coverage On Biogen with Buy Rating, Announces $337 Price Target",2019-11-12 06:12:00-05:00,BIIB,neutral
161699.0,Biotech Stock On The Radar: Alkermes At A Crossroads,2019-11-07 11:53:00-05:00,BIIB,neutral
161700.0,AstraZeneca Named The Most Innovative Global Pharma Company,2019-11-06 11:20:00-05:00,BIIB,positive
161701.0,Biogen Announces Proposed Transaction With Samsung Bioepis To Secure Exclusive Rights To Two Ophthalmology Biosimilars,2019-11-06 07:35:00-05:00,BIIB,positive
161702.0,Chinese Regulators Tentatively Approve Novel Alzheimer's Drug — The First Since 2003,2019-11-04 14:24:00-05:00,BIIB,positive
161703.0,Standpoint Research Downgrades Biogen to Hold,2019-11-01 13:33:00-04:00,BIIB,neutral
161704.0,Cramer Makes The Case Why Biogen's Stock Could Double In Value,2019-10-31 13:57:00-04:00,BIIB,positive
161705.0,"Benzinga's Top Upgrades, Downgrades For October 30, 2019",2019-10-30 10:34:00-04:00,BIIB,positive
161706.0,"Biogen shares are trading higher after the company announced it has recieved FDA approval for VUMERITY, a treatment of relapsing forms of multiple sclerosis. Bernstein earlier upgraded the stock from Market Perform to Outperform.",2019-10-30 08:24:00-04:00,BIIB,positive
161707.0,Biogen And Alkermes Announce FDA Approval Of VUMERITY (diroximel fumarate) For Multiple Sclerosis,2019-10-30 07:30:00-04:00,BIIB,positive
161708.0,Bernstein Upgrades Biogen to Outperform,2019-10-30 05:59:00-04:00,BIIB,neutral
161709.0,"Hearing Bernstein Upgrades Biogen To Outperform, $370 Price Target",2019-10-29 17:31:00-04:00,BIIB,neutral
161710.0,"The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings",2019-10-27 12:56:00-04:00,BIIB,neutral
161711.0,WeTrader Competition: Round Three Wrap-up,2019-10-25 16:03:00-04:00,BIIB,neutral
161712.0,Biogen Analysts Debate About-Face On Aducanumab: 'Path To Market An Uphill Battle',2019-10-23 11:37:00-04:00,BIIB,negative
161713.0,'7 burning questions now that Biogen $BIIB  has resurrected its 'failed' Alzheimer's drug' -Tweet From Stat News Snr Writer,2019-10-23 11:17:00-04:00,BIIB,neutral
161714.0,"UPDATE: Morgan Stanley Maintains Underweight On Biogen, Raises Target To $262 As Firm Notes 'We add 35% risk-adjusted aducanumab sales into our model but remain UW given our concerns around the updated filing strategy and base business'",2019-10-23 11:16:00-04:00,BIIB,neutral
161715.0,"UPDATE:H.C. Wainwright Reiterates Buy On Biogen, Raises Tgt To $335 Notes 'In light of the new analysis from the aducanumab Phase 3 trials and plans for BLA submission based on discussions with the FDA, we raised our probability of success to 15%' From 0%",2019-10-23 10:59:00-04:00,BIIB,positive
161716.0,"UPDATE: Canaccord On Biogen Also Notes 'we would like to wait until BIIB presents a fuller data set at the Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego, CA (12/4-12/7)'",2019-10-23 10:54:00-04:00,BIIB,positive
161717.0,"UPDATE: Canaccord Maintains Hold On Biogen, Raises Target To $305 Notes 'There is still a lot of uncertainty and investor skepticism as it is unclear whether the FDA could approve adu based on one successful EMERGE trial supported by ENGAGE that failed'",2019-10-23 10:54:00-04:00,BIIB,positive
161718.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 23, 2019",2019-10-23 09:53:00-04:00,BIIB,positive
161719.0,10 Biggest Price Target Changes For Wednesday,2019-10-23 09:13:00-04:00,BIIB,neutral
161720.0,"BMO Capital Maintains Market Perform on Biogen, Raises Price Target to $297",2019-10-23 08:59:00-04:00,BIIB,neutral
161721.0,"Canaccord Genuity Maintains Hold on Biogen, Raises Price Target to $305",2019-10-23 08:58:00-04:00,BIIB,neutral
161722.0,"Credit Suisse Maintains Underperform on Biogen, Raises Price Target to $260",2019-10-23 08:57:00-04:00,BIIB,positive
161723.0,"SVB Leerink Upgrades Biogen to Outperform, Raises Price Target to $350",2019-10-23 08:51:00-04:00,BIIB,neutral
161724.0,33 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-23 08:48:00-04:00,BIIB,neutral
161725.0,"JP Morgan Maintains Neutral on Biogen, Raises Price Target to $260",2019-10-23 08:38:00-04:00,BIIB,positive
161726.0,"Cowen & Co. Maintains Outperform on Biogen, Raises Price Target to $325",2019-10-23 08:28:00-04:00,BIIB,neutral
161727.0,"Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $262",2019-10-23 07:49:00-04:00,BIIB,neutral
161728.0,"H.C. Wainwright Reiterates Buy on Biogen, Raises Price Target to $335",2019-10-23 07:14:00-04:00,BIIB,neutral
161729.0,Guggenheim Upgrades Biogen to Buy,2019-10-23 06:20:00-04:00,BIIB,neutral
161730.0,41 Biggest Movers From Yesterday,2019-10-23 05:09:00-04:00,BIIB,neutral
161731.0,"PreMarket Prep: A Biotech Surprise, Stamps Shorts Take A Licking, Debating McDonald's Earnings Move",2019-10-22 15:55:00-04:00,BIIB,positive
161732.0,Jon Najarian Highlights Unusual Options Activity In Biogen,2019-10-22 15:54:00-04:00,BIIB,neutral
161733.0,Biogen Alzheimer Drug Has 0% Chance Of Winning Approval -Raymond James,2019-10-22 15:51:00-04:00,BIIB,positive
161734.0,"Mid-Afternoon Market Update: Health Care Shares Climb 1.04%, Biogen Shares Spike",2019-10-22 14:47:00-04:00,BIIB,positive
161735.0,25 Stocks Moving In Tuesday's Mid-Day Session,2019-10-22 13:28:00-04:00,BIIB,neutral
161736.0,Mid-Day Market Update: Energy Up 1.10%; Biogen Shares Spike Higher,2019-10-22 12:58:00-04:00,BIIB,positive
161737.0,"Mid-Morning Market Update: Healthcare Shares Trend Higher, Biogen Shares Spike",2019-10-22 11:30:00-04:00,BIIB,positive
161738.0,Alzheimer's Association Issues Statement Saying Is Encouraged To Learn Biogen Will Pursue Regulatory Approval From FDA For Aducanumab,2019-10-22 10:27:00-04:00,BIIB,positive
161739.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 22, 2019",2019-10-22 10:20:00-04:00,BIIB,positive
161740.0,"Mixed Bag: Better Outlooks From Lockheed, United Technologies, But McDonald's Misses",2019-10-22 10:14:00-04:00,BIIB,positive
161741.0,Biogen Plans Filing For Failed Alzheimer's Drug After New Analysis,2019-10-22 09:12:00-04:00,BIIB,negative
161742.0,Biogen Inc Executive Says FDA Thought It Was 'Reasonable' To File For Regulatory Approval Of Aducanumab After Meeting With Co.,2019-10-22 09:08:00-04:00,BIIB,positive
161743.0,Biogen Inc Executive Says Results From New Analysis Of Aducanumab Are Positive For Other Alzheimer's Drug Ban2401,2019-10-22 08:34:00-04:00,BIIB,positive
161744.0,"The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug",2019-10-22 07:51:00-04:00,BIIB,positive
161745.0,8 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-10-22 07:30:00-04:00,BIIB,neutral
161746.0,16 Stocks Moving in Tuesday's Pre-Market Session,2019-10-22 07:26:00-04:00,BIIB,neutral
161747.0,Biogen Earnings Call To Begin At 8:00 a.m. (Stream Link),2019-10-22 07:10:00-04:00,BIIB,neutral
161748.0,UPDATE: Seeing Reports Of Biogen Q3 Adj. EPS $9.17,2019-10-22 07:00:00-04:00,BIIB,neutral
161749.0,A Peek Into The Markets: US Stock Futures Flat Ahead Of Earnings,2019-10-22 06:54:00-04:00,BIIB,neutral
161750.0,"Biogen Q3 GAAP EPS $8.39, Adj. EPS $9.17 Beats $8.27 Estimate, Sales $3.6B Beat $3.54B Estimate",2019-10-22 06:53:00-04:00,BIIB,neutral
161751.0,Biogen shares are trading higher after the company announced it plans a regulatory filing for Aducanumab in Alzheimer's disease following new analysis. The terminated Phase 3 EMERGE study met its primary endpoint and the company now believes a subset of patients in the Phase 3 ENGAGE study also support the findings of EMERGE.,2019-10-22 06:42:00-04:00,BIIB,positive
161752.0,Biogen Plans Regulatory Filing For Aducanumab In Alzheimer's Disease Based On New Analysis Of Larger Dataset From Phase 3 Studies,2019-10-22 06:32:00-04:00,BIIB,neutral
161753.0,"12 Stocks To Watch For October 22, 2019",2019-10-22 06:00:00-04:00,BIIB,neutral
161754.0,"Earnings Scheduled For October 22, 2019",2019-10-22 05:40:00-04:00,BIIB,neutral
161755.0,Earnings Season Kicks Into Full Gear In Round 3 Of The WeTrader Competition,2019-10-21 11:16:00-04:00,BIIB,neutral
161756.0,"Earnings Roll On With Light Schedule Today But McDonald's, Biogen On Tuesday Calendar",2019-10-21 10:00:00-04:00,BIIB,neutral
161757.0,"Bank of America Reinstates Underperform on Biogen, Announces $200 Price Target",2019-10-17 07:28:00-04:00,BIIB,neutral
161758.0,"Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $212",2019-10-11 08:43:00-04:00,BIIB,neutral
161759.0,Biogen Reports Biogen Canada's Results From NURTURE Study,2019-10-03 08:06:00-04:00,BIIB,positive
161760.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,BIIB,negative
161761.0,"Apple, Biogen And More 'Fast Money' Picks For October 1",2019-10-01 11:05:00-04:00,BIIB,neutral
161762.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,BIIB,neutral
161763.0,"Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company",2019-09-25 17:32:00-04:00,BIIB,neutral
161764.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,BIIB,negative
161765.0,Shares of several drug companies are trading higher after Senate Majority Leader McConnell suggested a new Democratic drug price reform proposal would be dead on arrival.,2019-09-20 13:00:00-04:00,BIIB,negative
161766.0,Biogen Reports To Initiate DEVOTE Trial To Evaluate A Higher Dose Of SPINRAZA For Treatment Of Spinal Muscular Atrophy,2019-09-18 07:30:00-04:00,BIIB,positive
161767.0,Biogen Shares Tick Lower On Volume As Traders Circulate Word Of Negative Comments From RBC Capital Suggesting Firm's Checks Have Detected Co.'s Study Of BG00011 Has Been Discontinued Due To Toxicity,2019-09-16 14:31:00-04:00,BIIB,negative
161768.0,"Eisai, Biogen Will Discontinue Phase 3 Studies Of BACE Inhibitor Elenbeccestat In Early Alzheimer's Disease",2019-09-13 08:03:00-04:00,BIIB,negative
161769.0,Biogen shares are trading lower following reports that an intellectual property trial has been instituted against the company by Sawai Pharmaceutical.,2019-09-12 11:54:00-04:00,BIIB,positive
161770.0,"Biogen Shares Fall ~1.3% Amid Report Intellectual Property Right Patent Trial Against Co.'s '514 Tecfidera By Sawai Has Been Instituted By Patent Trial, Appeal Board As Claims Have Been Determined To Be Likely Invalid",2019-09-12 11:43:00-04:00,BIIB,positive
161771.0,"New Data Demonstrate Potential Benefits of Treatment With Tysabri, Plegridy and Avonex in Specific MS Patient Populations",2019-09-12 05:04:00-04:00,BIIB,positive
161772.0,"The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway",2019-09-11 07:09:00-04:00,BIIB,neutral
161773.0,Biogen Announces New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA Over 10 Years,2019-09-11 05:59:00-04:00,BIIB,positive
161774.0,Biogen And Invitae Announce Availability Of SMA STAT Rapid-Turnaround Genetic Test For Spinal Muscular Atrophy,2019-08-20 07:31:00-04:00,BIIB,neutral
161775.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,BIIB,positive
161776.0,Shares of several healthcare companies are trading lower in sympathy with the overall market.,2019-08-07 10:31:00-04:00,BIIB,positive
161777.0,"Alkermes, Biogen Report Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events",2019-07-30 07:36:00-04:00,BIIB,positive
161778.0,"The Week In Cannabis: Tobacco And Retail Stray In The Weeds, Congress Holds SAFE Banking Hearings, New ETFs, And More",2019-07-28 15:51:00-04:00,BIIB,positive
161779.0,"Morgan Stanley Maintains Underweight, $211 Target On Biogen As Firm Notes '2Q Beats But Doesn't Change Our LT View';  Firm Notes 'With our tail concerns around Tecfidera IP, MS pricing, Rituxan biosimilars and Spinraza competition unchanged, we remain UW'",2019-07-24 11:19:00-04:00,BIIB,neutral
161780.0,"Canaccord Genuity Maintains Hold on Biogen, Raises Price Target to $285",2019-07-24 08:12:00-04:00,BIIB,neutral
161781.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,BIIB,neutral
161782.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-07-23 13:09:00-04:00,BIIB,neutral
161783.0,"ICC International Cannabis, Biotii Technologie Sign Advisory Agreement With Dr. Alexandros Makriyannis",2019-07-23 10:55:00-04:00,BIIB,positive
161784.0,"Budget Deal, Earnings Strength From Lockheed, CocaCola, United Technologies Lift Spirits",2019-07-23 10:11:00-04:00,BIIB,positive
161785.0,Biogen shares are trading higher after the company reported better-than-expected Q2 EPS and sales and raised FY19 guidance.,2019-07-23 09:52:00-04:00,BIIB,positive
161786.0,"Biogen Reports Q2 Earnings Beat, Raises Guidance",2019-07-23 08:52:00-04:00,BIIB,neutral
161787.0,Biogen Raises FY19 Adj. EPS Guidance From $28-$29 To $31.50-$32.30 vs $29.70 Est.,2019-07-23 08:31:00-04:00,BIIB,neutral
161788.0,"Biogen Earlier Reported Q2 EPS $9.15 Beats $7.53 Estimate, Sales $3.617B Beat $3.48B Estimate",2019-07-23 08:29:00-04:00,BIIB,neutral
161789.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,BIIB,negative
161790.0,"Earnings Scheduled For July 23, 2019",2019-07-23 04:51:00-04:00,BIIB,neutral
161791.0,The Week Ahead In Biotech: Pharma Earnings Pick Up Pace,2019-07-20 09:53:00-04:00,BIIB,neutral
161792.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,BIIB,negative
161793.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,BIIB,positive
161794.0,"Biogen to Collaborate with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers, Biogen to Make Upfront and Milestone Payments",2019-07-08 07:34:00-04:00,BIIB,positive
161795.0,Biogen Announces New Data Further Establishing SPINRAZA as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients,2019-07-01 07:32:00-04:00,BIIB,positive
161796.0,10 Biggest Price Target Changes For Friday,2019-06-28 10:22:00-04:00,BIIB,neutral
161797.0,"Benzinga's Top Upgrades, Downgrades For June 28, 2019",2019-06-28 09:24:00-04:00,BIIB,positive
161798.0,A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Reports,2019-06-28 07:04:00-04:00,BIIB,positive
161799.0,"Piper Jaffray Downgrades Biogen to Neutral, Lowers Price Target to $250",2019-06-28 06:47:00-04:00,BIIB,negative
161800.0,Shares of multiple drugmakers and biotech companies are trading higher after AbbVie announced it will acquire Allergan.,2019-06-25 11:21:00-04:00,BIIB,positive
161801.0,"Biogen's Canada Unit Wins Broader Access To Spinraza By Province Of Ontario, Canada",2019-06-13 06:14:00-04:00,BIIB,positive
161802.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,BIIB,positive
161803.0,Biogen Reports New Phase 3 Interim Results Support Safety And Efficacy Of Diroximel Fumarate In Multiple Sclerosis,2019-05-30 07:33:00-04:00,BIIB,positive
161804.0,Nightstar Therapeutics Offers Expected Timetable For Purchase By Biogen,2019-05-29 09:05:00-04:00,BIIB,neutral
161805.0,"Benzinga's Top Upgrades, Downgrades For May 23, 2019",2019-05-23 09:01:00-04:00,BIIB,positive
161806.0,"Wedbush Initiates Coverage On Biogen Inc. - Common Stock with Neutral Rating, Announces $231 Price Target",2019-05-23 08:01:00-04:00,BIIB,neutral
161807.0,"Benzinga's Top Upgrades, Downgrades For May 21, 2019",2019-05-21 09:16:00-04:00,BIIB,positive
161808.0,"Credit Suisse Initiates Coverage On Biogen Inc. - Common Stock with Underperform Rating, Announces $198 Price Target",2019-05-21 07:08:00-04:00,BIIB,positive
161809.0,Biogen Shares Quiet After Hours Despite Report Credit Suisse Initiated Coverage With An Underperform Rating And $198 Price Target,2019-05-20 17:07:00-04:00,BIIB,neutral
161810.0,Biogen Reports Received Notice Of Unsolicited Mini-Tender Offer By TRC Capital To Buy 500K Shares At $216.25/Share In Cash,2019-05-20 07:31:00-04:00,BIIB,positive
161811.0,"Shares of many Healthcare companies are trading higher as markets rebound from the recent volatility caused by uncertainty regarding US-China trade talks. Also, lawmakers were not able to pass a bill that would end 'surprise medical bills'.",2019-05-16 15:09:00-04:00,BIIB,positive
161812.0,"The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi",2019-05-15 07:50:00-04:00,BIIB,negative
161813.0,"Biogen Reported Late Tues. SPINRAZA Received Positive Recommendation From NICE For Funding In US For Treatment of Infants, Children and Adults with Spinal Muscular Atrophy",2019-05-15 07:42:00-04:00,BIIB,positive
161814.0,"Shares of several healthcare companies are trading higher as the US market rebounds from recent weakness, driven by renewed cautious optimism surrounding US-China trade talks.",2019-05-14 13:32:00-04:00,BIIB,positive
161815.0,"Barclays Maintains Equal-Weight on Biogen Inc. - Common Stock, Lowers Price Target to $245",2019-05-09 09:13:00-04:00,BIIB,negative
161816.0,Nightstar Therapeutics Reports Shareholders Approved Purchase By Biogen,2019-05-08 09:43:00-04:00,BIIB,positive
161817.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,BIIB,neutral
161818.0,"Notable Insider Buys This Past Week: ADM, Biogen, Grubhub and More",2019-05-06 07:44:00-04:00,BIIB,neutral
161819.0,"Biogen Highlights Data For Long-Term Safety, Durability Study With SPINRAZA At 2019 AAN Annual Meeting",2019-05-06 07:34:00-04:00,BIIB,positive
161820.0,What's The Buzz Around Novartis' Gene Therapy Zolgensma?,2019-05-02 09:22:00-04:00,BIIB,neutral
161821.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,BIIB,positive
161822.0,"Biogen Highlights Will Present New Data For Its Neuroscience Portfolio, Advancing Clinical Development Programs At American Academy of Neurology",2019-05-01 07:45:00-04:00,BIIB,neutral
161823.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2019-04-30 13:00:00-04:00,BIIB,neutral
161824.0,Biogen Highlights Publication Of SPINRAZA Data In Neurology Jounrnal,2019-04-30 07:35:00-04:00,BIIB,neutral
161825.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs",2019-04-27 11:44:00-04:00,BIIB,neutral
161826.0,From Abbvie Conference Call; Co. Says Humira Biosimilars From Biogen And Amgen In Europe Have Been The Most Aggressive In The Market So Far,2019-04-25 09:44:00-04:00,BIIB,negative
161827.0,"The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova",2019-04-24 08:09:00-04:00,BIIB,neutral
161828.0,"Biogen Q1 Sales $3.49B vs $3.39B Estimate, Adj. EPS $6.98 vs $6.84",2019-04-24 06:31:00-04:00,BIIB,neutral
161829.0,"Earnings Scheduled For April 24, 2019",2019-04-24 04:18:00-04:00,BIIB,neutral
161830.0,"Earnings Beats Keep Coming, With Verizon, CocaCola, Twitter, Procter & Gamble All Solid",2019-04-23 09:57:00-04:00,BIIB,positive
161831.0,"The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs",2019-04-21 14:06:00-04:00,BIIB,neutral
161832.0,Shares of several drug companies are trading lower. Weakness may be tied to uncertainty over healthcare policy going into the 2020 primaries and Washington's recent efforts to curb prescription drug prices.,2019-04-16 15:34:00-04:00,BIIB,negative
161833.0,"'$BIIB *ALEX DENNER TALKS BIOGEN AT 13D CONFERENCE *DENNER: BIOGEN CASH FLOWS ARE THERE, 'LOTS AND LOTS OF CASH''-Tweets Christian Fromhertz",2019-04-16 12:35:00-04:00,BIIB,neutral
161834.0,"Biogen Reports Will Present New Data Showing Progressive Nature Of Spinal Muscular Atrophy In Adults, Adolescents, Older Children At The Muscular Dystrophy Association Clinical and Scientific Conference",2019-04-12 07:33:00-04:00,BIIB,neutral
161835.0,"UBS Upgrades Gilead, Sees EPS Upside In 2019",2019-04-10 11:17:00-04:00,BIIB,neutral
161836.0,"Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds",2019-04-10 09:59:00-04:00,BIIB,neutral
161837.0,"The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead",2019-03-29 07:42:00-04:00,BIIB,positive
161838.0,6 Gene Therapy M&A Targets On The Radar,2019-03-27 12:45:00-04:00,BIIB,neutral
161839.0,Biogen Announces a $5B Buyback,2019-03-25 07:22:00-04:00,BIIB,neutral
161840.0,"Bulls & Bears Of The Week: Boeing, Facebook, Fox, Netflix, Starbucks And More",2019-03-24 17:07:00-04:00,BIIB,neutral
161841.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,BIIB,neutral
161842.0,'Biogen-Eisai partnership may be hitting a rough patch following Alzheimer's drug blowup' -STAT News,2019-03-22 16:16:00-04:00,BIIB,neutral
161843.0,Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About',2019-03-22 13:30:00-04:00,BIIB,negative
161844.0,Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback,2019-03-22 09:55:00-04:00,BIIB,positive
161845.0,10 Biggest Price Target Changes For Friday,2019-03-22 09:40:00-04:00,BIIB,neutral
161846.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 22, 2019",2019-03-22 09:23:00-04:00,BIIB,positive
161847.0,"Nomura Maintains Buy on Biogen, Lowers Price Target to $320",2019-03-22 09:14:00-04:00,BIIB,negative
161848.0,"Benzinga's Top Upgrades, Downgrades For March 22, 2019",2019-03-22 09:10:00-04:00,BIIB,positive
161849.0,"Mizuho Downgrades Biogen to Neutral, Lowers Price Target to $235",2019-03-22 09:08:00-04:00,BIIB,negative
161850.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,BIIB,negative
161851.0,"Canaccord Genuity Downgrades Biogen to Hold, Lowers Price Target to $275",2019-03-22 07:52:00-04:00,BIIB,negative
161852.0,A Peek Into The Markets: US Stock Futures Tumble Ahead Of Economic Data,2019-03-22 07:13:00-04:00,BIIB,neutral
161853.0,"Citigroup Downgrades Biogen to Neutral, Lowers Price Target to $230",2019-03-22 06:49:00-04:00,BIIB,negative
161854.0,UBS Downgrades Biogen to Neutral,2019-03-22 06:46:00-04:00,BIIB,neutral
161855.0,Morgan Stanley Downgrades Biogen to Underweight,2019-03-22 06:43:00-04:00,BIIB,neutral
161856.0,60 Biggest Movers From Yesterday,2019-03-22 05:36:00-04:00,BIIB,neutral
161857.0,Mid-Afternoon Market Update: Dow Surges 250 Points; Micron Shares Gain On Upbeat Earnings,2019-03-21 14:41:00-04:00,BIIB,positive
161858.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-03-21 12:56:00-04:00,BIIB,neutral
161859.0,'@petenajarian biib goes way lower  they are losing a patient too  stk to 200 maybe 175 THIS drug was their  future  future dead  150 before 280' -sam tweets,2019-03-21 12:43:00-04:00,BIIB,negative
161860.0,Mid-Day Market Update: Superconductor Technologies Rises After Q4 Results; Staffing 360 Solutions Shares Slide,2019-03-21 12:09:00-04:00,BIIB,positive
161861.0,Cantor Fitzgerald Downgrades Biogen to Neutral,2019-03-21 12:07:00-04:00,BIIB,neutral
161862.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Mar. 21, 2019",2019-03-21 11:26:00-04:00,BIIB,positive
161863.0,Hearing Goldman Sachs Downgrades Biogen From Buy To Neutral,2019-03-21 11:15:00-04:00,BIIB,neutral
161864.0,Biogen Shares Relatively Quiet As Hearing Wells Fargo Downgrades From Outperform To Market Perform,2019-03-21 11:05:00-04:00,BIIB,positive
161865.0,JP Morgan Removes Biogen From Analyst Focus List,2019-03-21 10:42:00-04:00,BIIB,positive
161866.0,"JP Morgan Says Believes Without Alzheimer's Lottery Ticket In Hand, The Company Faces An Uncertain And Difficult Path Forward",2019-03-21 10:41:00-04:00,BIIB,positive
161867.0,Mid-Morning Market Update: Markets Open Higher; Conagra Earnings Top Expectations,2019-03-21 10:12:00-04:00,BIIB,positive
161868.0,Hearing Biogen Downgraded To Neutral By BTIG,2019-03-21 09:38:00-04:00,BIIB,neutral
161869.0,"'$BIIB Scorecard for its ""high RISK high reward"" R&D strategy. Pretty much everything except Spinraza on this pipeline chart from 2015 failed' -Tweet From Notable Biotech Source",2019-03-21 09:27:00-04:00,BIIB,positive
161870.0,Atlantic Equities Downgrades Biogen to Neutral,2019-03-21 09:23:00-04:00,BIIB,neutral
161871.0,William Blair Downgrades Biogen to Market Perform,2019-03-21 09:21:00-04:00,BIIB,neutral
161872.0,Hearing Baird Cuts Price Target On Biogen From $348 To $250,2019-03-21 08:21:00-04:00,BIIB,negative
161873.0,Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study,2019-03-21 08:17:00-04:00,BIIB,neutral
161874.0,Biogen shares are trading lower after the company said it will discontinue phase 3 trials of the company's Alzheimer's drug candidate.,2019-03-21 08:05:00-04:00,BIIB,neutral
161875.0,iShares Nasdaq Biotech ETF Down 3% Premarket,2019-03-21 07:57:00-04:00,BIIB,neutral
161876.0,"The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering",2019-03-21 07:51:00-04:00,BIIB,negative
161877.0,31 Stocks Moving In Thursday's Pre-Market Session,2019-03-21 07:50:00-04:00,BIIB,neutral
161878.0,"Watching Stocks With Alzheimer's Treatment Candidates: Merck, Roche, AbbVie, Neurotrope, AC Immune, Denali, INmune Bio, BioXcel Therapeutics, Intra-Cellular, Anavex, Pain Therapeutics, Grifols",2019-03-21 07:37:00-04:00,BIIB,negative
161879.0,Biogen Down ~$16B In Market Cap Following News Alzheimer's Candidate Trial Will Be Discontinued,2019-03-21 07:33:00-04:00,BIIB,neutral
161880.0,"Biogen Shares Resume Trade, Down 25%",2019-03-21 07:32:00-04:00,BIIB,positive
161881.0,Biogen Shares To Resume Trade At 7:30 a.m. EDT,2019-03-21 07:05:00-04:00,BIIB,positive
161882.0,"UPDATE: Biogen Says 'Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials'",2019-03-21 07:01:00-04:00,BIIB,neutral
161883.0,"Biogen, Eisai To Discontinue Phase 3 ENGAGE, EMERGE Trials Of Aducanumab In Alzheimer's",2019-03-21 07:00:00-04:00,BIIB,positive
161884.0,Biogen Shares Halted News Pending,2019-03-21 06:58:00-04:00,BIIB,positive
161885.0,Fujifilm To Acquire Large-Scale Biologics Manufacturing Site From Biogen  for ~$890M in Cash,2019-03-12 04:35:00-04:00,BIIB,neutral
161886.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,BIIB,neutral
161887.0,"Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.",2019-03-06 11:59:00-05:00,BIIB,negative
161888.0,Analysts Laud Biogen's M&A Strategy Following Deal to Buy Gene Therapy Company Nightstar,2019-03-05 13:01:00-05:00,BIIB,neutral
161889.0,62 Biggest Movers From Yesterday,2019-03-05 05:19:00-05:00,BIIB,neutral
161890.0,Mid-Afternoon Market Update: Nightstar Therapeutics Surges On Acquisition News; Evoke Pharma Shares Plunge,2019-03-04 14:34:00-05:00,BIIB,positive
161891.0,50 Stocks Moving In Monday's Mid-Day Session,2019-03-04 12:44:00-05:00,BIIB,neutral
161892.0,Mid-Day Market Update: U.S. Stocks Turn Negative; Dow Down Over 350 Points,2019-03-04 12:29:00-05:00,BIIB,negative
161893.0,Mid-Morning Market Update: Markets Open Higher; Childrens Place Misses Q4 Expectations,2019-03-04 10:38:00-05:00,BIIB,negative
161894.0,"Biogen Bets On Gene Therapy, Agrees To Acquire Nightstar For $800M",2019-03-04 09:11:00-05:00,BIIB,positive
161895.0,30 Stocks Moving In Monday's Pre-Market Session,2019-03-04 08:02:00-05:00,BIIB,neutral
161896.0,A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street,2019-03-04 06:56:00-05:00,BIIB,neutral
161897.0,Nightstar Therapeutics Announces Agreement to be Acquired by Biogen for $25.50/Share in Cash,2019-03-04 04:01:00-05:00,BIIB,positive
161898.0,Biogen Reports SPINRAZA Has Received Approval From China National Medical Products Association,2019-02-28 07:44:00-05:00,BIIB,positive
161899.0,Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis,2019-02-25 07:37:00-05:00,BIIB,positive
161900.0,8 Biggest Price Target Changes For Friday,2019-02-22 09:42:00-05:00,BIIB,neutral
161901.0,"Benzinga's Top Upgrades, Downgrades For February 22, 2019",2019-02-22 09:26:00-05:00,BIIB,positive
161902.0,"Guggenheim Downgrades Biogen to Neutral, Lowers Price Target to $325",2019-02-22 08:05:00-05:00,BIIB,negative
161903.0,"BMO Capital Initiates Coverage On Biogen with Market Perform Rating, Announces $322 Price Target",2019-02-22 07:16:00-05:00,BIIB,neutral
161904.0,Biogen shares are trading lower after Stifel Nicolaus downgraded the company's stock from Buy to Hold and lowered its price target from $397 to $346 per share.,2019-02-21 10:34:00-05:00,BIIB,positive
161905.0,10 Biggest Price Target Changes For Thursday,2019-02-21 09:55:00-05:00,BIIB,neutral
161906.0,"Benzinga's Top Upgrades, Downgrades For February 21, 2019",2019-02-21 08:53:00-05:00,BIIB,positive
161907.0,"Stifel Nicolaus Downgrades Biogen to Hold, Lowers Price Target to $346",2019-02-21 06:52:00-05:00,BIIB,negative
161908.0,UPDATE: USPTO Says Mylan Has 'demonstrated a reasonable likelihood of success in proving that at least claim 1 of the '514 patent is unpatentable',2019-02-07 09:50:00-05:00,BIIB,positive
161909.0,Biogen shares are trading lower after the U.S. Patent and Trademark Office reportedly stated that Mylan could likely succeed in a patent challenge against a Biogen multiple sclerosis drug.,2019-02-07 09:50:00-05:00,BIIB,positive
161910.0,Documents From Wednesday Show Mylan Pharmaceuticals Has Filed Petition Requesting Review Of Patent Claims Against Biogen,2019-02-07 09:47:00-05:00,BIIB,neutral
161911.0,"Insider Buys Of The Week: Biogen, Discover Financial, Kinder Morgan",2019-02-02 13:52:00-05:00,BIIB,positive
161912.0,Ionis Wins Price Target Hike On Partner Biogen's Guidance,2019-01-30 11:18:00-05:00,BIIB,positive
161913.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-01-30 08:12:00-05:00,BIIB,neutral
161914.0,"Biogen Earlier Guided FY19 Adj. EPS $28-$29 vs $28.02 Estimate, Sales $13.6B-$13.8B vs $13.65B Est.",2019-01-29 08:35:00-05:00,BIIB,neutral
161915.0,"The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive",2019-01-29 07:25:00-05:00,BIIB,neutral
161916.0,"Biogen Idec Q4 Adj. EPS $6.99 Beats $6.71 Estimate, Sales $3.53B Beat $3.39B Estimate",2019-01-29 06:51:00-05:00,BIIB,neutral
161917.0,"12 Stocks To Watch For January 29, 2019",2019-01-29 04:35:00-05:00,BIIB,neutral
161918.0,"Earnings Scheduled For January 29, 2019",2019-01-29 04:13:00-05:00,BIIB,neutral
161919.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-01-27 16:07:00-05:00,BIIB,neutral
161920.0,Biogen shares are trading higher after the company announced it entered a strategic collaboration with C4 Therapeutics to discover and develop new treatments for neurological conditions.,2019-01-04 15:46:00-05:00,BIIB,positive
161921.0,"Activision Blizzard, Biogen, Expedia, Newmont Mining: 'Fast Money' Picks For January 4",2019-01-04 07:48:00-05:00,BIIB,neutral
161922.0,"Biogen, Skyhawk Therapeutics Reports Deal To Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets",2019-01-04 07:32:00-05:00,BIIB,positive
161923.0,"Biogen, C4 Therapeutics Reports Strategic Collaboration To Discover, Develop Potential New Treatments For Neurological Conditions",2019-01-04 07:31:00-05:00,BIIB,neutral
161924.0,Biogen Reports First Patient Enrolled In Phase 3b Study To Evaluate Extended Interval Dosing With Natalizumab In Multiple Sclerosis,2019-01-03 07:33:00-05:00,BIIB,neutral
161925.0,6 Valuable Pipeline Drugs With Upcoming Catalysts,2018-12-26 14:22:00-05:00,BIIB,positive
161926.0,When Larger Firms Walk Away From Partnerships With Smaller Ones: How Bad Is The Damage?,2018-12-21 13:38:00-05:00,BIIB,negative
161927.0,"BTIG Research Initiates Coverage On Biogen with Buy Rating, Announces $362 Price Target",2018-12-21 08:56:00-05:00,BIIB,neutral
161928.0,"Nearly 30 Drug Companies, Including Novartis, Bayer, Amgen, Biogen Notified Payers In California Of Plans To Raise Prices In January",2018-12-19 19:29:00-05:00,BIIB,neutral
161929.0,"Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $401",2018-12-19 08:15:00-05:00,BIIB,negative
161930.0,Alkermes And Biogen Announce Submission Of New Drug Application To U.S. Food And Drug Administration For Diroximel Fumarate In Multiple Sclerosis,2018-12-17 07:31:00-05:00,BIIB,neutral
161931.0,Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?,2018-12-13 13:40:00-05:00,BIIB,neutral
161932.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,BIIB,positive
161933.0,UPDATE: Applied Genetic Technologies Reports Will 'regain rights to 5 clinical and preclinical development programs; Biogen terminates collaboration agreement',2018-12-12 16:02:00-05:00,BIIB,positive
161934.0,UPDATE: Biogen Made 1-Time $35M Payment To Ionis; Future Payments May Include Potential Post-Licensing Milestone Payments Of Up To $55M And Royalties In Low To Mid Teen Percent Range,2018-12-06 07:32:00-05:00,BIIB,negative
161935.0,"Biogen Reports Exercise Of Option With Ionis Pharma For Development, Commercialization Of BIIB067 For Subtype Of Familial Amyotrophic Lateral Sclerosis",2018-12-06 07:32:00-05:00,BIIB,neutral
161936.0,HitGen Reports DNA-Encoded Library-Based Drug Discovery Research Collaboration With Biogen,2018-11-21 07:02:00-05:00,BIIB,neutral
161937.0,"From 13-F Filing: Temasek Dissolves Share Stakes in Disney, Amgen, Celgene, Biogen, Medtronic",2018-11-14 06:24:00-05:00,BIIB,positive
161938.0,"Jim Cramer Weighs In On Biogen, Colgate-Palmolive And More",2018-11-02 06:57:00-04:00,BIIB,neutral
161939.0,"These Are The Biggest Stocks Reporting Earnings This Week, And Their Recent Track Records",2018-10-29 10:39:00-04:00,BIIB,neutral
161940.0,"Biogen, Eisai Announce Presentation of Detailed Analyses from  Phase 1b Long-Term Extension Study of Aducanumab at CTAD",2018-10-29 03:49:00-04:00,BIIB,neutral
161941.0,Biogen And Eisai Presented Analyses From Previous Phase 1b Long-Term Extension Study Of Aducanumab At Clinical Trials On Alzheimer's Disease (CTAD),2018-10-26 09:19:00-04:00,BIIB,neutral
161942.0,"The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default",2018-10-26 08:17:00-04:00,BIIB,negative
161943.0,"Eisai, Biogen Announce Presentation of Additional Data from Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease at CTAD Conference",2018-10-26 04:18:00-04:00,BIIB,neutral
161944.0,Eisai And Biogen To Present Additional Data From Phase II Clinical Trial Of BAN2401 In Early Alzheimer's Disease At The 2018 Clinical Trials On Alzheimer's Disease (CTAD) Conference Today,2018-10-25 08:33:00-04:00,BIIB,neutral
161945.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,BIIB,negative
161946.0,US Appeals Court Has Affirmed Its Ruling For Biogen In Tecfidera Patent Dispute Against Forward Pharma,2018-10-24 10:05:00-04:00,BIIB,negative
161947.0,"JP Morgan Maintains Overweight on Biogen, Lowers Price Target to $436",2018-10-24 09:48:00-04:00,BIIB,negative
161948.0,Hearing Biogen Has Highlighted Adverse Events In Phase 1b Trial For Aducanumab,2018-10-24 07:25:00-04:00,BIIB,negative
161949.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,BIIB,positive
161950.0,A Peek Into The Markets: US Stock Futures Tumble Ahead Of Earnings,2018-10-23 07:38:00-04:00,BIIB,neutral
161951.0,"Biogen Earlier Highlighted Topline Results From Phase 2b Study Of Dapirolizumab Pegol In Systemic Lupus Erythematosus: Primary Endpoint Not Met, But Study Did Show Consistent, Potentially Meaningful Improvements For Majority Of Endpoints vs Placebo",2018-10-23 07:17:00-04:00,BIIB,positive
161952.0,"Biogen Earlier Reported Q3 EPS $7.40 Beats $6.80 Estimate, Sales $3.439B Beat $3.33B Estimate",2018-10-23 07:16:00-04:00,BIIB,neutral
161953.0,"Earnings Scheduled For October 23, 2018",2018-10-23 04:22:00-04:00,BIIB,neutral
161954.0,Biogen Q3 Earnings Outlook,2018-10-22 14:39:00-04:00,BIIB,neutral
161955.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,BIIB,neutral
161956.0,"Benzinga's Top Upgrades, Downgrades For October 19, 2018",2018-10-19 09:17:00-04:00,BIIB,positive
161957.0,Bernstein Downgrades Biogen to Market Perform,2018-10-19 08:20:00-04:00,BIIB,neutral
161958.0,"Biogen, Samsung Bioepis Announce European Launch of IMRALDI",2018-10-17 04:22:00-04:00,BIIB,neutral
161959.0,Equillium's IPO: What You Need To Know,2018-10-12 07:24:00-04:00,BIIB,neutral
161960.0,Biogen Advances Research To Improve Outcomes f=For Patients With Multiple Sclerosis,2018-10-11 07:33:00-04:00,BIIB,positive
161961.0,Biogen On Saturday Reported SPINRAZA Data At Annual Congress Of The World Muscle Society; Study Achieved Motor Milestones,2018-10-08 07:30:00-04:00,BIIB,neutral
161962.0,"Cantor Fitzgerald Reinstates Overweight on Biogen, Announces $400 Price Target",2018-10-01 08:21:00-04:00,BIIB,negative
161963.0,Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update,2018-09-24 09:29:00-04:00,BIIB,positive
161964.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,BIIB,positive
161965.0,Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093,2018-09-04 07:31:00-04:00,BIIB,neutral
161966.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,BIIB,positive
161967.0,"Biogen, Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab",2018-08-29 03:45:00-04:00,BIIB,neutral
161968.0,Biogen And Eisai Report Data From Long-Term Extension Phase 1b Study Of Investigational Alzheimer's Disease Treatment Aducanumab,2018-08-28 07:33:00-04:00,BIIB,neutral
161969.0,"Stifel Buys Back Into Biogen, Sees Upside In Alzheimer's Candidate",2018-08-07 14:26:00-04:00,BIIB,neutral
161970.0,"Stifel Nicolaus Reinstates Buy on Biogen, Announces $394",2018-08-07 07:21:00-04:00,BIIB,neutral
161971.0,Biogen 8-K Shows News Of $3.5B Buyback Plan,2018-08-03 07:07:00-04:00,BIIB,neutral
161972.0,60 Biggest Movers From Yesterday,2018-07-27 04:06:00-04:00,BIIB,neutral
161973.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Jul. 26, 2018",2018-07-26 13:19:00-04:00,BIIB,positive
161974.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-07-26 12:02:00-04:00,BIIB,neutral
161975.0,"Stocks Which Set New 52-Week High Yesterday, July 25th",2018-07-26 11:00:00-04:00,BIIB,neutral
161976.0,"Biogen Shares Down 12% After Announcing Results Of Phase 2 Clinical Study Of BAN2401, Developed With Drugmaker Eisai, In Early Alzheimer's Disease Patients, ""No Reasonable Conclusions"" To Dar From Data According To Baird's Brian Skorney",2018-07-26 09:45:00-04:00,BIIB,neutral
161977.0,"UBS Maintains Buy on Biogen, Raises Price Target to $395",2018-07-26 08:43:00-04:00,BIIB,neutral
161978.0,"Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold",2018-07-26 08:40:00-04:00,BIIB,negative
161979.0,32 Stocks Moving In Thursday's Pre-Market Session,2018-07-26 08:11:00-04:00,BIIB,neutral
161980.0,"Eisai, Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at AAIC 2018",2018-07-26 03:53:00-04:00,BIIB,neutral
161981.0,"Biogen and Eisai Announce BAN2401 Data Presented at AAIC, Showed Statistically Significant Amyloid Plaque Reduction In All Doses",2018-07-25 16:28:00-04:00,BIIB,positive
161982.0,Biogen Shares Gain On Midstage Results For Alzheimer's Candidate,2018-07-25 14:59:00-04:00,BIIB,positive
161983.0,"Stocks That Made New 52-Week Highs Earlier Include: Adobe, S&P Global, Baxter, Salesforce, Microsoft, Biogen, Becton, Norfolk Southern, Target, IHS Markit, Tiffany, Eli Lilly, Thermo Fisher, Facebook, FLIR Systems, Medtronic, and Mastercard",2018-07-25 12:25:00-04:00,BIIB,neutral
161984.0,"Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $320",2018-07-25 12:15:00-04:00,BIIB,neutral
161985.0,"Stocks Which Set New 52-Week High Yesterday, July 24th:",2018-07-25 12:14:00-04:00,BIIB,neutral
161986.0,'I find the $BIIB stock reaction this morning astonishing.'-STAT's Adam Feuerstein Tweets,2018-07-25 11:06:00-04:00,BIIB,neutral
161987.0,"UPDATE: Eisai, Biogen Say 'Although a small sample size, using the florbetapir PET tracer demonstrated a statistically significant decrease in brain amyloid load compared to placebo for the 50 mg total group arm at 18 months'",2018-07-25 10:34:00-04:00,BIIB,positive
161988.0,"UPDATE: Eisai, Biogen Report 'a statistically significant reduction of brain amyloid load as compared to placebo was observed in the 50 mg total group arm with a reduction in SUVr of 0.104'",2018-07-25 10:33:00-04:00,BIIB,positive
161989.0,"UPDATE: Eisai, Biogen On Elenbecestat Study Data: 'no dose-dependent response was observed for adverse events,' 'No adverse reactions suggestive of hepatic toxicity were observed in this study'",2018-07-25 10:32:00-04:00,BIIB,negative
161990.0,"Eisai, Biogen Offer Detailed Results From Phase II Study Of Elenbecestat In MCI, Mild To Moderate Alzheimer's Disease At AAIC Conference",2018-07-25 10:31:00-04:00,BIIB,neutral
161991.0,"Concerns About Trade Picture Overshadowing Earnings As GM, Boeing Report",2018-07-25 09:55:00-04:00,BIIB,neutral
161992.0,10 Biggest Price Target Changes For Wednesday,2018-07-25 09:52:00-04:00,BIIB,neutral
161993.0,"Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile",2018-07-25 08:41:00-04:00,BIIB,positive
161994.0,"Baird Maintains Neutral on Biogen, Raises Price Target to $348",2018-07-25 08:33:00-04:00,BIIB,neutral
161995.0,"Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $392",2018-07-25 08:01:00-04:00,BIIB,negative
161996.0,Biogen Holding Investor Webcast 6pm ET Today To Discuss Its Alzheimer's Disease Portfolio,2018-07-25 07:14:00-04:00,BIIB,neutral
161997.0,46 Biggest Movers From Yesterday,2018-07-25 04:03:00-04:00,BIIB,neutral
161998.0,34 Stocks Moving In Tuesday's Mid-Day Session,2018-07-24 12:28:00-04:00,BIIB,neutral
161999.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,BIIB,positive
162000.0,From Biogen Q2 Earnings Conference Call: Co. Recently Informed FDA Placed Clinical Hold On Investigational New Drug For SMA Gene Therapy Program,2018-07-24 08:41:00-04:00,BIIB,neutral
162001.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-07-24 08:02:00-04:00,BIIB,neutral
162002.0,A Peek Into The Markets: US Stock Futures Rise Ahead Of Earnings,2018-07-24 07:06:00-04:00,BIIB,neutral
162003.0,Biogen Acquires Muscle Enhancement Program From Alivegen For $27.5M,2018-07-24 06:39:00-04:00,BIIB,neutral
162004.0,"Biogen Reports Q2 EPS $5.80 vs $5.21 Est., Sales $3.4B vs $3.25B Est.",2018-07-24 06:38:00-04:00,BIIB,neutral
162005.0,"'$BIIB Q2 Spinraza sales $423M, topping $390M consensus.'-STAT's Adam Feuerstein Tweets",2018-07-24 06:36:00-04:00,BIIB,neutral
162006.0,"Earnings Scheduled For July 24, 2018",2018-07-24 04:20:00-04:00,BIIB,neutral
162007.0,Biogen Q2 Earnings Preview,2018-07-23 15:20:00-04:00,BIIB,neutral
162008.0,"The Week Ahead: FANG Earnings Continue, Fox Vote On Disney Deal, More IPOs",2018-07-23 12:41:00-04:00,BIIB,neutral
162009.0,10 Biggest Price Target Changes For Monday,2018-07-23 09:42:00-04:00,BIIB,neutral
162010.0,"Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $396",2018-07-23 07:55:00-04:00,BIIB,neutral
162011.0,AGTC Treats First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study; Earns $10M Enrollment Milestone,2018-07-23 07:01:00-04:00,BIIB,neutral
162012.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-07-22 17:03:00-04:00,BIIB,neutral
162013.0,Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus,2018-07-21 08:44:00-04:00,BIIB,neutral
162014.0,"Biogen To Host Investor Webcast Alzheimer's Disease Portfolio on July 25th, 6pm ET",2018-07-20 08:41:00-04:00,BIIB,neutral
162015.0,"Jim Cramer Advises His Viewers On BlackRock, Target And More",2018-07-20 07:30:00-04:00,BIIB,neutral
162016.0,Delivering Alpha 2018: Everything You Need To Know,2018-07-19 08:48:00-04:00,BIIB,neutral
162017.0,"American Express, Biogen, Huntsman, Take-Two: 'Fast Money' Picks For July 19",2018-07-19 07:38:00-04:00,BIIB,neutral
162018.0,"Biogen Shares Tick ~$2 Higher Over Last Few Mins. As Alex Denner Of Sarissa Capital, At Delivering Alpha Conference, Reiterating He Is On Co. Board; Says He Will Mention 2 Other Stocks During His Presentation",2018-07-18 15:04:00-04:00,BIIB,positive
162019.0,"Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $366",2018-07-13 07:37:00-04:00,BIIB,negative
162020.0,"Benzinga's Top Upgrades, Downgrades For July 10, 2018",2018-07-10 09:03:00-04:00,BIIB,positive
162021.0,Baird Downgrades Biogen to Neutral,2018-07-10 07:45:00-04:00,BIIB,neutral
162022.0,Hearing RBC Capital Raised Biogen Price Target From $320 To $349,2018-07-09 18:01:00-04:00,BIIB,neutral
162023.0,What Trade War? Positive Sentiment Seems To Continue From Friday,2018-07-09 09:42:00-04:00,BIIB,negative
162024.0,"5 Stocks To Watch For July 9, 2018",2018-07-09 04:28:00-04:00,BIIB,neutral
162025.0,34 Biggest Movers From Friday,2018-07-09 04:25:00-04:00,BIIB,neutral
162026.0,Mid-Afternoon Market Update: Dow Rises 150 Points; Biogen Shares Climb On Positive Alzheimer's Drug Trial,2018-07-06 14:30:00-04:00,BIIB,positive
162027.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Fri., Jul. 6, 2018",2018-07-06 13:38:00-04:00,BIIB,positive
162028.0,"After Biogen's Alzheimer's Update, Wall Street Reacts",2018-07-06 13:27:00-04:00,BIIB,neutral
162029.0,32 Stocks Moving In Friday's Mid-Day Session,2018-07-06 12:38:00-04:00,BIIB,neutral
162030.0,Mid-Day Market Update: Crude Oil Up Over 1%; Black Box Shares Spike Higher,2018-07-06 12:12:00-04:00,BIIB,negative
162031.0,PreMarket Prep Recap For July 6: Digesting Biogen's News With Adam Feuerstein; A Sector Breakdown With Dan Russo,2018-07-06 11:11:00-04:00,BIIB,neutral
162032.0,"Mid-Morning Market Update: Markets Mostly Higher; U.S. Adds 213,000 Jobs For June",2018-07-06 10:10:00-04:00,BIIB,neutral
162033.0,Adam Feuerstein Cautious On Biogen Following Alzheimer's Study,2018-07-06 10:08:00-04:00,BIIB,negative
162034.0,"Benzinga's Top Upgrades, Downgrades For July 6, 2018",2018-07-06 09:31:00-04:00,BIIB,positive
162035.0,"The Market In 5 Minutes: Biogen, Pruitt, Unemployment, Tariffs And More",2018-07-06 09:00:00-04:00,BIIB,negative
162036.0,Benzinga Pro's 5 Stocks To Watch Today,2018-07-06 08:53:00-04:00,BIIB,neutral
162037.0,"Citigroup Upgrades Biogen to Buy, Announces $371 Price Target",2018-07-06 08:51:00-04:00,BIIB,neutral
162038.0,Biogen Rallies On Positive Alzheimer's Drug Trial,2018-07-06 08:38:00-04:00,BIIB,positive
162039.0,"STAT News' Adam Feuerstein On Benzinga's PreMarket Prep Says 'Something like [Biogen Alzheimer's news] could get people more interested in the larger cap [biotech stocks], like a Biogen,' But Again Warns Of Cautiousness In General Moving Forward",2018-07-06 08:16:00-04:00,BIIB,positive
162040.0,"STAT News' Adam Feuerstein Is Currently Discussing Biogen's Alzheimer's News On Benzinga's PreMarket Prep; Is Urging Caution, Sees This 'as a sliver of good news'",2018-07-06 08:11:00-04:00,BIIB,positive
162041.0,18 Stocks Moving In Friday's Pre-Market Session,2018-07-06 08:05:00-04:00,BIIB,neutral
162042.0,STAT News' Adam Feuerstein Will Be On Benzinga's PreMarket Prep Morning Trade Show At 8:10 a.m. EDT; He'll Be Discussing The Big Biogen News; Tune In At premarket.benzinga.com,2018-07-06 08:04:00-04:00,BIIB,neutral
162043.0,"Benzinga's Daily Biotech Pulse: Biogen And Eisai's Alzheimer's Drug Meets End Points In Mid-Stage Trial, Obseva To List Shares On Swiss Exchange",2018-07-06 08:02:00-04:00,BIIB,positive
162044.0,A Peek Into The Markets: US Stock Futures Drop As US-China Trade War Begins,2018-07-06 07:21:00-04:00,BIIB,negative
162045.0,"Mizuho Earlier Noted Biogen, Eisai's BAN2401 Unexpectedly Hit In Phase 2 Trial, Said Expectations On Trial Were 'really low,' Sees Biogen Shares Being Up 10%+",2018-07-06 06:58:00-04:00,BIIB,positive
162046.0,Biogen Shares Up 13.8% Premarket After Data From Co.'s Phase II Study Of BAN2401 Showed Statistically Significant Slowing Of Clinical Decline In Early Alzheimer's Patients; Hearing Citi Upgraded To Buy,2018-07-06 06:20:00-04:00,BIIB,positive
162047.0,"Eisai, Biogen Announce Positive Topline Results Of The Final Analysis For BAN2401 At 18 Months in Early Alzheimer's Disease",2018-07-06 04:13:00-04:00,BIIB,positive
162048.0,"Barron's Picks And Pans: Apple, Mastercard, Sirius XM, Verizon And More",2018-06-30 18:02:00-04:00,BIIB,neutral
162049.0,"Biogen Exercises Option to Increase Ownership in Samsung Bioepis, Biogen Will Pay Samsung BioLogics ~$700M To Increase Its Ownership In Samsung Bioepis To ~49.9%; Transaction To Close 2H Of 2018",2018-06-28 16:09:00-04:00,BIIB,positive
162050.0,"Biogen To Report Q2 Earnings On Tues., Jul. 24, 2018 Before Market Opens",2018-06-25 16:03:00-04:00,BIIB,neutral
162051.0,"The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs",2018-06-25 14:00:00-04:00,BIIB,neutral
162052.0,"Samsung Bioepis and Biogen Announce Pooled Analysis Results of Anti-TNF Biosimilars BENEPALI, FLIXABI and IMRALDI",2018-06-13 08:04:00-04:00,BIIB,neutral
162053.0,Biogen Enters Exclusive Option Agreement To Acquire TMS' Phase 2 Asset For Acute Stroke; Co. To Pay $4M Upfront And $18M Upon Exercise Of Option And Potential Milestones Of Up To $335M,2018-06-07 07:32:00-04:00,BIIB,positive
162054.0,UPDATE: Alkermes Says May Also Receive $150M Milestone Payment From Biogen Upon FDA Approval Of NDA For BIIB098,2018-06-06 07:04:00-04:00,BIIB,positive
162055.0,Alkermes Reports Received $50M Payment From Biogen Related To Review Of Prelim. Gastrointestinal Tolerability Data From Ongoing BIIB098 Development Program,2018-06-06 07:04:00-04:00,BIIB,neutral
162056.0,Ionis Closes Strategic Collaboration With Biogen To Develop Drugs For Broad Range of Neurological Diseases; Biogen Paid Ionis $1B In Cash Including $625M For Purchase Of ~11.5M Shares Of Common Stock @ $54.34/Share And An Upfront Payment Of $375M,2018-06-05 16:01:00-04:00,BIIB,positive
162057.0,"Biogen, Eisai Report Phase II Study Of Elenbecestat Showed Safety, Tolerability In MCI, Mild To Moderate Alzheimer's Disease At 18 Months",2018-06-05 14:00:00-04:00,BIIB,positive
162058.0,"Benzinga's Daily Biotech Pulse: Mylan's Neulasta Biosimilar Approved, Portola's CEO To Retire, Regenxbio To Join S&P SmallCap Index",2018-06-05 08:05:00-04:00,BIIB,positive
162059.0,"Eisai, Merck Announce Data from Investigational Studies of Lenvima and Keytruda Combination Therapy in Four Different Tumor Types at #ASCO2018",2018-06-05 04:51:00-04:00,BIIB,negative
162060.0,"Eisai, Biogen Report PhaseII Clinical Study of Elenbecestat Demonstrate Safety and Tolerability in MCI and Mild to Moderate Alzheimer's Disease at 18-Months",2018-06-05 04:49:00-04:00,BIIB,positive
162061.0,"Canaccord Upgrades Biogen On Deal Opportunities, Alzheimer's Pipeline",2018-05-31 15:41:00-04:00,BIIB,positive
162062.0,Hearing RBC Says Allergan And Biogen Are Two Companies That Could Be Interested In Either Partnering Or Acquiring Alder Biophamraceuticals,2018-05-31 13:35:00-04:00,BIIB,positive
162063.0,"Benzinga's Top Upgrades, Downgrades For May 31, 2018",2018-05-31 09:23:00-04:00,BIIB,positive
162064.0,"The Market In 5 Minutes: Right To Try, Uber, Buffett, Jobless Claims And More",2018-05-31 09:00:00-04:00,BIIB,neutral
162065.0,A Peek Into The Markets: US Stock Futures Flat Ahead Of Economic Data,2018-05-31 07:46:00-04:00,BIIB,neutral
162066.0,Canaccord Genuity Upgrades Biogen to Buy,2018-05-31 06:14:00-04:00,BIIB,neutral
162067.0,"UPDATE: FDA Offers Guidelines, Background For Reference Listed Drug Access Inquiries, Related To Claim Of Blocking Generic Rivals",2018-05-17 12:38:00-04:00,BIIB,negative
162068.0,"FDA Commissioner Scot Gottlieb Highlights List Of Cos. Which Have Potentially Blocked Access To Samples Of Their Branded Products: Pfizer, Biogen, INSYS, VIVUS, Valeant, Corcept Therapeutics",2018-05-17 09:57:00-04:00,BIIB,negative
162069.0,8 Biggest Price Target Changes For Wednesday,2018-05-02 09:57:00-04:00,BIIB,neutral
162070.0,"Citigroup Maintains Neutral on Biogen, Lowers Price Target to $290.00",2018-05-02 07:58:00-04:00,BIIB,negative
162071.0,UPDATE: Biogen To Make 1-Time $50M Payment To Neurimmune In Exchange For 5% Reduction In Original Royalty Rates On Potential Commercial Sales Of Aducanumab,2018-05-01 07:33:00-04:00,BIIB,positive
162072.0,Biogen Reports Exercise Of Option To Further Reduce Royalty Rates On Potential Future Sales Of Aducanumab With Neurimmune,2018-05-01 07:33:00-04:00,BIIB,neutral
162073.0,"Insider Buys Of The Week: Apollo Global, Biogen And More",2018-04-29 09:26:00-04:00,BIIB,neutral
162074.0,"Baird: Biogen A Buy On M&A Prospects, Underappreciated Franchises",2018-04-25 12:11:00-04:00,BIIB,positive
162075.0,"Benzinga's Top Upgrades, Downgrades For April 25, 2018",2018-04-25 09:36:00-04:00,BIIB,positive
162076.0,"Morgan Stanley Maintains Overweight on Biogen, Raises Price Target to $369.00",2018-04-25 09:04:00-04:00,BIIB,negative
162077.0,Baird Upgrades Biogen to Outperform,2018-04-25 07:29:00-04:00,BIIB,neutral
162078.0,"'Cowen defending $BIIB. ""We haven't seen a quality name this inexpensive in awhile.'",2018-04-24 12:31:00-04:00,BIIB,neutral
162079.0,"Biogen Q1 Adj. EPS $6.05 Beats $5.94 Est., Sales $3.131B Misses $3.16B",2018-04-24 06:59:00-04:00,BIIB,negative
162080.0,"Earnings Scheduled For April 24, 2018",2018-04-24 04:14:00-04:00,BIIB,neutral
162081.0,What's In Store For Biogen This Earnings Season?,2018-04-23 11:25:00-04:00,BIIB,neutral
162082.0,"The Week Ahead: Sohn Conference, FANG Earnings, DocuSign IPO",2018-04-23 10:44:00-04:00,BIIB,neutral
162083.0,Biogen Announces New data for SPINRAZA to Present at the American Academy of Neurology Event,2018-04-23 07:33:00-04:00,BIIB,neutral
162084.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-04-20 14:00:00-04:00,BIIB,neutral
162085.0,Benzinga Pro's 5 Stocks To Watch Today,2018-04-20 08:47:00-04:00,BIIB,neutral
162086.0,"Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases, Will Pay Ionis $1B In Cash Which Will Include $625M TO Purchase 11.5M Shares Of Ionis Stock At $54.34/Share",2018-04-20 06:33:00-04:00,BIIB,positive
162087.0,"Alnylam's President Talks Strategy To Become A Top Biotech Company, 'Developing An Entirely New Class Of Medicine'",2018-04-17 11:21:00-04:00,BIIB,positive
162088.0,"Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More",2018-04-11 14:31:00-04:00,BIIB,neutral
162089.0,Mizuho: Samsung Bioepis Renegotiation 'A Positive' For Biogen,2018-04-11 12:09:00-04:00,BIIB,positive
162090.0,"UPDATE: Mizuho Says Alleged Negotiation Between Biogen, Samsung 'hasn't hit many investors' inboxes...so we're putting everything here'",2018-04-11 10:54:00-04:00,BIIB,neutral
162091.0,UPDATE: Mizuho Highlights Business Korea Article Describing Samsung Group Negotiation With Biogen To Buy Stake Or Part Of Samsung Bioepis,2018-04-11 10:53:00-04:00,BIIB,neutral
162092.0,UPDATE: Mizuho On Biogen Says Sees Business Korea Article As Seemingly 'Potential Upside Catalyst For BIIB',2018-04-11 10:52:00-04:00,BIIB,neutral
162093.0,"Biogen Shares Up 1.3%; Asian Publications Overnight Discussed 'Samsung Begins Talks with Biogen to secure control of biosimilar joint venture'; BZ NOTE: Biogen Announced Last Thurs. Commercialization Deal With Samsung Bioepis, AbbVie For IMRALDI",2018-04-11 10:51:00-04:00,BIIB,positive
162094.0,"Biogen Shares Spike Over $268 Level, Up 0.5% Over Last Few Mins. As Traders Circulate Word Mizuho Believes Stock Should Be Up $11-$20 On News Out Of Korea",2018-04-11 10:47:00-04:00,BIIB,positive
162095.0,"Benzinga's Top Upgrades, Downgrades For April 5, 2018",2018-04-05 09:23:00-04:00,BIIB,positive
162096.0,"UPDATE: Biogen Says Expects To Launch IMRALDI In Europe On Oct. 16, 2018",2018-04-05 08:08:00-04:00,BIIB,neutral
162097.0,"Biogen, Samsung Bioepis Reach Deal With AbbVie For Commercialization Of IMRALDI In Europe",2018-04-05 08:06:00-04:00,BIIB,neutral
162098.0,Barclays Downgrades Biogen to Equal-Weight,2018-04-05 06:39:00-04:00,BIIB,neutral
162099.0,Biogen Shares Spike ~$1.20 Higher Over Last Min. As Traders Circulate Questionable Takeover Chatter In Name; Stock Showing Resistance At $268 Level,2018-04-03 09:48:00-04:00,BIIB,neutral
162100.0,"Biogen To Report Q1 Earnings Tues., Apr. 24 Before Market Open",2018-03-28 16:05:00-04:00,BIIB,neutral
162101.0,Biogen to Acquire a Phase 2b Ready Asset for Cognitive Impairment from Pfizer for $75M Upfront and Up to $515M in Milestones and Royalties,2018-03-12 07:34:00-04:00,BIIB,positive
162102.0,Don't Bail On Biotech ETFs: 'There Are Several Reasons Why The Sector Took A Breather',2018-03-09 11:28:00-05:00,BIIB,neutral
162103.0,Height Casts 65% Odds That Congress Rolls Back Pharma Discounts,2018-03-07 11:31:00-05:00,BIIB,neutral
162104.0,5 Biggest Price Target Changes For Monday,2018-03-05 10:00:00-05:00,BIIB,neutral
162105.0,"BMO Capital Maintains Outperform on Biogen, Lowers Price Target to $393.00",2018-03-05 08:16:00-05:00,BIIB,negative
162106.0,Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA for Relapsing Multiple Sclerosis,2018-03-02 06:26:00-05:00,BIIB,neutral
162107.0,"Biogen Shares Up 0.1% Wed.; Credit Suisse Earlier Commented On Celgene's Ozanimod News, Said, 'we would also view this as an incremental positive for Biogen, since it's a delay for a competitor'",2018-02-28 11:16:00-05:00,BIIB,positive
162108.0,"Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More",2018-02-18 14:16:00-05:00,BIIB,neutral
162109.0,"Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs",2018-02-16 09:37:00-05:00,BIIB,neutral
162110.0,"Benzinga's Top Upgrades, Downgrades For February 16, 2018",2018-02-16 09:21:00-05:00,BIIB,positive
162111.0,Argus Downgrades Biogen to Hold,2018-02-16 07:40:00-05:00,BIIB,neutral
162112.0,RBC Issues Negative Comments On Biogen In Mid-Day Note Following Variability Comment On Alzheimer's Treatment: 'highlights the inherent challenges in Alzheimer's studies and risks to this outcome',2018-02-14 15:09:00-05:00,BIIB,negative
162113.0,"STAT News' Adam Feuerstein Tweets '...$BIIB told investors at the Leerink conference 510 Alzheimer's patients are being added to the aducanumab clinical trial due to ""increased variability."" Stock reacting negatively to this selective disclosure'",2018-02-14 15:03:00-05:00,BIIB,positive
162114.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,BIIB,neutral
162115.0,The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease,2018-02-08 09:41:00-05:00,BIIB,negative
162116.0,Biogen Misses Primary and Secondary Efficacy Endpoints in its ACTION 2 Study for Natalizumab,2018-02-07 07:34:00-05:00,BIIB,negative
162117.0,"Mizuho Maintains Buy on Biogen, Raises Price Target to $433.00",2018-02-05 07:39:00-05:00,BIIB,neutral
162118.0,"UBS: Buy Biogen For Pipeline, M&A Potential",2018-01-31 09:29:00-05:00,BIIB,neutral
162119.0,"Benzinga's Top Upgrades, Downgrades For January 31, 2018",2018-01-31 09:21:00-05:00,BIIB,positive
162120.0,UBS Upgrades Biogen to Buy,2018-01-31 07:36:00-05:00,BIIB,neutral
162121.0,Here's Why Forward Pharma Lost 30% Today,2018-01-29 13:17:00-05:00,BIIB,negative
162122.0,5 Biggest Price Target Changes For Friday,2018-01-26 10:29:00-05:00,BIIB,neutral
162123.0,44 Biggest Movers From Yesterday,2018-01-26 04:43:00-05:00,BIIB,neutral
162124.0,Benzinga Pro's 4 Stocks To Watch Today,2018-01-25 09:11:00-05:00,BIIB,neutral
162125.0,Biogen to Acquire Karyopharm's KPT-350 for $10M Upfront an Up to An Additional $207M in Milestones and Royalties,2018-01-25 06:43:00-05:00,BIIB,neutral
162126.0,"Biogen Sees FY18 Adj. EPS $24.20 to $25.20 vs $24.16 Est., Sales $12.7B to $13.0B vs $12.7B Est.",2018-01-25 06:30:00-05:00,BIIB,neutral
162127.0,"Biogen Reports Q4 EPS $5.26 vs $5.45 Est., Sales $3.31B vs $3.08B Est.",2018-01-25 06:30:00-05:00,BIIB,neutral
162128.0,"Earnings Scheduled For January 25, 2018",2018-01-25 04:41:00-05:00,BIIB,neutral
162129.0,Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer,2018-01-24 11:40:00-05:00,BIIB,positive
162130.0,Biotech M&A Off To A Strong Start In 2018: More Deals To Follow?,2018-01-23 10:58:00-05:00,BIIB,positive
162131.0,"The Week Ahead: IPOs, Earnings, And FDA Actions Provide Catalysts",2018-01-22 15:35:00-05:00,BIIB,neutral
162132.0,34 Biggest Movers From Friday,2018-01-22 04:30:00-05:00,BIIB,neutral
162133.0,28 Stocks Moving In Friday's Mid-Day Session,2018-01-19 13:00:00-05:00,BIIB,neutral
162134.0,14 Stocks Moving In Friday's Pre-Market Session,2018-01-19 09:22:00-05:00,BIIB,neutral
162135.0,Benzinga Pro's 6 Stocks To Watch Today,2018-01-19 08:40:00-05:00,BIIB,neutral
162136.0,"Acorda Therapeutics Shares Indicated Up 8.8% Premarket Fri. Following Renewed Takeover Chatter; Thurs. Stock Rallied As Much As ~7%, Only to Sell Off During Afternoon Session; Report Fri. Morning Suggests Biogen, UCB Are Interested",2018-01-19 07:32:00-05:00,BIIB,positive
162137.0,The 10 Most Undervalued Stocks Kicking Off Earnings Season,2018-01-16 08:49:00-05:00,BIIB,neutral
162138.0,"JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma",2018-01-08 09:00:00-05:00,BIIB,positive
162139.0,BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A,2018-01-05 17:31:00-05:00,BIIB,positive
162140.0,"Biogen To Report Q4 Earnings Thurs., Jan 25 Before Market Open",2018-01-04 16:02:00-05:00,BIIB,neutral
162141.0,Biogen Issues Response To Coverage Recommendation By CDEC For SPINRAZA,2017-12-22 16:13:00-05:00,BIIB,neutral
162142.0,On Today's PreMarket Prep: An Interview With The CME's Tim McCourt On Bitcoin Futures,2017-12-21 07:58:00-05:00,BIIB,neutral
162143.0,"UPDATE: Biogen, Eisai Say, 'Study to Remain Blinded Per Protocol until Final Readout of Comprehensive 18-Month Data'",2017-12-21 07:03:00-05:00,BIIB,positive
162144.0,"UPDATE: Biogen, Eisai Say, 'Criteria for Success at 12-Month Analysis of ADCOMS Not Met'",2017-12-21 07:03:00-05:00,BIIB,positive
162145.0,"Biogen, Eisai Report Adaptive Phase II Study Of BAN2401 In Early Alzhemier's Disease Continues Toward 18-Month Endpoint",2017-12-21 07:03:00-05:00,BIIB,neutral
162146.0,5 Stocks Moving In Wednesday's After-Hours Session,2017-12-20 17:07:00-05:00,BIIB,neutral
162147.0,"Biogen To Report Q4 Earnings Thurs., Jan. 25 Before Market Open",2017-12-20 16:01:00-05:00,BIIB,neutral
162148.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,BIIB,neutral
162149.0,"UPDATE: Ionis To Receive $25M Upfront Payment, Development, Regulatory Milestone Payments From Biogen",2017-12-19 16:13:00-05:00,BIIB,neutral
162150.0,Biogen Reports New Collaboration With Ionis Pharma For Identification Of Novel Therapies For Treatment Of Spinal Muscular Atrophy,2017-12-19 16:08:00-05:00,BIIB,positive
162151.0,Biogen Issues Response To INESSS Recommendation For SPINRAZA,2017-12-15 12:10:00-05:00,BIIB,neutral
162152.0,CMS Head Verma Says Agency Considering Ways To Curb Costs For Expensive New Medications,2017-11-30 16:47:00-05:00,BIIB,neutral
162153.0,"Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, Plans to Submit NDA in 2018",2017-11-27 07:04:00-05:00,BIIB,positive
162154.0,Biogen Names Jeff Capello CFO,2017-11-21 07:30:00-05:00,BIIB,neutral
162155.0,Steven Cohen's 6 Best Performing Stocks That Still Have Big Upside,2017-11-15 15:26:00-05:00,BIIB,positive
162156.0,Buybacks And Dividends In One ETF,2017-11-10 09:07:00-05:00,BIIB,neutral
162157.0,"Benzinga's Top Upgrades, Downgrades For November 9, 2017",2017-11-09 08:57:00-05:00,BIIB,positive
162158.0,"Oppenheimer Initiates Coverage On Biogen with Outperform Rating, Announces $350.00 Price Target",2017-11-09 08:50:00-05:00,BIIB,neutral
162159.0,A Big Biotech ETF Is About To Get Cheaper,2017-11-08 15:28:00-05:00,BIIB,neutral
162160.0,Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab,2017-11-02 07:45:00-04:00,BIIB,neutral
162161.0,"Benzinga's Top Upgrades, Downgrades For October 27, 2017",2017-10-27 09:11:00-04:00,BIIB,positive
162162.0,"Canaccord Genuity Initiates Coverage On Biogen with Hold Rating, Announces $340.00 Price Target",2017-10-27 06:52:00-04:00,BIIB,neutral
162163.0,It's A Bad Day For Biotechs,2017-10-26 10:30:00-04:00,BIIB,negative
162164.0,"Lightning Round: Jim Cramer Shares His Thoughts On Kroger, Corning And More",2017-10-26 07:23:00-04:00,BIIB,positive
162165.0,"BMO: Biogen's Risks Quickly Becoming Priced In, But This May Not Be The Bottom",2017-10-25 12:24:00-04:00,BIIB,negative
162166.0,"Benzinga's Top Upgrades, Downgrades For October 25, 2017",2017-10-25 09:12:00-04:00,BIIB,positive
162167.0,BMO Capital Upgrades Biogen to Outperform,2017-10-25 07:39:00-04:00,BIIB,neutral
162168.0,Biogen Announces Initiation of AFFINITY Phase 2 Trial for Opicinumab in MS,2017-10-25 03:50:00-04:00,BIIB,neutral
162169.0,Mid-Day Market Update: Dow Rises 175 Points; Identiv Shares Plunge,2017-10-24 12:09:00-04:00,BIIB,positive
162170.0,Adam Feuerstein Tweets: $BIIB blockbuster rare-disease therapy staggers after a strong start statnews.com/2017/10/24/bio… Spinraza $IONS w/ @damiangarde co-byline!,2017-10-24 10:27:00-04:00,BIIB,positive
162171.0,14 Technical Levels Discussed On Tuesday's PreMarket Prep,2017-10-24 10:08:00-04:00,BIIB,neutral
162172.0,"Guggenheim Initiates Coverage On Biogen with Buy Rating, Announces $402.00 Price Target",2017-10-24 09:16:00-04:00,BIIB,neutral
162173.0,"Biogen Earnings Release Included Collaboration Deal Update Showing Co. 'will now receive 55% of potential aducanumab profits in the U.S., 68.5% of profits in Europe, and 20% of profits in Japan'",2017-10-24 08:22:00-04:00,BIIB,positive
162174.0,"A Peek Into The Markets: U.S. Stock Futures Gain; McDonald's, General Motors Earnings In Focus",2017-10-24 07:15:00-04:00,BIIB,positive
162175.0,"Biogen Q3 EPS $6.31 vs $5.70 Est., Sales $3.08B vs $3.03B Est.",2017-10-24 07:01:00-04:00,BIIB,neutral
162176.0,Biogen to Pay Neurimmune Holding $150M for a 15% Reduction in Royalty Rates for Aducanumab,2017-10-24 06:41:00-04:00,BIIB,negative
162177.0,"Biogen, Eisai Expand Existing Collaboration Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab",2017-10-24 05:12:00-04:00,BIIB,positive
162178.0,"Earnings Scheduled For October 24, 2017",2017-10-24 04:09:00-04:00,BIIB,neutral
162179.0,"Biogen Bull Thesis Baked In, No Longer A Buy At Citi",2017-10-23 11:05:00-04:00,BIIB,negative
162180.0,"Benzinga's Top Upgrades, Downgrades For October 23, 2017",2017-10-23 09:19:00-04:00,BIIB,positive
162181.0,The Week Ahead: Earnings Season Starts In Earnest,2017-10-23 09:00:00-04:00,BIIB,positive
162182.0,Citigroup Downgrades Biogen to Neutral,2017-10-23 07:41:00-04:00,BIIB,neutral
162183.0,Biogen and Eisai Expand Existing Partnership Agreement to Develop and Commercialize Investigational Alzheimer's Disease Treatments Including Phase 3 Aducanumab,2017-10-23 07:18:00-04:00,BIIB,positive
162184.0,"PiperJaffray Assumes Biogen at Overweight, Announces price target $390.00",2017-10-23 07:17:00-04:00,BIIB,negative
162185.0,Biogen Offers Highlights From Efforts 'To Tackle MS' At ECTRIMS-ACTRIMS,2017-10-18 07:36:00-04:00,BIIB,neutral
162186.0,Biogen's Best-In-Class R&D Earn Makes It A Buy,2017-10-17 11:35:00-04:00,BIIB,neutral
162187.0,5 Biggest Price Target Changes For Tuesday,2017-10-17 09:45:00-04:00,BIIB,neutral
162188.0,"Benzinga's Top Upgrades, Downgrades For October 17, 2017",2017-10-17 09:25:00-04:00,BIIB,positive
162189.0,"The Market In 5 Minutes: Netflix, Goldman Sachs, And Morgan Stanley Keep The Earnings Beats Going",2017-10-17 09:18:00-04:00,BIIB,neutral
162190.0,A Peek Into The Markets: U.S. Stock Futures Flat; Goldman Sachs Earnings In Focus,2017-10-17 07:20:00-04:00,BIIB,neutral
162191.0,Mizuho Upgrades Biogen to Buy,2017-10-17 07:13:00-04:00,BIIB,neutral
162192.0,Stifel Nicolaus Upgrades Biogen to Buy,2017-10-17 06:36:00-04:00,BIIB,neutral
162193.0,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 12:52:00-04:00,BIIB,positive
162194.0,Life (Science) Lessons: The Hows And Whos To Play Biotech,2017-10-06 11:09:00-04:00,BIIB,positive
162195.0,Heaps Of Healthy Health Care ETFs,2017-10-06 10:02:00-04:00,BIIB,positive
162196.0,Biogen's Core Business Impresses While Potential Alzheimer's Catalyst Looms,2017-10-05 10:54:00-04:00,BIIB,positive
162197.0,"The Market In 5 Minutes: Shopify, Equifax And More",2017-10-05 09:55:00-04:00,BIIB,neutral
162198.0,"Benzinga's Top Upgrades, Downgrades For October 5, 2017",2017-10-05 09:26:00-04:00,BIIB,positive
162199.0,Biogen Reports SPINRAZA Data Showed Earlier Treatment Initiation Could Lead to Improved Motor Function Across Broad Population Of People Living With Spinal Muscular Atrophy,2017-10-05 07:31:00-04:00,BIIB,positive
162200.0,Morgan Stanley Upgrades Biogen to Overweight,2017-10-05 06:47:00-04:00,BIIB,negative
162201.0,Amgen Enters Into An Immuno-Oncology Partnership With CytomX,2017-10-04 12:29:00-04:00,BIIB,neutral
162202.0,"After Strong Q3, Vetr Issues Hold Downgrade On Biogen",2017-10-04 07:54:00-04:00,BIIB,positive
162203.0,"Biogen To Report Q3 Earnings On Tues., Oct. 24, Before Market Open",2017-09-26 16:03:00-04:00,BIIB,neutral
162204.0,"Benzinga's Top Upgrades, Downgrades For September 21, 2017",2017-09-21 09:14:00-04:00,BIIB,positive
162205.0,Raymond James Downgrades Biogen to Market Perform,2017-09-21 08:44:00-04:00,BIIB,neutral
162206.0,Biogen Spinoff Bioverativ Is A Buy,2017-09-20 10:51:00-04:00,BIIB,neutral
162207.0,"Benzinga's Top Upgrades, Downgrades For September 20, 2017",2017-09-20 09:12:00-04:00,BIIB,positive
162208.0,"SunTrust Robinson Humphrey Initiates Coverage On Biogen with Buy Rating, Announces $360.00 Price Target",2017-09-20 08:16:00-04:00,BIIB,neutral
162209.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,BIIB,neutral
162210.0,"Morgan Stanley Healthcare Conference Begins Today, Presenters Include: Veeva Systems, Quorum Health, Neurocrine Biosciences, Vertex Pharma, Merck, Ocular Therapeutix, Biogen, Gilead, and Bristol-Myers",2017-09-11 09:15:00-04:00,BIIB,neutral
162211.0,Why It's Useful To Know A Company's Competitors When Trading,2017-09-05 11:26:00-04:00,BIIB,positive
162212.0,Biogen Says Aducanumab Phase 1b Study Supports Ongoing Phase 3 Studies,2017-08-28 07:31:00-04:00,BIIB,positive
162213.0,"Democrats On House Committe On Oversight & Govt. Reform Say Launching Into MS Drug Pricing, Committee Send Letters To Biogen, Teva, Sanofi, Roche, Novartis, And Bayer",2017-08-17 11:17:00-04:00,BIIB,neutral
162214.0,Goldman Sachs Adds Biogen to Conviction Buy,2017-08-16 08:01:00-04:00,BIIB,neutral
162215.0,Meg Tirrell Tweets: And what $IONS says of the $BIIB @CSHL relationships in its last 10K sec.gov/Archives/edgar…,2017-08-02 11:30:00-04:00,BIIB,neutral
162216.0,"CNBC's Meg Tirrell Tweets: I don't see the specifics laid out anywhere. 2012 $BIIB $IONS  announcement just cited ""double-digit royalties"" newsroom.biogen.com/press-release/…",2017-08-02 11:24:00-04:00,BIIB,neutral
162217.0,CNBC's Meg Tirrell Tweets: Cuban calls for pressure on $BIIB & $IONS CEOs for Spinraza price $IBB,2017-08-02 11:20:00-04:00,BIIB,negative
162218.0,CNBC's Meg Tirrell Tweets: .@mcuban is tweeting about biotech and drug pricing ,2017-08-02 11:00:00-04:00,BIIB,neutral
162219.0,3 ETFs To Watch Out For On Biotech Earnings,2017-08-01 12:41:00-04:00,BIIB,neutral
162220.0,"19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug",2017-07-26 10:09:00-04:00,BIIB,positive
162221.0,5 Biggest Price Target Changes For Wednesday,2017-07-26 09:56:00-04:00,BIIB,neutral
162222.0,"Benzinga's Top Upgrades, Downgrades For July 26, 2017",2017-07-26 09:25:00-04:00,BIIB,positive
162223.0,The Market In 5 Minutes,2017-07-26 09:03:00-04:00,BIIB,neutral
162224.0,"A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Earnings, Fed Decision",2017-07-26 07:13:00-04:00,BIIB,neutral
162225.0,Goldman Sachs Upgrades Biogen to Buy,2017-07-26 06:56:00-04:00,BIIB,neutral
162226.0,Biogen 10-Q Just Out; Prosecution Office of Milan Investigates Biogen For Interactions With Italian Health-Care Providers,2017-07-25 16:37:00-04:00,BIIB,negative
162227.0,Biogen Surrenders All Early Gains After Q2 Beat And Raise,2017-07-25 12:38:00-04:00,BIIB,positive
162228.0,Adam Feurestein Tweets: $BIIB is shopping for neuroscience drug assets. Here's a target list —>  statnews.com/2017/07/25/bio…,2017-07-25 10:32:00-04:00,BIIB,positive
162229.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-07-25 08:24:00-04:00,BIIB,neutral
162230.0,Biogen On Conf. Call Says It's 'Making Progress' In Search For A New CFO To Replace Paul Clancy,2017-07-25 08:14:00-04:00,BIIB,positive
162231.0,"Biogen Raises FY 2017 Guidance, Sees EPS $20.80-$21.40 from $20.45-$21.25 vs $20.38 Est., Sees Sales $11.5B-$11.8B from $11.1B-$11.4B vs $11.4B Est",2017-07-25 06:32:00-04:00,BIIB,neutral
162232.0,"Biogen Q2 EPS $5.04 vs $4.41 Est., Sales $3.08B vs $2.81B Est.",2017-07-25 06:30:00-04:00,BIIB,neutral
162233.0,"Earnings Scheduled For July 25, 2017",2017-07-25 05:52:00-04:00,BIIB,neutral
162234.0,2 Ways To Trade This Week's Healthcare Earnings,2017-07-24 11:51:00-04:00,BIIB,neutral
162235.0,"Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock",2017-07-17 12:52:00-04:00,BIIB,positive
162236.0,"Benzinga's Top Upgrades, Downgrades For July 11, 2017",2017-07-11 09:27:00-04:00,BIIB,positive
162237.0,"Jefferies Assumes Biogen at Hold, Announces price target $310.00",2017-07-11 07:44:00-04:00,BIIB,neutral
162238.0,The Royalty-Amassing Strategy Of Royalty Pharma,2017-07-10 16:11:00-04:00,BIIB,neutral
162239.0,Cowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up,2017-07-10 14:54:00-04:00,BIIB,positive
162241.0,Biogen Issues Release Highlighting New Data Reaffirmed Clinically Meaningful Benefit Of SPINRAZA For Spinal Muscular Atrophy Across Disease Severity,2017-06-29 07:31:00-04:00,BIIB,positive
162242.0,Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold,2017-06-23 09:54:00-04:00,BIIB,neutral
162243.0,Biogen's IMRALDI Was Granted Positive Opinion by Committee for Medicinal Products for Human Use,2017-06-23 08:02:00-04:00,BIIB,positive
162244.0,"Deutsche Bank Initiates Coverage On Biogen with Buy Rating, Announces $315.00 Price Target",2017-06-23 07:28:00-04:00,BIIB,neutral
162245.0,Watching Biogen Shares Following Roche Press Release To Highlight Approval For RITUXAN HYCELA; BZ NOTE: Biogen Holds A Trademark For Roche Product,2017-06-22 14:22:00-04:00,BIIB,positive
162246.0,"Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma",2017-06-22 07:06:00-04:00,BIIB,neutral
162247.0,"ACADIA Pharma Shares Spike ~$0.90 Over Last Min, Now Pulling Back From Session Highs; Traders Circulating Chatter Of Biogen Interest",2017-06-21 10:09:00-04:00,BIIB,positive
162249.0,The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It,2017-06-19 15:16:00-04:00,BIIB,positive
162250.0,"Benzinga's Top Upgrades, Downgrades For June 19, 2017",2017-06-19 09:31:00-04:00,BIIB,positive
162251.0,The Market In 5 Minutes,2017-06-19 09:07:00-04:00,BIIB,neutral
162252.0,UBS Upgrades Biogen to Neutral,2017-06-19 06:22:00-04:00,BIIB,neutral
162254.0,"C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen",2017-06-15 09:26:00-04:00,BIIB,negative
162257.0,Biogen CFO Paul Clancy To Leave Co. For 'Another Biopharmaceutical Company',2017-06-13 16:15:00-04:00,BIIB,negative
162258.0,"Biogen Shares Volatile Over Last Min, Briefly Pullback from Afternoon Highs as Traders Circulating FDA.gov Link Listing Tecfidera with Paragraph IV Patent Certification",2017-06-05 12:30:00-04:00,BIIB,positive
162259.0,Ionis Pharma Reports Earning of $50M Milestone Payment from Biogen Following EC Marketing Authorization for SPINRAZA,2017-06-01 07:47:00-04:00,BIIB,neutral
162260.0,Biogen Reports EC Has Granted Marketing Authorization for SPINRAZA for Treatment of 5q SMA,2017-06-01 07:31:00-04:00,BIIB,positive
162261.0,"Bernstein Strategic Decisions Conference Begins Today, Presenters Include: Eli Lilly, Clorox, Celgene, Discovery Communications, Mastercard, Biogen, Nasdaq, Motorola, And Yum Brands",2017-05-31 09:32:00-04:00,BIIB,neutral
162262.0,"Q1 Seasonality In The Pharma/Biotech Space: What It Is, Why It Happens And Who Is Affected",2017-05-24 11:02:00-04:00,BIIB,negative
162263.0,"Biogen Reports Purchase of Remedy Pharma's CIRARA for Upfront Payment of $120M Plus Added Milestone Payments, Royalties",2017-05-18 09:07:00-04:00,BIIB,neutral
162264.0,Biogen Acquires Remedy Pharmaceuticals' CIRARA for Large Hemispheric Stroke For $120M In Upfront Payment Plus Potential Milestone And Royalty Payments,2017-05-15 07:38:00-04:00,BIIB,neutral
162265.0,A New Active Alternative For Equity Exposure,2017-05-05 08:29:00-04:00,BIIB,positive
162266.0,"With House Vote, Trump And GOP Cheer As Obamacare Officially Begins Roll-Back Process",2017-05-04 16:30:00-04:00,BIIB,positive
162267.0,Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here',2017-05-01 09:24:00-04:00,BIIB,negative
162268.0,"Adam Feuerstein on Alzheimer's and the Market: 'Its an Exceedingly Difficult Disease to Treat,' Highlights Biogen as 'the Next Big Co. Which Will Have Results from a Phase 3 Trial,' But That Won't Be Til 2019",2017-05-01 08:16:00-04:00,BIIB,negative
162269.0,"Forward Pharma A/S Offers Update on Strategic Focus, Related Initiatives to Reduce Operating, Personnel Costs Following Statement, License Deal with Biogen",2017-05-01 07:39:00-04:00,BIIB,neutral
162270.0,20 Biggest Mid-Day Gainers For Tuesday,2017-04-25 12:43:00-04:00,BIIB,neutral
162271.0,Biogen Gains After Q1 Beat,2017-04-25 12:00:00-04:00,BIIB,positive
162272.0,"Eying 6,000: Nasdaq Close To New Big Number As Relief Rally Seen Continuing",2017-04-25 10:47:00-04:00,BIIB,positive
162273.0,Adam Feuerstein Tweets: $BIIB says < $10M Spinraza sales were from inventory build.,2017-04-25 09:00:00-04:00,BIIB,neutral
162274.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-04-25 08:21:00-04:00,BIIB,neutral
162275.0,"Biogen Reports Q1 Adj. EPS $5.20 vs $5 Est., Sales $2.8B vs $2.74B Est.",2017-04-25 07:01:00-04:00,BIIB,neutral
162276.0,"Earnings Scheduled For April 25, 2017",2017-04-25 05:03:00-04:00,BIIB,neutral
162277.0,"Adam Feurestein Tweets: $BIIB Hopes New Spine Drug Data Convinces Insurers to Loosen Patient Access, Boosts Sales thestreet.com/story/14099459… via @TheStreet",2017-04-24 08:53:00-04:00,BIIB,positive
162278.0,"Biogen Reports Data Further Confirmed Strong Efficacy of TECFIDERA in Newly Diagnosed, Early Switch Patients",2017-04-24 07:32:00-04:00,BIIB,positive
162279.0,Biogen Reports Final Phase 3 Study Data Show SPINRAZA Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy,2017-04-24 07:31:00-04:00,BIIB,positive
162280.0,"Hearing Biogen Head of R&D, Michael Ehlers, Has Said More Deals for Drugs Are Expected",2017-04-21 14:50:00-04:00,BIIB,neutral
162281.0,EMA Recommends Approval Of Biogen's Spinraza For Spinal Muscular Atrophy Drug,2017-04-21 13:26:00-04:00,BIIB,positive
162282.0,"Biogen Issues Release Highlighting Advances from Neurology Research Programs: TECFIDERA, TYSABRI Data Support Early Treatment to Improve MS Patient Outcomes, New SPINRAZA® Data Show Robust Efficacy and Safety Across a Broad Range of Individuals with SMA",2017-04-18 07:33:00-04:00,BIIB,positive
162283.0,A Peek Into The Markets: U.S. Stock Futures Mostly Lower Ahead Of Initial Jobless Claims Report,2017-04-13 07:30:00-04:00,BIIB,negative
162284.0,UPDATE: Bristol-Myers Says Will Receive Combined $470M Upfront,2017-04-13 07:00:00-04:00,BIIB,neutral
162285.0,"Bristol-Myers Squibb Reports Separate Deals with Biogen, Roche to License Anti-eTau, Anti-Myostatin Compounds, Respectively",2017-04-13 06:59:00-04:00,BIIB,positive
162286.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,BIIB,negative
162287.0,Mid-Afternoon Market Update: Dow Drops 50 Points; TRC Companies Shares Spike Higher,2017-03-31 14:46:00-04:00,BIIB,positive
162288.0,"Acorda Issues Press Release Confirming US District Court Decision to Invalidate 4 AMPYRA Patents, Says Co. Will Appeal Ruling",2017-03-31 12:31:00-04:00,BIIB,neutral
162289.0,Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient,2017-03-31 12:15:00-04:00,BIIB,neutral
162290.0,"BZ NOTE: Forward Pharma Has Been Arguing Its Patent On dimethyl fumarate (DMF), Which Is The Active Ingredient In Tecfidera, Was filed Before Biogen's; Forward Is Claiming Royalty Rights To Drug Via Patent Dispute",2017-03-31 11:55:00-04:00,BIIB,negative
162291.0,Biogen Spikes to High of $275 on Volume,2017-03-31 11:35:00-04:00,BIIB,neutral
162292.0,Argus Initiates Bioverativ With Hold,2017-03-31 10:43:00-04:00,BIIB,neutral
162293.0,Diplomat Pharmacy Reports Will Dispense OCREVUS to Treat MS,2017-03-29 16:33:00-04:00,BIIB,positive
162294.0,Earlier FDA.gov Release Confirmed FDA Approval of Biogen's Ocrevus,2017-03-29 09:59:00-04:00,BIIB,positive
162295.0,"Adam Feuerstein Tweets: Tomorow's FDA drug approval decision will be Roche Ocrevus in MS. (Also affecting $BIIB)

Wednesday — $REGN $SNY Dupixent in eczema.",2017-03-27 16:31:00-04:00,BIIB,positive
162296.0,"Hearing Biogen Prevails In Kyle Bass IPR Challenge of Tecfidera '514 Patent Claim, Upheld In Final Written Decision",2017-03-21 10:19:00-04:00,BIIB,positive
162297.0,Biogen Spikes to $279.50 on Volume,2017-03-21 10:18:00-04:00,BIIB,neutral
162298.0,Get Ready For A Slew of Data As Weekend Nears,2017-03-17 10:29:00-04:00,BIIB,positive
162299.0,AC Immune Says Entered R&D Collaboration in Neurodegenerative Diseases with Biogen,2017-03-17 06:56:00-04:00,BIIB,positive
162300.0,18 Biggest Mid-Day Losers For Thursday,2017-03-16 13:10:00-04:00,BIIB,negative
162301.0,Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher,2017-03-16 12:17:00-04:00,BIIB,negative
162302.0,Biogen's Catalysts May Be Waning; Leerink Downgrades To Market Perform,2017-03-16 10:41:00-04:00,BIIB,neutral
162303.0,7 Biggest Price Target Changes For Thursday,2017-03-16 10:06:00-04:00,BIIB,neutral
162304.0,"Morgan Stanley Takes A Breather On Biogen, Downgrades Stock",2017-03-16 09:32:00-04:00,BIIB,neutral
162305.0,"Benzinga's Top Upgrades, Downgrades For March 16, 2017",2017-03-16 09:30:00-04:00,BIIB,positive
162306.0,The Market In 5 Minutes,2017-03-16 09:25:00-04:00,BIIB,neutral
162307.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-03-16 08:36:00-04:00,BIIB,neutral
162308.0,Leerink Swann Downgrades Biogen To Market Perform,2017-03-16 06:20:00-04:00,BIIB,neutral
162309.0,"Morgan Stanley Downgrades Biogen To Equal-Weight, Lowers Price Target To $305",2017-03-16 06:19:00-04:00,BIIB,negative
162310.0,Icahn's (Potential) Move Into Biotech,2017-03-04 19:25:00-05:00,BIIB,neutral
162311.0,Why Perrigo Is Divesting Rights To The Best Multiple Sclerosis Drug,2017-03-02 15:38:00-05:00,BIIB,positive
162312.0,Ionis Shares Pop As Aetna Adds Spinraza To Precertification List,2017-02-28 16:04:00-05:00,BIIB,positive
162313.0,"Ionis Shares Up 5.42%; Ionis And Biogen's Spinraza Added To Aetna's Precertification List, Aetna Spokesperson Tells Benzinga 'Appearance on this list does not indicate one way or the other what the clinical policy will be.'",2017-02-28 14:07:00-05:00,BIIB,positive
162314.0,Carl Icahn's Track Record In Big Pharma,2017-02-24 09:40:00-05:00,BIIB,neutral
162315.0,Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market',2017-02-23 14:06:00-05:00,BIIB,positive
162316.0,"After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?",2017-02-16 16:13:00-05:00,BIIB,negative
162317.0,Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One,2017-02-16 10:43:00-05:00,BIIB,neutral
162318.0,"Leerink Partners Global Healthcare Conference Began Today; Presenters Include Mannkind, Universal Health Services, Celgene, Inogen, Endologix, Biogen, GW Pharma, Regulus, Fate Therapeutics, Puma Biotech, Allergan, Bristol Myers And Synergy Pharma",2017-02-15 10:29:00-05:00,BIIB,neutral
162319.0,Key Presenters At Leerink's Healthcare Conference,2017-02-13 15:52:00-05:00,BIIB,neutral
162320.0,"Forward Pharma Reports Received $1.25B Pursuant to Settlement, License Deal with Biogen",2017-02-09 08:31:00-05:00,BIIB,neutral
162321.0,Humana To Only Cover Ionis Spinraza For Type 1 SMA and Will Be Medically Necessary When Certain Criteria Is Met,2017-02-08 10:10:00-05:00,BIIB,positive
162322.0,"Benzinga's Top Upgrades, Downgrades For February 8, 2017",2017-02-08 09:51:00-05:00,BIIB,positive
162323.0,Citigroup Upgrades Biogen To Buy,2017-02-08 08:00:00-05:00,BIIB,neutral
162324.0,Biogen's Slow Rebound Prompts A Vetr Downgrade,2017-02-07 16:53:00-05:00,BIIB,neutral
162325.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2017",2017-02-07 09:30:00-05:00,BIIB,positive
162326.0,"The Market In 5 Minutes: GM And Gap Earnings, Retail Sales Data",2017-02-07 09:04:00-05:00,BIIB,neutral
162327.0,A Peek Into The Markets: U.S. Stock Futures Climb Ahead Of General Motors Earnings,2017-02-07 07:09:00-05:00,BIIB,neutral
162328.0,Citigroup Upgrades Biogen To Buy,2017-02-07 06:34:00-05:00,BIIB,neutral
162329.0,Chardan Analyst Suggests An AveXis-Ionis Pair Trade,2017-02-06 10:41:00-05:00,BIIB,neutral
162330.0,Hemophilia Fighter Bioverativ Launches On NASDAQ,2017-02-02 15:41:00-05:00,BIIB,positive
162331.0,Ionis Earns $5 Million Milestone Payment from Biogen For Advancing Program Under Neurology Strategic Partnership,2017-02-02 07:05:00-05:00,BIIB,neutral
162332.0,Taking A Clinical Road Less Traveled: Neurotrope Hopes To Succeed In Alzheimer's Where Competitors Fail,2017-01-30 14:04:00-05:00,BIIB,positive
162333.0,"Biogen Higher After Mixed Q4 Report, Lower Guidance",2017-01-26 11:53:00-05:00,BIIB,negative
162334.0,Q4 2016 Real-Time Call Brief,2017-01-26 09:16:00-05:00,BIIB,neutral
162335.0,"Adam Feuerstein Tweets: $BIIB call: Striking to me, no questions about drug pricing, particularly co.'s habit of raising price of old MS drugs multiple times/yr.",2017-01-26 09:04:00-05:00,BIIB,negative
162336.0,Biogen Says Patients Enrolling Ahead Of Expectations For Phase 3 Aducanumab Alzheimer's Trial,2017-01-26 08:22:00-05:00,BIIB,neutral
162337.0,"Biogen Sees FY 2017 EPS $20.45 to $21.25 vs $21.02 Est, Revenue $11.1B to $11.4B vs $12.07B Est",2017-01-26 06:31:00-05:00,BIIB,neutral
162338.0,"Biogen Q4 EPS $5.04 vs $4.96 Est, Revenue $2.87B vs $2.94B Est",2017-01-26 06:30:00-05:00,BIIB,neutral
162339.0,"Earnings Scheduled For January 26, 2017",2017-01-26 06:03:00-05:00,BIIB,neutral
162340.0,UPDATE: Bernstein on Biogen Says Would Not Be Surprised to See Near-Term Pressure on Shares as News on Tecfidera Label Change Over the Weekend Becomes Known,2017-01-25 12:38:00-05:00,BIIB,negative
162341.0,Biogen Shares Pullback from Highs as Bernstein Cautious Amid Tecfidera Label Change,2017-01-25 12:37:00-05:00,BIIB,positive
162342.0,"STAT News Reports, Consumer Group Will Urge Feds To Take Patents For A Pricey New Biogen Drug",2017-01-24 11:11:00-05:00,BIIB,neutral
162343.0,"The Street's Adam Feuerstein Posts Story, Says 5 Reasons Celgene Should Buy Biogen",2017-01-23 11:25:00-05:00,BIIB,neutral
162344.0,Don't Get Too Excited About Biogen's Q4 Earnings,2017-01-20 13:20:00-05:00,BIIB,negative
162345.0,Orphan Drugs Among 2015's Top 10 Best-Selling Medications,2017-01-18 10:40:00-05:00,BIIB,positive
162346.0,15 Biggest Mid-Day Gainers For Tuesday,2017-01-17 12:43:00-05:00,BIIB,neutral
162347.0,Mid-Day Market Update: Clayton Williams Energy Surges On Acquisition News; Christopher & Banks Shares Slide,2017-01-17 12:17:00-05:00,BIIB,positive
162348.0,"Forward Pharma Reports Deal to Settle, License with Biogen; Biogen Will Pay Forward Non-Refundable Cash Fee of $1.25B",2017-01-17 11:02:00-05:00,BIIB,negative
162349.0,Mid-Morning Market Update: Markets Open Lower; Morgan Stanley Tops Q4 Estimates,2017-01-17 09:57:00-05:00,BIIB,positive
162350.0,18 Stocks Moving In Tuesday's Pre-Market Session,2017-01-17 08:17:00-05:00,BIIB,neutral
162351.0,Biogen to Pay $1.25B to FOrward Pharma Intellectual Property for License Agreement,2017-01-17 07:33:00-05:00,BIIB,positive
162352.0,Biogen Spin-off to Begin Trading on a When Issue Basis Under Ticker BIVVV,2017-01-12 08:06:00-05:00,BIIB,neutral
162353.0,All The Markets Trump Moved During His Speech Today,2017-01-11 15:51:00-05:00,BIIB,neutral
162354.0,Trump: Drug Industry Is 'Getting Away With Murder',2017-01-11 12:15:00-05:00,BIIB,negative
162355.0,"Watching Weakness In Amgen,Biogen, Gilead, Mylan, Pfizer And Other Biotechs After Pres. Elect Trump Negative Statement On Drug Pricing",2017-01-11 11:25:00-05:00,BIIB,negative
162356.0,Why Spinraza Is The Only Exciting Thing About Ionis Pharmaceuticals,2017-01-06 10:26:00-05:00,BIIB,positive
162357.0,"Biogen exercises option to enter exclusive, worldwide License Agreement for Factor IX utilizing Amunix' XTEN",2017-01-05 12:30:00-05:00,BIIB,positive
162358.0,TheStreet's Adam Feuerstein Recently Tweets Article Highlighting Call from RBC Analyst on Ionis-Biogen Drug Which Failed Due to Projectile Vomiting,2017-01-05 11:12:00-05:00,BIIB,negative
162359.0,Spinraza Cost Estimates Could Reignite The Drug Pricing Debate,2017-01-03 10:37:00-05:00,BIIB,neutral
162360.0,Hemispherx BioPharma CEO Explains Chronic Fatigue Syndrome And How The Company Is Treating It,2016-12-30 09:23:00-05:00,BIIB,negative
162361.0,"Biogen's Spinraza Could Cost $125,000 Per Dose",2016-12-29 11:43:00-05:00,BIIB,neutral
162362.0,Ionis Pharma's Target Lifted To $68 Following More Favorable Spinraza Ramp Estimates,2016-12-29 10:35:00-05:00,BIIB,positive
162363.0,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 14:32:00-05:00,BIIB,positive
162364.0,Biogen Inc. Retreats From High After FDA Approval Of Spinraza,2016-12-27 12:11:00-05:00,BIIB,positive
162365.0,Why The Biogen-Ionis News Is A Boon For AveXis,2016-12-27 11:13:00-05:00,BIIB,neutral
162366.0,"Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis",2016-12-27 10:56:00-05:00,BIIB,positive
162367.0,Ionis Pharmaceuticals +8.6% Premarket @ $58; FDA Said on Friday it had Approved Spinraza to Treat Spinal Muscular Atrophy,2016-12-27 06:19:00-05:00,BIIB,positive
162368.0,"Biogen Says Effectiveness of Bioverativ as Independent Co. Expected to be Closed on Feb. 1, 2017",2016-12-22 16:38:00-05:00,BIIB,neutral
162369.0,"Biogen Approves Separation Of Bioverative Unit, Declares Special Dividend Related To Separation; Every 2 Shares Of Biogen Stock, Biogen Shareholders Will Receive One Bioverativ Stock",2016-12-20 16:04:00-05:00,BIIB,positive
162370.0,What Does Biogen's New CEO Mean For The Buyout Argument?,2016-12-20 10:58:00-05:00,BIIB,negative
162371.0,Biogen PR Confirms Michel Vounatsos as CEO,2016-12-19 16:20:00-05:00,BIIB,neutral
162372.0,Biogen to Name Chief Commercial Officer Michel Vounatsos as CEO -Reuters,2016-12-19 15:57:00-05:00,BIIB,neutral
162373.0,Hearing Biogen Will Name Chief Commercial Officer Michael Vounatsos as CEO,2016-12-19 15:56:00-05:00,BIIB,neutral
162374.0,"Benzinga's Top Upgrades, Downgrades For December 16, 2016",2016-12-16 09:02:00-05:00,BIIB,positive
162375.0,"Cantor Fitzgerald Initiates Coverage On Biogen at Neutral, Announces $293.00 Target",2016-12-16 08:49:00-05:00,BIIB,neutral
162376.0,Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups,2016-12-15 11:03:00-05:00,BIIB,neutral
162377.0,"Adam Feuerstein Tweets: If $AVXS gene therapy works, it has significant advantages over $BIIB nusinersen. Data will tell us.",2016-12-14 15:46:00-05:00,BIIB,positive
162378.0,"Barron's Picks And Pans: Goodyear, Johnson & Johnson And More",2016-12-12 06:50:00-05:00,BIIB,neutral
162379.0,"Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher",2016-12-09 13:18:00-05:00,BIIB,positive
162380.0,Biogen CTAD Conf. Slides Say One Patient Taking aducanumab Had Treatment-Related Seizure With Loss of Pulse,2016-12-09 13:05:00-05:00,BIIB,negative
162381.0,"Biogen Shares Sell Off To Below $300 Level, Now Trading At $295.58/Share",2016-12-09 12:59:00-05:00,BIIB,positive
162382.0,Technical Alert: Biogen Inc. Higher Off Trial Results For Aducanumab,2016-12-09 12:07:00-05:00,BIIB,positive
162383.0,18 Stocks Moving In Friday's Pre-Market Session,2016-12-09 08:13:00-05:00,BIIB,neutral
162384.0,Biogen Presents Data from Phase 1b Study of Investigational Alzheimer's Disease Treatment Aducanumab at CTAD 2016,2016-12-09 04:18:00-05:00,BIIB,neutral
162385.0,Biogen Spikes On Leaked Data,2016-12-08 16:15:00-05:00,BIIB,negative
162386.0,"Bernstein Out Cautious On Biogen, Says Large Discontinuation Between Blind Stage And Open Label; Results Should Be Interpreted With Caution",2016-12-08 15:47:00-05:00,BIIB,negative
162387.0,"UPDATE: Biogen PRIME Results Show Slowing Of Decline On CDR-SB Was Statistically Significant With Titrated aducanumab vs. Placebo, Titration of aducanumab Appears To Reduce Incidence Of ARIA-E vs. Fixed Dosing In This Cohort",2016-12-08 15:08:00-05:00,BIIB,positive
162388.0,Biogen Results For PRIME Include Significant Decreases In Brain Amyloid Plaque Burden Were Observed With titrated aducanumab Compared With Placebo In 196 Patients With 31 Patients In titration Cohort,2016-12-08 15:06:00-05:00,BIIB,negative
162389.0,"Adam Feuerstein Tweets: Media are embargoed from disclosing $BIIB aducanumab data but I'm getting really close to breaking that.,…",2016-12-08 15:04:00-05:00,BIIB,neutral
162390.0,Adam Feuerstein Tweets: $BIIB — I believe updated and embargoed aducanumab titration data have leaked from CTAD conference. Stock ticking higher.,2016-12-08 15:00:00-05:00,BIIB,negative
162391.0,Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell,2016-12-05 15:55:00-05:00,BIIB,negative
162392.0,Biogen Announces Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE and ALPROLIX at ASH 2016,2016-12-03 14:54:00-05:00,BIIB,positive
162393.0,Reasons To Be Optimistic On Biogen's Alzheimer's Treatment Prospects,2016-11-25 10:12:00-05:00,BIIB,positive
162394.0,The Market In 5 Minutes: Black Friday Closes Shortened Trading Week,2016-11-25 09:33:00-05:00,BIIB,neutral
162395.0,Experts React To Concerning Alzheimer's News From Eli Lilly,2016-11-25 08:39:00-05:00,BIIB,neutral
162396.0,Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock,2016-11-23 13:22:00-05:00,BIIB,negative
162397.0,18 Biggest Mid-Day Losers For Wednesday,2016-11-23 13:06:00-05:00,BIIB,negative
162398.0,"Biotech Down In Early Trading: PDL BioPharma 15%, Eli Lilly 13%, Biogen, 6%, Cellectis, Insys 5.5%, Dynavax, Kite 5%",2016-11-23 10:02:00-05:00,BIIB,neutral
162399.0,"Credit Suisse Says Hard To Get Strong Read-Through Conclusions On Biogen From Lilly's Study Without More Details, Today's News Represents Negative Headline In A Time Where Positive Headlines Are Needed; Biotech Space Could Be Weak On This Headline News",2016-11-23 09:23:00-05:00,BIIB,positive
162400.0,"JP Morgan Highlighting Downside in Biogen Shares This Morning (Down ~8%) Related to Lilly's Alzheimer Drug News; Sees Transient 5-15% Move Lower in Biogen Shares, But Sees Possibility Stock Recovers",2016-11-23 09:21:00-05:00,BIIB,positive
162401.0,Eli Lilly's Solanezumab Failure Is Bad News For Biogen,2016-11-23 09:14:00-05:00,BIIB,negative
162402.0,"Morgan Stanley Calling For Biogen To End The Day Flat To Slightly Up Following Eli Lilly Data Results; Says aducanumab More Potent Than solanezumab, Believes Indication Of Activity/Trends Could Keep Amyloid Debate Alive",2016-11-23 09:00:00-05:00,BIIB,positive
162403.0,Raymond James Out Saying They Would Be Buyers of Biogen On Weakness Following Eli Lilly's Failed EXPEDITION 3 Trail; May Actually Be Clearing Event With Respect To Any Takeout,2016-11-23 08:57:00-05:00,BIIB,negative
162404.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-11-23 08:35:00-05:00,BIIB,neutral
162405.0,Can You Guess This Chart?,2016-11-23 07:36:00-05:00,BIIB,neutral
162406.0,Biogen -10.41% Premarket @$285 Following Lilly Trial Results,2016-11-23 07:30:00-05:00,BIIB,neutral
162407.0,"Adam Feuerstein Tweets: Worst thing: $LLY gamed sola study to win but still failed badly, which tells you these amyloid mAbs are weak drugs. Watch out, $BIIB",2016-11-23 07:23:00-05:00,BIIB,negative
162408.0,Can Trump Make Your Portfolio Great Again?,2016-11-09 11:27:00-05:00,BIIB,positive
162409.0,Benzinga's Top Initiations,2016-11-08 09:22:00-05:00,BIIB,positive
162410.0,"Mizuho Initiates Coverage On Biogen Inc. - Common Stock at Neutral, Announces $290.00",2016-11-08 05:42:00-05:00,BIIB,neutral
162411.0,18 Biggest Mid-Day Gainers For Monday,2016-11-07 12:27:00-05:00,BIIB,neutral
162412.0,Mid-Day Market Update: Dow Gains Over 300 Points; Concordia International Shares Drop Following Disappointing Earnings,2016-11-07 12:08:00-05:00,BIIB,negative
162413.0,Technical Alert: Biogen Inc. Higher Off Piper-Jaffray Upgrade,2016-11-07 11:33:00-05:00,BIIB,positive
162414.0,Leerink Swann Upgrades Biogen Inc. - Common Stock to Outperform,2016-11-07 10:49:00-05:00,BIIB,neutral
162415.0,Benzinga's Volume Movers,2016-11-07 10:37:00-05:00,BIIB,neutral
162416.0,Mid-Morning Market Update: Markets Open Higher; LendingClub Posts Narrower-Than-Expected Loss,2016-11-07 10:07:00-05:00,BIIB,negative
162417.0,The Market In 5 Minutes: Stock Futures Boosted By FBI's Latest Clinton News,2016-11-07 09:09:00-05:00,BIIB,positive
162418.0,"Biogen Is A Frustrating Case, And Piper Jaffray Hopes It Doesn't Regret Upgrade",2016-11-07 08:58:00-05:00,BIIB,positive
162419.0,Benzinga's Top Upgrades,2016-11-07 08:52:00-05:00,BIIB,positive
162420.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-07 08:34:00-05:00,BIIB,neutral
162421.0,Adam Feuerstein @adamfeuerstein Tweet: Piper's Josh Schimmer calls for $BIIB to buy $AVXS to defend the SMA franchise.,2016-11-07 08:24:00-05:00,BIIB,neutral
162422.0,Biogen and Ionis Pharmaceuticals Announce SPINRAZA Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy,2016-11-07 07:30:00-05:00,BIIB,positive
162423.0,PiperJaffray Upgrades Biogen Inc. - Common Stock to Overweight,2016-11-07 07:17:00-05:00,BIIB,negative
162424.0,"Biogen Reports Nusinersen Granted Priority Review by FDA, EMA Planning to Follow Accelerated Assessment Timeline",2016-10-28 07:32:00-04:00,BIIB,positive
162425.0,"Biogen Reports Q3 EPS $5.19 vs. Est. $4.97, Rev. $2.95B vs. Est. $2.9B",2016-10-26 06:59:00-04:00,BIIB,neutral
162426.0,"Earnings Scheduled For October 26, 2016",2016-10-26 04:02:00-04:00,BIIB,neutral
162427.0,"25 Stocks Which Rallied Four Days, Then Sold Off On Friday",2016-10-24 06:24:00-04:00,BIIB,neutral
162428.0,AC Immune Is An Alzheimer's Pure Play With A Lot On The Line,2016-10-18 11:15:00-04:00,BIIB,positive
162429.0,John Stumpf And 15 Major CEO Departures In 2016,2016-10-13 12:53:00-04:00,BIIB,neutral
162430.0,A Possible Trading Opportunity Presents Itself In Biogen's Approaching Phase 3 Results,2016-10-03 13:53:00-04:00,BIIB,positive
162431.0,Anavex Life Sciences Shares Experimenting With 2-Month Highs,2016-09-28 14:32:00-04:00,BIIB,positive
162432.0,Anavex Compound to be Tested in Biogen Neurological Protection Model,2016-09-28 07:04:00-04:00,BIIB,neutral
162433.0,Biogen Completes Rolling Submission of New Drug Application to FDA for Nusinersen as a Treatment for Spinal Muscular Atrophy,2016-09-26 07:30:00-04:00,BIIB,neutral
162434.0,Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers',2016-09-21 10:30:00-04:00,BIIB,positive
162435.0,"Biogen, AbbVie Presented Data at ECTRIMS Reinforce Efficacy of ZINBRYTA, Support Long-Term Safety Profile",2016-09-15 07:32:00-04:00,BIIB,positive
162436.0,"Biogen Reports TECFIDERA Treatment Significantly Reduced Time to First Relapse vs Glatiramer Acetate, Interferon ß, Teriflunomide, Showed Comparable Efficacy to Fingolimod",2016-09-14 07:31:00-04:00,BIIB,neutral
162437.0,Benzinga's Top Downgrades,2016-09-06 09:07:00-04:00,BIIB,positive
162438.0,The Market In 5 Minutes: Stocks Return Higher From Three-Day Weekend,2016-09-06 08:34:00-04:00,BIIB,neutral
162439.0,"Biogen Downgraded To Hold At Jefferies, Citing Valuation",2016-09-06 07:59:00-04:00,BIIB,neutral
162440.0,Biogen Expands Ophthalmology Partnership With BioMotive,2016-09-06 07:10:00-04:00,BIIB,positive
162441.0,Jefferies Downgrades Biogen to Hold,2016-09-06 01:43:00-04:00,BIIB,neutral
162442.0,Biogen's Aducanumab For Alzheimers Gets Fast Track Designation,2016-09-01 16:01:00-04:00,BIIB,neutral
162443.0,Nature Publishes Results from Pre-Clinical Research and Phase 1b Study of Biogen's Investigational Alzheimer's Disease Treatment Aducanumab,2016-08-31 13:17:00-04:00,BIIB,neutral
162444.0,"ETFs, Stocks See Dwindling Buyback Support",2016-08-17 13:15:00-04:00,BIIB,positive
162445.0,10 Biggest Price Target Changes For Wednesday,2016-08-17 10:01:00-04:00,BIIB,neutral
162446.0,Morgan Stanley Adjusts Their View Of Biogen After Spinoff,2016-08-17 09:17:00-04:00,BIIB,neutral
162447.0,"Jefferies Upgrades AveXis To Buy Following Positive AVXS-101 Data, Doc Feedback",2016-08-12 09:03:00-04:00,BIIB,positive
162448.0,Biogen Cancels Out Of Citigroup Conference Following Weeks Of Rumors,2016-08-11 15:02:00-04:00,BIIB,negative
162449.0,"Biogen Spokesperson Confirms Co. Has Canceled Out Of Citi's Biotech Conf., Cites Executive Scheduling Conflict; Says Mgmt Will Be Attending Morgan Stanley Conf. Next Week",2016-08-11 13:31:00-04:00,BIIB,negative
162450.0,"Biogen Shares Spike to Session Highs as Hearing Co. Has Cancelled Out of Citi's 11th Annual Biotech Conference, Scheduled Sept. 6-8",2016-08-11 13:06:00-04:00,BIIB,positive
162451.0,"Biogen Shares Unaffected Amid Dealreporter Report Suggesting Pfizer, J&J Could Also Be Looking at Co.",2016-08-08 11:28:00-04:00,BIIB,positive
162452.0,"Benzinga's M&A Chatter for Thursday August 4, 2016",2016-08-04 21:11:00-04:00,BIIB,neutral
162453.0,"Benzinga's M&A Chatter for Wednesday August 3, 2016",2016-08-03 20:26:00-04:00,BIIB,neutral
162454.0,"Biogen Shares Down $3 Over Last Min Following Reuters Report Co. Not Soliciting Offers; Allergan, Merck Shares Relatively Quiet, Not Impacted",2016-08-03 14:16:00-04:00,BIIB,positive
162455.0,Hearing Biogen Has Said Co. Has Not Received Any Formal Expressions of Interest from Suitors and is Not Soliciting Offers,2016-08-03 14:14:00-04:00,BIIB,positive
162456.0,Technical Alert: Finding Support In Biogen As Takeover Rumors Subside,2016-08-03 10:33:00-04:00,BIIB,positive
162457.0,The Market In 5 Minutes: Downtrend Continues,2016-08-03 08:59:00-04:00,BIIB,neutral
162458.0,Amyris Enters Partnership with Biogen to Develop Alternative Cell Lines Supporting Production of Therapeutics,2016-08-03 08:30:00-04:00,BIIB,positive
162459.0,Why Is Biogen Attractive? Credit Suisse Sees 12-24% Upside Takeout Potential,2016-08-03 07:42:00-04:00,BIIB,positive
162460.0,"Benzinga's M&A Chatter for Tuesday August 2, 2016",2016-08-02 19:35:00-04:00,BIIB,neutral
162461.0,"Standpoint Research Earlier Issued Late-Intraday Downgrade on Biogen, from Buy to Hold",2016-08-02 17:27:00-04:00,BIIB,neutral
162462.0,CNBC's Meg Tirrell Reports Allergan Unlikely to Pursue Biogen Deal,2016-08-02 17:26:00-04:00,BIIB,neutral
162463.0,6 Stocks Moving In Tuesday's After-Hours Session,2016-08-02 17:03:00-04:00,BIIB,neutral
162464.0,TheStreet's Adam Feuerstein Tweets: '$BIIB Takeover value baked in? A lot surely is.',2016-08-02 15:33:00-04:00,BIIB,positive
162465.0,Hearing RBC Capital Analyst Has Said Biogen Could Be Worth $375-$475/Share in Takeover Scenario,2016-08-02 15:33:00-04:00,BIIB,positive
162466.0,Option Alert: BIIB Oct16 290 Calls: 504 @  Above Ask!  $48.00: 814 traded vs 726 OI: $328.59 Ref,2016-08-02 15:05:00-04:00,BIIB,positive
162467.0,"Biogen Shares Resume, Spiking Higher",2016-08-02 14:47:00-04:00,BIIB,positive
162468.0,"Wall Street Journal Reports Biogen Drawing Interest From Merck, Allergan On Possibility Of Huge Deal",2016-08-02 14:46:00-04:00,BIIB,positive
162469.0,Adam Feuerstein Tweet: 'That having a lame-duck CEO thing has a way of motivating sellers and buyers. $BIIB',2016-08-02 14:45:00-04:00,BIIB,positive
162470.0,Biogen Shares Halted On Volatility,2016-08-02 14:43:00-04:00,BIIB,positive
162471.0,"Biogen Sees Takeover Interest from Allergan, Merck-DJ",2016-08-02 14:43:00-04:00,BIIB,positive
162472.0,"Biogen, JC Penney And More: Fast Money Picks For August 2",2016-08-02 06:30:00-04:00,BIIB,neutral
162473.0,Mid-Afternoon Market Update: Trina Solar Gains Following Go-Private Deal; Insperity Shares Drop,2016-08-01 15:01:00-04:00,BIIB,positive
162474.0,Can You Name This Chart?,2016-08-01 12:40:00-04:00,BIIB,neutral
162475.0,15 Biggest Mid-Day Gainers For Monday,2016-08-01 12:37:00-04:00,BIIB,neutral
162476.0,Mid-Day Market Update: Crude Oil Down 3%; FleetMatics Group Shares Rise Following Acquisition News,2016-08-01 12:18:00-04:00,BIIB,negative
162477.0,Benzinga's Volume Movers,2016-08-01 10:47:00-04:00,BIIB,neutral
162478.0,Mid-Morning Market Update: Markets Mostly Higher; Tesla To Acquire SolarCity,2016-08-01 10:19:00-04:00,BIIB,neutral
162479.0,15 Stocks Moving In Monday's Pre-Market Session,2016-08-01 08:34:00-04:00,BIIB,neutral
162480.0,"Biogen, Ionis Reveal Nusinersen Meets Primary Endpoint At Interim Analysis Of Final Stage ENDEAR Trial",2016-08-01 08:32:00-04:00,BIIB,neutral
162481.0,"UPDATE: Biogen To Pay Ionis A $75M License Fee, Will Initiate Regulatory Filings Globally In Months To Come",2016-08-01 07:32:00-04:00,BIIB,negative
162482.0,"Biogen, Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy",2016-08-01 07:32:00-04:00,BIIB,neutral
162483.0,Baird Still Isn't Buying Biogen,2016-07-22 11:45:00-04:00,BIIB,neutral
162484.0,15 Biggest Mid-Day Gainers For Thursday,2016-07-21 12:55:00-04:00,BIIB,neutral
162485.0,Earnings Parade: Technology Shines While Other Sectors Also Out-Perform,2016-07-21 12:22:00-04:00,BIIB,neutral
162486.0,The Market In 5 Minutes: Jam-Packed Day Of Earnings And Economic Data,2016-07-21 08:52:00-04:00,BIIB,neutral
162487.0,"Biogen's Q2 Numbers, Outlook Exceed Street Expectations",2016-07-21 08:36:00-04:00,BIIB,neutral
162488.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-07-21 08:23:00-04:00,BIIB,neutral
162489.0,"Biogen +6.13% Premarket @$278.50 Following Announcement of Earnings Beat, Raised Guidance, $5B Share Buyback",2016-07-21 08:20:00-04:00,BIIB,positive
162490.0,"Biogen Sees FY16 Rev. $11.2-$11.4B vs. Est. $11.28B, EPS $19.70-$20.00 vs. Est. $18.96",2016-07-21 07:03:00-04:00,BIIB,neutral
162491.0,Biogen CEO George Scangos Will Be Leaving Company One Successor Identified,2016-07-21 07:02:00-04:00,BIIB,positive
162492.0,Biogen Raises Guidance,2016-07-21 07:01:00-04:00,BIIB,neutral
162493.0,Biogen Authorizes $5B Buyback,2016-07-21 07:01:00-04:00,BIIB,neutral
162494.0,"Biogen Reports Q2 EPS $5.21 vs. Est. $4.67, Rev. $2.9B vs. Est. $2.79B",2016-07-21 07:00:00-04:00,BIIB,neutral
162495.0,"Earnings Scheduled For July 21, 2016",2016-07-21 05:18:00-04:00,BIIB,neutral
162496.0,A Peek Into The Markets: U.S. Stock Futures Up; Bank of America Profit Tops Views,2016-07-18 07:50:00-04:00,BIIB,positive
162497.0,"Biogen, Sobi to Report Long-Term Efficacy, Safety Data from A-LONG, ASPIRE, B-Long, B-YOND Trials at World Federation of Hemophilia World Congress",2016-07-18 07:31:00-04:00,BIIB,positive
162498.0,"Biogen's SB5 Adalimumab Biosimilar Referencing Humira, Accepted for Review by EMA",2016-07-18 04:46:00-04:00,BIIB,positive
162499.0,Biogen And AbbVie's Once-Monthly ZINBRYTA Gets European Union Approval For Multiple Sclerosis Treatment,2016-07-05 09:21:00-04:00,BIIB,positive
162500.0,"Biogen, AbbVie Report Once-Monthly ZINBRYTA Approved in EU for Treatment of MS",2016-07-05 08:00:00-04:00,BIIB,positive
162501.0,Biogen Optionality Looking Attractive; Bernstein Initiates At Outperform,2016-06-29 13:56:00-04:00,BIIB,positive
162502.0,Stiff Biosimilar Headwinds To Negatively Impact Amgen's Aging Drug Portfolio,2016-06-29 12:07:00-04:00,BIIB,neutral
162503.0,The Market In 5 Minutes: Swoosh And A Miss,2016-06-29 08:43:00-04:00,BIIB,negative
162504.0,Bernstein Initiates Coverage on Biogen at Outperform,2016-06-29 07:42:00-04:00,BIIB,neutral
162505.0,Is Biogen Becoming A Reasonable Target For Acquisition? Baird Says So,2016-06-22 15:21:00-04:00,BIIB,neutral
162506.0,Stocks Hitting 52-Week Lows,2016-06-21 10:19:00-04:00,BIIB,negative
162507.0,Biogen And Gilead Sciences Buck Biotech Short Interest Trend,2016-06-12 14:35:00-04:00,BIIB,positive
162508.0,New Data Presented at the Annual European Congress of Rheumatology Demonstrate Safety and Efficacy of Biogen's Anti-TNF Biosimilars Portfolio,2016-06-09 07:09:00-04:00,BIIB,positive
162509.0,"Biogen Shares Selling Off Further, Traders Passing Around Comments From Moody's Saying Anti-Lingo Study Failure Is Credit Negative",2016-06-08 15:22:00-04:00,BIIB,negative
162510.0,Lingo Failure Leads Citi To Downgrade Biogen,2016-06-08 10:03:00-04:00,BIIB,negative
162511.0,Mid-Afternoon Market Update: Navistar Climbs Following Earnings Beat; Biogen Shares Tumble,2016-06-07 14:31:00-04:00,BIIB,positive
162512.0,8 Biggest Mid-Day Losers For Tuesday,2016-06-07 12:50:00-04:00,BIIB,negative
162513.0,Mid-Day Market Update: LDR Rises On Acquisition News; DryShips Shares Drop,2016-06-07 12:07:00-04:00,BIIB,neutral
162514.0,"Biogen Blitzed, Hits Lowest Level Since March",2016-06-07 11:46:00-04:00,BIIB,negative
162515.0,Mid-Morning Market Update: Markets Mostly Higher; Valeant Earnings Miss Views,2016-06-07 10:03:00-04:00,BIIB,negative
162516.0,Citigroup Downgrades Biogen to Neutral,2016-06-07 09:44:00-04:00,BIIB,neutral
162517.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-07 08:27:00-04:00,BIIB,neutral
162518.0,"Biogen -9% to $263 as Phase 2 Study of Opicinumab Misses Primary, Secondary Endpoint",2016-06-07 07:37:00-04:00,BIIB,negative
162519.0,Biogen Phase 2 Study of Opicinumab Misses Primary and Secondary Endpoint,2016-06-07 07:33:00-04:00,BIIB,negative
162520.0,Acadia Pharmaceuticals May Be Subject Of A Bidding War,2016-06-06 12:21:00-04:00,BIIB,negative
162521.0,Benzinga's Weekend M&A Chatter,2016-06-05 20:21:00-04:00,BIIB,neutral
162522.0,"AstraZeneca, Teva, Biogen, Allergan Said to be Potential Bidders for Acadia -Daily Mail",2016-06-03 18:38:00-04:00,BIIB,neutral
162523.0,Biogen Says EU Medicines Agency Accepted Its Investigational Alzheimer's Disease Treatment Aducanumab,2016-06-01 14:32:00-04:00,BIIB,positive
162524.0,Biogen Announces Aducanumab Was Accepted Into EMA's PRIME Program,2016-06-01 11:46:00-04:00,BIIB,positive
162525.0,Biogen Gets Favorable View For TYSABRI Use In Highly Active RRMS,2016-05-31 10:10:00-04:00,BIIB,positive
162526.0,Biogen Announces Positive CHMP Opinion for TYSABRI,2016-05-31 07:32:00-04:00,BIIB,positive
162527.0,Government Study: Cellphone Radiation Linked To Cancer,2016-05-27 11:37:00-04:00,BIIB,negative
162528.0,Option Alert:  SWEEP (SELL) - BIIB May 27 $270 Call - 772 @ 2.02 in 13 orders. 848 traded. OI: 68,2016-05-20 10:31:00-04:00,BIIB,positive
162529.0,Has A Biotech Recovery Started Yet?,2016-05-17 17:56:00-04:00,BIIB,neutral
162530.0,Biogen and Regenexbio to Collaborate with University of Pennsylvania on Gene Therapy Programs,2016-05-16 07:06:00-04:00,BIIB,neutral
162531.0,"Biogen, Swedish Orphan Biovitrum Announce EC Approves  Alprolix for Treatment of Haemophilia B",2016-05-13 04:47:00-04:00,BIIB,positive
162532.0,The Next Sector Rotation Will Be To Biotechs,2016-05-03 12:17:00-04:00,BIIB,neutral
162533.0,Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm,2016-05-03 08:42:00-04:00,BIIB,neutral
162534.0,"Biogen to Spin-off Hemophilia Business, Anchored by ELOCTATE and ALPROLIX into Separate Publicly-Traded Company",2016-05-03 07:37:00-04:00,BIIB,neutral
162535.0,"Biogen to Spin Off Its Hemophilia Business as Independent, Publicly Traded Company",2016-05-03 07:31:00-04:00,BIIB,neutral
162536.0,Barron's 500: America's Top Companies,2016-05-01 16:11:00-04:00,BIIB,positive
162537.0,EMA Recommends Approval of Biogen's/Abbvie's Daclizumab to Treat MS,2016-04-29 07:25:00-04:00,BIIB,positive
162538.0,Biotech Boom May Continue Through Earnings Season,2016-04-28 12:00:00-04:00,BIIB,neutral
162539.0,Biogen Says Received Subpoena from Federal Government for Documents Relating to Relationship with Non-profit Organizations,2016-04-21 17:10:00-04:00,BIIB,neutral
162540.0,"Goldman Sachs Maintains Neutral on Biogen, Raises PT to $285.00",2016-04-21 16:23:00-04:00,BIIB,neutral
162541.0,12 Stocks Moving In Thursday's Pre-Market Session,2016-04-21 08:27:00-04:00,BIIB,neutral
162542.0,"Biogen Reports Q1 EPS $4.79 vs. Est. $4.47, Rev. $2.7B vs. Est. $2.75B",2016-04-21 07:15:00-04:00,BIIB,neutral
162543.0,"Earnings Scheduled For April 21, 2016",2016-04-21 04:14:00-04:00,BIIB,neutral
162544.0,Biogen Presented Data Of ZINBRYTA Impact On Cognitive Outcomes And Reversibility Of Targeted Mechanism Of Action,2016-04-20 07:33:00-04:00,BIIB,neutral
162545.0,"Biogen Reports TECFIDERA Data Confirms Strong, Sustained Efficacy in Newly-Diagnosed MS Patients",2016-04-18 07:31:00-04:00,BIIB,positive
162546.0,Option Alert: BIIB Fri 4/22 280 Calls (Wkly) Sweep: 580 @  ASK  $4.67: 867 traded vs 191 OI:  Earnings 4/21 Before Open  $267.30 Ref,2016-04-15 12:30:00-04:00,BIIB,positive
162547.0,"Citi Surprised, Confused Amid Report Biogen May Divest Hemophilia Unit",2016-04-11 08:16:00-04:00,BIIB,negative
162548.0,"Citigroup Confused Over Possible Biogen Sale Of Hemophilia Business, Questions If Co. May Be Setting Itself Up As An M&A Target",2016-04-11 05:52:00-04:00,BIIB,negative
162549.0,Biogen Explores Sale Of Hemophilia Assets -Reuters,2016-04-08 14:42:00-04:00,BIIB,positive
162550.0,How One Analyst Is Playing The Biotech Rebound This Week,2016-04-07 15:45:00-04:00,BIIB,positive
162551.0,"BMO Capital Initiates Coverage on Biogen at Market Perform, Announces $283.00 PT",2016-04-05 16:49:00-04:00,BIIB,neutral
162552.0,Biogen Announces CHMP Has Issued Positive Opinion on FLIXABI,2016-04-01 11:30:00-04:00,BIIB,positive
162553.0,"Ionis Pharmaceuticals Advances Nusinersen in the Ongoing SHINE Study in Patients with SMA, Earns $7.5M Milestone Payment From Biogen",2016-03-31 08:02:00-04:00,BIIB,neutral
162554.0,Biogen Names Michel Vounatsos Chief Commercial Officer,2016-03-30 08:00:00-04:00,BIIB,neutral
162555.0,What's Going On With Kyle Bass And Biogen?,2016-03-23 14:23:00-04:00,BIIB,neutral
162556.0,A Rare Opportunity With A Biotechnology ETF,2016-03-17 07:54:00-04:00,BIIB,positive
162557.0,"Morgan Stanley Calls AMGN, BMY, BIIB, MCK, STJ It's Favorite Health Care Names",2016-03-11 05:52:00-05:00,BIIB,positive
162558.0,Option Alert: BIIB Apr16 280 Calls: 540 @  ASK  $8.60: 600 traded vs 597 OI:  Earnings 4/22  $268.66 Ref,2016-03-03 09:59:00-05:00,BIIB,positive
162559.0,Stocks To Watch During Cowen's 36th Annual Healthcare Conference,2016-03-01 13:21:00-05:00,BIIB,neutral
162560.0,"Sobi, Biogen Receive Positive Opinion from CHMP for Alprolix for the Treatment of Hemophilia B",2016-02-26 07:12:00-05:00,BIIB,positive
162561.0,EMA Recommends Approval of Biogen's Eftrenonacog Alfa to Treat Haemophilia B‍​,2016-02-26 07:05:00-05:00,BIIB,positive
162562.0,Benzinga's Top Initiations,2016-02-25 09:35:00-05:00,BIIB,positive
162563.0,"Citi: Buy Celgene, Gilead, Biogen And Regeneron As Biotechs Recover",2016-02-25 08:51:00-05:00,BIIB,neutral
162564.0,Citigroup Initiates Coverage on Biogen at Buy,2016-02-25 06:49:00-05:00,BIIB,neutral
162565.0,"Biotech Investors Shouldn't Fear Legislation, Even If Hillary Is President And Dems Win Senate Majority",2016-02-24 11:00:00-05:00,BIIB,positive
162566.0,Slump Could Be Healthcare ETF Buying Opportunity,2016-02-22 07:44:00-05:00,BIIB,positive
162567.0,Biotech Conference Suggests Tempering Expectations For Eli Lilly Drug,2016-02-16 13:47:00-05:00,BIIB,neutral
162568.0,Schroer: Biotech Will Turn Around,2016-02-13 22:12:00-05:00,BIIB,neutral
162569.0,"Schoenebaum: Biotech P/Es Show 'Buying Signal' With Caveat; Amgen, Biogen, Celgene & Gilead Have Catalysts",2016-02-08 15:27:00-05:00,BIIB,neutral
162570.0,Leerink Is Back On Board The Biotech Train,2016-02-05 10:32:00-05:00,BIIB,neutral
162571.0,Leerink Swann Initiates Coverage on Biogen at Market Perform,2016-02-05 04:08:00-05:00,BIIB,neutral
162572.0,The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors,2016-02-03 14:53:00-05:00,BIIB,neutral
162573.0,Joe McCann: Here's How To Play Biotech Market In Earnings Season,2016-02-03 11:48:00-05:00,BIIB,positive
162574.0,"Biogen Drug 'Increasingly Vulnerable,' Analyst Warns After Speaking With MS Expert",2016-01-29 09:29:00-05:00,BIIB,negative
162575.0,"Piper Jaffray Considers Recent Meeting with High Volume MS Specialist: Biogen's Franchise is Increasingly Vulnerable, Roche's Ocrelizumab is Well Positioned",2016-01-29 08:52:00-05:00,BIIB,positive
162576.0,Maybe Some Good News For A Big Biotech ETF,2016-01-29 08:39:00-05:00,BIIB,positive
162577.0,7 Biotech Traders Pick Their Favorite Stocks For 2016,2016-01-28 16:53:00-05:00,BIIB,positive
162578.0,Sobi to present new interim ASPIRE data at EAHAD congress suggesting that patients can reduce bleeding rates with long-term Elocta treatment,2016-01-28 04:27:00-05:00,BIIB,neutral
162579.0,Earnings Recap For January 27,2016-01-27 17:17:00-05:00,BIIB,neutral
162580.0,"Apple and Boeing Earnings, Plus Oil Drag, Combine To Dent Stocks",2016-01-27 11:38:00-05:00,BIIB,negative
162581.0,Biogen's Stock Pops Following Better-Than-Expected Q4 Results,2016-01-27 08:37:00-05:00,BIIB,neutral
162582.0,10 Stocks Moving In Wednesday's Pre-Market Session,2016-01-27 08:26:00-05:00,BIIB,neutral
162583.0,"CORRECTION: Biogen Sees FY16 Sales ~$11.1B-$11.3B vs $11.3B Est., Adj. EPS $18.30-$18.60 vs $18.45 Est.",2016-01-27 07:21:00-05:00,BIIB,neutral
162584.0,"Biogen Sees FY16 Sales ~$11.1B-$11.3B vs $11.3B Est., Adj. EPS $18.30-$18.60 vs $18.45 Est.",2016-01-27 07:17:00-05:00,BIIB,neutral
162585.0,"Biogen Reports Q4 EPS $4.50 vs. Est. $4.08, Rev. $2.839B vs. Est. $2.71B",2016-01-27 07:16:00-05:00,BIIB,neutral
162586.0,"Earnings Scheduled For January 27, 2016",2016-01-27 04:05:00-05:00,BIIB,neutral
162587.0,Big Earnings Expectations For Big Biotech,2016-01-24 16:55:00-05:00,BIIB,neutral
162588.0,Barclays Prefers Biogen Over Celgene Heading Into Q4 Results,2016-01-22 08:44:00-05:00,BIIB,neutral
162589.0,Credit Suisse Bullish On Most Big Pharma Names,2016-01-20 10:34:00-05:00,BIIB,positive
162590.0,Why This Analyst Is Cautious On Biogen,2016-01-20 07:49:00-05:00,BIIB,negative
162591.0,"Credit Suisse Initiates BIIB At Neutral, Fears Competition From New Regiments To Impact Base Business Growth, Believes Pipeline Offers 'big upside driver'",2016-01-20 05:36:00-05:00,BIIB,positive
162592.0,"Credit Suisse Initiates Coverage on Biogen at Neutral, Announces $322.00 PT",2016-01-19 16:20:00-05:00,BIIB,positive
162593.0,Biogen Ticks Up Following EU Marketing Authorization Of Benepali,2016-01-19 08:39:00-05:00,BIIB,neutral
162594.0,"Biogen, Samsung JV Announces Etanercept Biosimilar Referencing Enbrel, BENEPALI, Approved in EU",2016-01-17 09:18:00-05:00,BIIB,positive
162595.0,This Week Is Paramount For Biotech Stocks,2016-01-11 13:10:00-05:00,BIIB,neutral
162596.0,Standpoint Research Initiates Coverage on Biogen at Buy,2016-01-07 15:25:00-05:00,BIIB,neutral
162597.0,Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences,2016-01-07 06:35:00-05:00,BIIB,neutral
162598.0,Jefferies' Best Biotech Ideas For 2016 (And Beyond),2016-01-06 15:52:00-05:00,BIIB,positive
162599.0,"Rodin Therapeutics Reports Financing Committments of $17.3M from Atlas Venture, Biogen, R&D Collaboration",2016-01-06 07:06:00-05:00,BIIB,neutral
162600.0,"Jacobs Reports Two Contracts: Option at NASA's Marshall Space Flight Center, with Biogen",2016-01-05 07:45:00-05:00,BIIB,neutral
162601.0,Cowen Thinks Biogen Has 20% Upside After MS Therapies Price Hike,2016-01-04 15:51:00-05:00,BIIB,neutral
162602.0,Not All Of Clinton's Policies Are Bad For Pharmaceuticals,2015-12-23 14:13:00-05:00,BIIB,negative
162603.0,Ionis Pharmaceuticals Receives Milestone Payment From Biogen Of $5M For Advancing A Neurology Program,2015-12-22 07:02:00-05:00,BIIB,neutral
162604.0,"Biogen No Longer 'Too Risky,' Atlantic Analyst Sees Massive Upside",2015-12-18 09:13:00-05:00,BIIB,negative
162605.0,"Atlantic Equities Initiates Coverage on Biogen at Overweight, Announces $344.00 PT",2015-12-18 08:40:00-05:00,BIIB,negative
162606.0,"Arsia Therapeutics, Biogen Report Signing of Research Collab for Development of Subcutaneous Biologics",2015-12-16 07:06:00-05:00,BIIB,neutral
162607.0,"Biogen Releases Eloctate and Alprolix Data, Says May Help Joint Bleeds in People With Hemophilia A and B",2015-12-08 07:06:00-05:00,BIIB,positive
162608.0,"Early Global News: Virtual Reality Market Getting Really Big, Facebook To Sell You Concert Tickets, And More",2015-12-04 07:37:00-05:00,BIIB,neutral
162609.0,Sobi and Biogen's Elocta Approved by EC for Treatment of Haemophilia A,2015-11-24 04:19:00-05:00,BIIB,positive
162610.0,Biogen Reports Benepali is the First Biosimilar of Enbrel to Receive a Positive Opinion from CHMP,2015-11-20 07:15:00-05:00,BIIB,positive
162611.0,Samsung-Biogen Biosimilar for Amgen's Enbrel Could Receive EMA Recommendation This Week -Reuters,2015-11-18 05:13:00-05:00,BIIB,neutral
162612.0,5 Biotechs That Can Win From Ophthalmology Innovation,2015-11-16 13:21:00-05:00,BIIB,positive
162613.0,3 Top Biotech Stocks See Their Short Interest Plunge,2015-11-12 13:46:00-05:00,BIIB,positive
162614.0,10 S&P 500 Companies With Green Operations,2015-11-10 15:10:00-05:00,BIIB,neutral
162615.0,ISIS Pharma Called A 'Sleeper Awakening' At Piper Jaffray,2015-11-05 10:25:00-05:00,BIIB,neutral
162616.0,Biotechs Among Stocks That Insiders Have Been Buying Lately,2015-11-02 11:53:00-05:00,BIIB,neutral
162617.0,Wild Short Interest Swings For Three Top Biotech Stocks,2015-10-28 07:57:00-04:00,BIIB,positive
162618.0,"Biogen Shares Rise 5.5% Following Form 4 Filing Late Monday, Showing 310K Share Buy by Alexander Denner",2015-10-27 15:07:00-04:00,BIIB,positive
162619.0,"Biogen Volatile After Q3 Beat, Raised Guidance And Disappointing Phase 3 Study",2015-10-21 14:48:00-04:00,BIIB,negative
162620.0,Why Biogen Stock Is Having A Huge Day,2015-10-21 14:27:00-04:00,BIIB,positive
162621.0,Morning Market Gainers,2015-10-21 09:40:00-04:00,BIIB,neutral
162622.0,From Biogen Call: Exec Says Co. Expects to Complete $5B Buyback Plan by End of '15,2015-10-21 08:56:00-04:00,BIIB,neutral
162623.0,Biogen +5.5% Premarket Following Announcement of 11% Workforce Cut,2015-10-21 08:38:00-04:00,BIIB,negative
162624.0,Benzinga's Top #PreMarket Gainers,2015-10-21 08:19:00-04:00,BIIB,positive
162625.0,Shares of Biogen Resume; Now Up Nearly 6%,2015-10-21 08:02:00-04:00,BIIB,positive
162626.0,Shares of Biogen to Resume Trade at 8 a.m. EDT,2015-10-21 07:45:00-04:00,BIIB,positive
162627.0,"UPDATE: Biogen Sees FY15 Adj. EPS $16.20-$16.50 vs $15.84 Est., Sales Growth 8-9% YoY",2015-10-21 07:32:00-04:00,BIIB,positive
162628.0,"UPDATE: Biogen Phase 3 Study Did Not Meet Primary, Secondary Endpoints",2015-10-21 07:31:00-04:00,BIIB,neutral
162629.0,"UPDATE: Biogen Reports Q3 Adj. EPS $4.48 vs $3.80 Est., Sales $2.8B vs $2.65B Est.",2015-10-21 07:31:00-04:00,BIIB,neutral
162630.0,Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MS,2015-10-21 07:31:00-04:00,BIIB,neutral
162631.0,Biogen Reports Q3 Earnings; Raises FY Outlook,2015-10-21 07:30:00-04:00,BIIB,neutral
162632.0,Biogen Shares Halted News Pending,2015-10-21 07:25:00-04:00,BIIB,positive
162633.0,"Earnings Scheduled For October 21, 2015",2015-10-21 04:09:00-04:00,BIIB,neutral
162634.0,Fast Money Picks For October 20,2015-10-20 06:59:00-04:00,BIIB,neutral
162635.0,5 Must-Watch Stocks For This Week,2015-10-19 15:45:00-04:00,BIIB,neutral
162636.0,"Stock Week Ahead: Housing Data, Broad-Based Earnings Line Up",2015-10-19 14:52:00-04:00,BIIB,neutral
162637.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,BIIB,positive
162638.0,Watching Volatility In Other Big Pharma Names Amid Eli Lilly Halt,2015-10-12 07:48:00-04:00,BIIB,neutral
162639.0,"Biogen, Abbive Offer Results from ZINBRYTA Phase 3 DECIDE Study Showing Effect on Disability, Cognitive Outcomes: 'Additional Analyses Reinforce Safety Profile'",2015-10-08 06:21:00-04:00,BIIB,positive
162640.0,Biogen Says Tecfidera Data is Positive,2015-10-07 06:01:00-04:00,BIIB,positive
162641.0,Historical Biotech IPO Data From The 'Godfather Of Biotechnology',2015-10-06 14:36:00-04:00,BIIB,neutral
162642.0,Trans Pacific Trade Pact Finally Agreed,2015-10-06 07:35:00-04:00,BIIB,positive
162643.0,Fast Money Traders Share The Stocks They Would Buy In Fourth Quarter,2015-10-01 05:53:00-04:00,BIIB,positive
162644.0,Watch Out Biotech Investors: Outrage Culture + Election Season = Ugly Rhetoric Ahead,2015-09-22 10:46:00-04:00,BIIB,negative
162645.0,"Rich Ross Sees Upside Potential In Disney, United Continental And Biogen",2015-09-22 06:40:00-04:00,BIIB,positive
162646.0,"Feuerstein Says While Biogen Has Had Drug Pricing Issues As Well, They Are Currently Researching Drugs That Are Better To Replace AVONEX; Could Justify Higher, Older Drug Price",2015-09-21 15:21:00-04:00,BIIB,positive
162647.0,"Adam Feuerstein Agrees With Interviewee That Big Biotech Companies Could Be Shielded From Drug Pricing Issues, ""Yea, To Some Extent They Are A Bit Shielded As Long As They Continue To Innovate""",2015-09-21 15:14:00-04:00,BIIB,positive
162648.0,Biogen Approaches Support Levels In $290 Handle,2015-09-21 14:09:00-04:00,BIIB,positive
162649.0,Biotechs Are Getting Killed Because Of Hillary Clinton's Response To This Drug Price Hike,2015-09-21 12:45:00-04:00,BIIB,negative
162650.0,Why Leerink Is Cutting Biogen Targets (But Still Bullish On The Stock),2015-09-15 15:20:00-04:00,BIIB,negative
162651.0,Kyle Bass On CNBC Talking Drug Patents,2015-09-15 10:40:00-04:00,BIIB,neutral
162652.0,"Despite Flat Tecfidera Prescription Trends, Leerink Analyst Sees Attractive Risk-Reward Scenario For Biogen Given Negative Investor Sentiment, Achievable Guidance, And Discount Valuation To Peer Group",2015-09-15 08:21:00-04:00,BIIB,positive
162653.0,Amgen And Biogen Lead Short Interest Surge In Biotechs,2015-09-14 16:01:00-04:00,BIIB,positive
162654.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,BIIB,neutral
162655.0,JMP Analyst Says He Believes Biotech Megacaps Appear To Be Generating A Shopping List After Raising Cash; Implying Possible M&A Activity In Biotech Space After Recent Investor Conference Activity,2015-09-14 07:07:00-04:00,BIIB,neutral
162656.0,Biotech Investors Still Have Opportunity,2015-09-09 11:20:00-04:00,BIIB,positive
162657.0,Biogen Licenses Mitsubishi Tanabe Pharma's MT-1303 for Autoimmune Diseases,2015-09-09 04:25:00-04:00,BIIB,neutral
162658.0,JD.com Reports $1B Share Repurchase Program,2015-09-08 07:31:00-04:00,BIIB,positive
162659.0,Biogen Enrolls Initial Patient in Global Phase 3 Study of Investigational Treatment Aducanumab (BIIB037) for Early Alzheimer's Disease,2015-09-08 07:30:00-04:00,BIIB,neutral
162661.0,Biogen: 'A Nice Little Trade' Or Heading To New Lows?,2015-09-01 16:24:00-04:00,BIIB,positive
162662.0,Biogen And Gilead Sciences Catch The Eye Of Short Sellers,2015-08-27 11:06:00-04:00,BIIB,neutral
162663.0,"The Other Bearish Biotech ETF Is Looking Groovy, Too",2015-08-21 15:24:00-04:00,BIIB,neutral
162664.0,13G Filing from Biogen on Applied Genetic Technologies Shows New 8.1% Stake,2015-08-20 16:16:00-04:00,BIIB,neutral
162665.0,Using ETFs To Run Your Own Hedge Fund,2015-08-20 14:04:00-04:00,BIIB,neutral
162666.0,Morning Market Gainers,2015-08-20 09:44:00-04:00,BIIB,neutral
162667.0,Benzinga's Top #PreMarket Gainers,2015-08-20 08:18:00-04:00,BIIB,positive
162668.0,AGTC Release Confirms Strategic Collaboration With Biogen Effective and Biogen Equity Investment Closed,2015-08-19 16:09:00-04:00,BIIB,positive
162669.0,"Biogen Announces Collaboration with Columbia University, Funded With $30M From CUMC and $3.5M from ALS",2015-08-18 07:07:00-04:00,BIIB,neutral
162670.0,Biogen Announces Positive Interim Data Regarding Bleeding Rates,2015-08-17 07:03:00-04:00,BIIB,positive
162671.0,Biogen Canada Says Health Canada Approves Plegridy for Adults With Relapsing Remitting Multiple Sclerosis -Reuters,2015-08-13 08:08:00-04:00,BIIB,positive
162672.0,Benzinga's Top Initiations,2015-08-11 09:45:00-04:00,BIIB,positive
162673.0,H.C. Wainwright: Biogen Is Now A Buy Worth $380/Share,2015-08-11 09:06:00-04:00,BIIB,positive
162674.0,"H.C. Wainwright Initiates Coverage on Biogen at Buy, Announces $380.00 PT",2015-08-11 07:46:00-04:00,BIIB,neutral
162675.0,Biogen Releases Positive Interem Phase 3 Results For Eloctate Study,2015-08-10 07:07:00-04:00,BIIB,positive
162676.0,The Historical Correlation Between Biotech Stocks And Interest Rates,2015-08-07 14:39:00-04:00,BIIB,positive
162677.0,Is More M&A On The Way For Large-Cap Biotechs?,2015-07-28 13:18:00-04:00,BIIB,neutral
162678.0,"With The Teva Money, Allergan Could Engage In 'Large M&A' Next: Evercore ISI",2015-07-27 16:25:00-04:00,BIIB,positive
162679.0,"Evercore ISI says Allergan may now engage in ""large M&A,"" buyside survey indicates Biogen, AbbVie, BioMarin, or a combination with Pfizer as possible takeout targets.",2015-07-27 15:46:00-04:00,BIIB,positive
162680.0,Caution Continues In Options Market This Week,2015-07-27 14:08:00-04:00,BIIB,neutral
162681.0,A Big Day For Biotech And It's Not Going So Well,2015-07-27 13:10:00-04:00,BIIB,negative
162682.0,Morgan Stanley Still Likes Biogen After Bleak Earnings,2015-07-27 12:52:00-04:00,BIIB,positive
162683.0,Benzinga's Volume Movers,2015-07-27 10:23:00-04:00,BIIB,neutral
162684.0,A Look Ahead: Biotech And Energy ETFs To Watch This Week,2015-07-27 10:03:00-04:00,BIIB,positive
162685.0,"Bernstein Upgrades Biogen On 'Compelling' Pipeline, Stock Now Undervalued",2015-07-27 09:28:00-04:00,BIIB,neutral
162686.0,"Bernstein's Geoffrey Porges on Biogen upgrade to Outperform: ""The current value of the key pipeline programs was unaffected by Friday's disclosure""",2015-07-27 08:28:00-04:00,BIIB,positive
162687.0,"Bernstein Upgrades Biogen to Outperform, Lowers PT to $385.00",2015-07-27 07:52:00-04:00,BIIB,negative
162688.0,"Baird Cuts Biogen Rating, Says Near-Term Growth 'Diminished'",2015-07-27 07:41:00-04:00,BIIB,positive
162689.0,Biogen Enters Collaboration with the Parkinson's Institute and Clinical Center,2015-07-27 07:30:00-04:00,BIIB,neutral
162690.0,"Baird Downgrades Biogen to Neutral, Lowers PT to $316.00",2015-07-27 04:14:00-04:00,BIIB,negative
162691.0,"Biotech Stocks Falling Broadly, Here's Why And How Much",2015-07-26 21:57:00-04:00,BIIB,negative
162692.0,Mid-Day Market Update: U.S. Stocks Slide; Marketo Shares Surge On Earnings Beat,2015-07-24 13:46:00-04:00,BIIB,positive
162693.0,"Market Update: Friday's Mid-Day Market Movers: Amazon Shocks The Markets; Anthem, Cigna, StanCorp, Pandora",2015-07-24 13:28:00-04:00,BIIB,negative
162694.0,RBC's Michael Yee Still Sees Value in Biogen's Long-Term Pipeline,2015-07-24 12:45:00-04:00,BIIB,positive
162695.0,Evercore ISI's Schoenebaum Offers Downside/Worst Case Scenario Analysis on Biogen Amid ~18% Intraday Decline: Discounted Cash Flow Model Target ~$305,2015-07-24 11:21:00-04:00,BIIB,positive
162696.0,Mid-Morning Market Update: Markets Slightly Higher; Amazon Earnings Top Views,2015-07-24 11:08:00-04:00,BIIB,positive
162697.0,Morning Market Losers,2015-07-24 09:55:00-04:00,BIIB,negative
162698.0,From Conf Call Biogen Says Don't Think it's a Panic Situation; As We See Good Opportunities We Will Be Aggressive About Bringing Them In,2015-07-24 09:27:00-04:00,BIIB,positive
162699.0,"Biogen's Final Catalyst Of 2015 Is A 'Coin Flip,' Evercore ISI Analyst Says",2015-07-24 09:12:00-04:00,BIIB,neutral
162700.0,From Conf Call: Biogen Says Assuming Extremely Limited Patient Growth for Tecfidera on Sequential Basis for Balance of  Year in US,2015-07-24 09:09:00-04:00,BIIB,positive
162701.0,"From Conf Call Biogen Says if Stock is Under Pressure as it Was in Pre-Market, I Suspect We Will Look for Opportunities to Lower Share Base",2015-07-24 09:03:00-04:00,BIIB,negative
162702.0,From Conf Call: Biogen Says Expects Primary Source of Value Creation to Be from Introducing New Therapies,2015-07-24 08:56:00-04:00,BIIB,positive
162703.0,From Conf Call: Biogen Says Overall Very Disappointed in Change of Outlook for Year,2015-07-24 08:54:00-04:00,BIIB,negative
162704.0,From Conf Call: Biogen Says Overall Very Disappointed in Change of Outlook for Year,2015-07-24 08:54:00-04:00,BIIB,negative
162705.0,From Conf Call: Biogen's Douglas Williams Executive VP of R&D Leaving to Become CEO of Startup,2015-07-24 08:46:00-04:00,BIIB,neutral
162706.0,Benzinga's Top #PreMarket Losers,2015-07-24 08:22:00-04:00,BIIB,negative
162707.0,"On Biogen's earnings, Evercore analyst Mark Schoenebaum wrote, ""people expected a weak quarter, but this is probably even worse...need call.""",2015-07-24 08:18:00-04:00,BIIB,negative
162708.0,US Stock Futures Edge Higher; Amazon Profit Beats Views,2015-07-24 08:01:00-04:00,BIIB,positive
162709.0,"Biogen Posts Higher Q2 Earnings, But Sales Miss Views",2015-07-24 07:35:00-04:00,BIIB,negative
162710.0,Biogen Sees FY15 Sales Growth 6-8% YoY,2015-07-24 06:51:00-04:00,BIIB,positive
162711.0,Biogen Cuts FY15 Adj. EPS Guidance to $15.50-$15.95 vs $16.63 Est.,2015-07-24 06:51:00-04:00,BIIB,negative
162712.0,"Biogen Reports Q2 Adj. EPS $4.22 vs $4.10 Est., Sales $2.6B vs $2.71B Est.",2015-07-24 06:50:00-04:00,BIIB,neutral
162714.0,"Earnings Scheduled For July 24, 2015",2015-07-24 04:51:00-04:00,BIIB,neutral
162715.0,10 Must Watch Stocks for Today,2015-07-24 04:04:00-04:00,BIIB,neutral
162716.0,Wall Street Mixed On Biogen Before Earnings,2015-07-23 17:39:00-04:00,BIIB,neutral
162717.0,Deutsche Bank Bullish On Biogen: New Data Doesn't Change Probability Of Success For Alzheimer's,2015-07-22 16:16:00-04:00,BIIB,positive
162718.0,"Deutsche Bank's Karnauskas Keeps Buy On Biogen With $460 PT, Says Doesn't 'See Any Major Change To The Probability Of Alzheimer's Program'",2015-07-22 14:58:00-04:00,BIIB,neutral
162719.0,Piper Jaffray On Biogen Downgrade: '6 MG Data Does Not Inspire Confidence…Even More Speculative Than Before',2015-07-22 11:29:00-04:00,BIIB,negative
162720.0,Disappointing Drug News Sends Biogen And XOMA Shares Down,2015-07-22 10:34:00-04:00,BIIB,negative
162721.0,Piper Jaffray Downgrades Biogen to Neutral,2015-07-22 09:24:00-04:00,BIIB,neutral
162722.0,Biogen Shares Fall 6% Premarket on Mixed Results in Phase 1 Alzheimer's Sudy; 6MG Dose Failed to Significantly Slow Mental Decline,2015-07-22 07:22:00-04:00,BIIB,negative
162723.0,Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab at Alzheimer's Association International Conference 2015,2015-07-22 06:45:00-04:00,BIIB,neutral
162724.0,Piper Jaffray Still Overweight Biogen But Notes It's Least-Preferred Play; Hikes Celgene Target,2015-07-21 10:30:00-04:00,BIIB,positive
162725.0,Oppenheimer's 10 'Best Of The Best' Technical Buy Ideas,2015-07-20 12:19:00-04:00,BIIB,positive
162726.0,"Biogen's Parkinson's Antibody Could Boost Prothena, RBC Says",2015-07-20 10:54:00-04:00,BIIB,positive
162727.0,"Stifel, JMP Securities Discuss What To Expect From AAIC Conference",2015-07-20 08:30:00-04:00,BIIB,positive
162728.0,Why Big Biotech Could Have Another Leg Up,2015-07-17 10:49:00-04:00,BIIB,neutral
162729.0,Biogen Alert From Deutsche Bank: Tecfidera Could Hit Consensus Forecast,2015-07-15 08:13:00-04:00,BIIB,positive
162730.0,Nomura:  'We Are Bullish On Celgene's Acquisition Of Receptos',2015-07-15 06:13:00-04:00,BIIB,neutral
162731.0,Biogen Boost: Bank Of America Upgrades Stock To Buy Ahead Of Alzheimer's Data,2015-07-14 09:37:00-04:00,BIIB,positive
162732.0,Benzinga's Top Upgrades,2015-07-14 09:10:00-04:00,BIIB,positive
162733.0,"Bank of America Upgrades Biogen to Buy, Maintains $466.00 PT",2015-07-14 07:34:00-04:00,BIIB,neutral
162734.0,11 Stocks With Near-Term Catalysts,2015-07-13 15:32:00-04:00,BIIB,neutral
162735.0,RBC Says Biogen Can Move 10% After BIIB-037 Data Is Revealed,2015-07-10 12:04:00-04:00,BIIB,neutral
162736.0,Douglas Williams to Leave Biogen for Biotechnology Start-Up,2015-07-10 11:36:00-04:00,BIIB,negative
162737.0,Here's Why Biogen Shares Are Crashing Today,2015-07-10 10:28:00-04:00,BIIB,positive
162738.0,Morning Market Losers,2015-07-10 09:54:00-04:00,BIIB,negative
162739.0,Cowen On Biogen: View June 22 Aducanumab Presentation As 'having the potential to substantially alter perceptions of the probability of ph III success and be worth +/- $50 to BIIB',2015-07-10 09:40:00-04:00,BIIB,positive
162740.0,Biogen Bounces Back To $388.05/Share After Dropping To A Low Of $383 On The Open,2015-07-10 09:38:00-04:00,BIIB,negative
162741.0,"Large-Cap Biotechs Poised For Second-Half Rally, RBC Says",2015-07-09 09:21:00-04:00,BIIB,positive
162742.0,Benzinga's Volume Movers,2015-07-06 10:35:00-04:00,BIIB,neutral
162743.0,"Biogen Collaboration With Applied Genetic Is 'Interesting,' But Morgan Stanley Will Wait For More Data",2015-07-06 07:51:00-04:00,BIIB,neutral
162744.0,"AAIC Is Coming: Here's What To Expect, Biogen And Eli Lilly Investors",2015-07-03 10:21:00-04:00,BIIB,neutral
162745.0,Mid-Afternoon Market Update: International Speedway Slips On Weak Results; Applied Genetic Technologies Shares Spike Higher,2015-07-02 15:02:00-04:00,BIIB,negative
162746.0,"UPDATE: Wedbush's Nierengarten Views AGTC, Biogen Deal as 'validation of AGTC's patent-protected manufacturing technology and treatment focus on monogenic disorders'",2015-07-02 12:59:00-04:00,BIIB,neutral
162747.0,"Wedbush's David Nierengarten on Applied Genetics Following Biogen Deal: Calls Partnership an 'Operational Inflection Point' for AGTC; Outperform Rating, $36 Price Target Reiterated",2015-07-02 12:58:00-04:00,BIIB,neutral
162748.0,Mid-Day Market Update: US Stocks Down; Xoom Shares Jump On Acquisition News,2015-07-02 12:48:00-04:00,BIIB,positive
162749.0,"Thursday's Mid-Day Movers: Real Good Solar, Xoom, ConforMIS, Health Net And More",2015-07-02 12:02:00-04:00,BIIB,positive
162750.0,Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B,2015-07-02 11:05:00-04:00,BIIB,neutral
162751.0,Benzinga's Volume Movers,2015-07-02 10:21:00-04:00,BIIB,neutral
162752.0,Morning Market Gainers,2015-07-02 09:40:00-04:00,BIIB,neutral
162753.0,"JP Morgan Defends Biogen, Calls Initial $124M Applied Genetic Investment An 'incremental positive'",2015-07-02 09:26:00-04:00,BIIB,positive
162754.0,Benzinga's Top #PreMarket Gainers,2015-07-02 08:16:00-04:00,BIIB,positive
162755.0,Applied Genetic Technologies Shares to Resume Trading at 7:30AM ET,2015-07-02 07:06:00-04:00,BIIB,positive
162756.0,UPDATE: Biogen's Upfront Payment to AGTC Includes $30M Equity Investing in AGTC,2015-07-02 07:02:00-04:00,BIIB,neutral
162757.0,"UPDATE: AGTC Will Receive ~$124M Upfront Payment, Includes Potential for Future Milestone Payments",2015-07-02 07:02:00-04:00,BIIB,neutral
162758.0,"Biogen, AGTC Announce Entering of Collab Related to Development of Gene Therapies in Ophthalmology",2015-07-02 07:00:00-04:00,BIIB,neutral
162759.0,Biogen Announces 1B Swiss Franc Investment in New Production Plant in Luterbach in the Canton of Solothurn,2015-07-01 07:17:00-04:00,BIIB,neutral
162760.0,Biogen Announces 1B Swiss Franc Investment in New Production Plant in Luterbach in the Canton of Solothurn,2015-07-01 07:16:00-04:00,BIIB,neutral
162761.0,"Biogen, Sobi Announce EMA Validates ALPROLIX Marketing Authorization Application",2015-06-26 04:15:00-04:00,BIIB,positive
162762.0,Morgan Stanley On Biogen: Here's The 'Other' Coming Tysabri Catalyst,2015-06-23 10:51:00-04:00,BIIB,neutral
162763.0,"Morgan Stanley on Biogen: Sees Initial Data on Tysabri in SPMS 'Promising,' With 'Better Than 50/50 Odds of Clinical Success,' Maintains Overweight, $520 Price Target",2015-06-23 08:52:00-04:00,BIIB,positive
162764.0,Biogen Phase 3 Study Of Aducanumab,2015-06-23 08:42:00-04:00,BIIB,neutral
162765.0,"New Biogen Hemophilia Data At ISTH Congress to Showcase Extension Study Outcomes, Pediatric Use",2015-06-18 07:30:00-04:00,BIIB,neutral
162766.0,The Note Moving Pharma Giants Today,2015-06-17 16:06:00-04:00,BIIB,neutral
162767.0,Big Biotech Stocks See Declining Short Interest,2015-06-12 07:57:00-04:00,BIIB,positive
162768.0,Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference,2015-06-11 13:36:00-04:00,BIIB,neutral
162769.0,Hedge Funds Buying Biotech IPO Operated By Ex-Fund Manager,2015-06-10 11:19:00-04:00,BIIB,neutral
162770.0,Biogen Reports Samsung Bioepis Drugs Well Tollerated,2015-06-10 06:04:00-04:00,BIIB,positive
162771.0,5 NASDAQ Healthcare Stocks With The Highest EPS,2015-05-20 09:23:00-04:00,BIIB,neutral
162772.0,3 Biotech Stocks See Growing Short Interest,2015-05-13 09:40:00-04:00,BIIB,positive
162773.0,Biogen Announces $5B Buyback Plan To Take Place Over A Five Year Period,2015-05-07 17:20:00-04:00,BIIB,neutral
162774.0,Isis Pharma Reports Earned $10M Milestone Payment from Biogen,2015-04-30 17:19:00-04:00,BIIB,neutral
162775.0,Biogen Or Bluebird: Which Will Lead In SCD?,2015-04-30 12:42:00-04:00,BIIB,neutral
162776.0,Expert: Biogen Is Closing In On The 'Holy Grail' For Biotech Stocks,2015-04-30 12:01:00-04:00,BIIB,neutral
162777.0,"AbbVie, Biogen Announce FDA Acceptance of BLA for ZINBRYTA for Treatment of MS",2015-04-29 07:31:00-04:00,BIIB,positive
162778.0,"Hearing Biogen CEO Scangos Currently Speaking in Boston: Investing $2.5B Before Alzheimer's Trial Outcome Known, Planning Two Phase 3 Trials with 2.7-2.8K Patients",2015-04-27 16:40:00-04:00,BIIB,neutral
162779.0,Biogen Continues To Decline After Friday's Rout,2015-04-27 14:26:00-04:00,BIIB,neutral
162780.0,"Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?",2015-04-27 10:59:00-04:00,BIIB,neutral
162781.0,Oppenheimer Assumes Biogen at Perform,2015-04-27 08:34:00-04:00,BIIB,neutral
162782.0,Swedish Orphan Biovitrum AB Confirms Receipt of Preliminary and Conditional Non-binding Proposal for Acquisition of All Shares Issued by Company,2015-04-27 05:00:00-04:00,BIIB,positive
162783.0,"Pfizer, Biogen Potential Buyers for Swedish Orphan Biovitrum AB, According to Sources -Bloomberg",2015-04-25 17:45:00-04:00,BIIB,neutral
162784.0,Biogen Shares Not Too Healthy After Q1 Miss,2015-04-24 15:14:00-04:00,BIIB,negative
162785.0,Morgan Stanley Reviews Biogen Earnings,2015-04-24 09:56:00-04:00,BIIB,neutral
162786.0,"Biogen Misses Q1 Estimates, Shares Slide",2015-04-24 08:31:00-04:00,BIIB,positive
162787.0,"Biogen Q1 EPS $3.82 vs $3.91 est, Revenue $2.55B vs $2.6B Est.",2015-04-24 07:01:00-04:00,BIIB,neutral
162788.0,Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni,2015-04-24 06:36:00-04:00,BIIB,negative
162789.0,"Must Watch Stocks for April 24, 2015",2015-04-24 05:14:00-04:00,BIIB,neutral
162790.0,"Earning & Economic Calendar for Friday April 24, 2015",2015-04-24 04:52:00-04:00,BIIB,neutral
162791.0,"Earnings Scheduled For April 24, 2015",2015-04-24 04:19:00-04:00,BIIB,neutral
162792.0,Kyle Bass Challenges Biogen Fumaderm Patent,2015-04-22 12:58:00-04:00,BIIB,positive
162793.0,Kyle Bass Files IPR vs Biogen,2015-04-22 11:02:00-04:00,BIIB,neutral
162794.0,US Stock Futures Rise Ahead Of Earnings,2015-04-21 07:52:00-04:00,BIIB,neutral
162795.0,PLEGRIDY 3-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients,2015-04-21 07:32:00-04:00,BIIB,positive
162796.0,CAR-T Therapy Stocks Hit Hard Following AACR Data,2015-04-20 13:44:00-04:00,BIIB,negative
162797.0,5 Biotech Earnings Under The Microscope This Week,2015-04-20 11:18:00-04:00,BIIB,neutral
162798.0,"Biogen Announces TECFIDERA Data Reinforces Strong, Sustained Efficacy for Newly-Diagnosed MS Patients",2015-04-20 07:30:00-04:00,BIIB,positive
162799.0,Why This Trader Likes Gilead Better Than Biogen,2015-04-19 14:50:00-04:00,BIIB,positive
162800.0,It's A Big Weekend For Biotech,2015-04-17 16:31:00-04:00,BIIB,neutral
162801.0,"GoPro, Avon and Intel Highlight Tuesday's After-Hours Movers",2015-04-14 20:03:00-04:00,BIIB,positive
162802.0,Biogen Reports New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair,2015-04-14 16:06:00-04:00,BIIB,neutral
162803.0,Biogen Investors: Active Ingredient In Patient Death Is Not Changing BofA's Forecast,2015-04-09 12:20:00-04:00,BIIB,negative
162804.0,"Inovio Pharmaceuticals, Zynga Among Big Movers In Wednesday's After-Hours Session",2015-04-08 18:23:00-04:00,BIIB,neutral
162805.0,Bloomberg Reports Patient Using Drub Similar to Biogen's Tecfidera Died While Taking the Drug,2015-04-08 17:02:00-04:00,BIIB,negative
162806.0,"Biomed Realty Signs Biogen to 80,000 Square Feet Lease in Cambridge, MA",2015-04-02 12:04:00-04:00,BIIB,neutral
162807.0,How RBC Capital Called A 50% Gain In This Biotech Stock,2015-04-02 07:31:00-04:00,BIIB,positive
162808.0,Barclays Raises Biogen Forecasts After Physician Survey,2015-04-01 09:20:00-04:00,BIIB,neutral
162809.0,"Bulls, Bears Squaring Off At Biogen",2015-03-30 11:31:00-04:00,BIIB,neutral
162810.0,"US Stock Futures Edge Lower Ahead Of GDP, Consumer Sentiment Data",2015-03-27 08:07:00-04:00,BIIB,negative
162811.0,"Biogen, AbbVie Announce EMA Validates Marketing Authorisation Application for ZINBRYTA for Treatment of MS",2015-03-27 07:02:00-04:00,BIIB,positive
162812.0,Is It Closing Time At The Biotech Bar?,2015-03-26 13:45:00-04:00,BIIB,neutral
162813.0,"Biogen's Alzheimer's Drug Is Promising, Wall Street Says",2015-03-24 16:48:00-04:00,BIIB,positive
162814.0,Why Intercept Might Be A Better Bet Than Biogen Right Now,2015-03-24 07:43:00-04:00,BIIB,positive
162815.0,Weekly Options Outlook: Bulls Leave Money On The Table Despite A Week-End Win,2015-03-23 14:21:00-04:00,BIIB,negative
162816.0,Biogen: The Day After,2015-03-23 13:10:00-04:00,BIIB,neutral
162817.0,ICYMI: Pharmaceutical Stocks Are Moving Big On Monday,2015-03-23 12:13:00-04:00,BIIB,neutral
162818.0,Morning Market Losers,2015-03-23 10:02:00-04:00,BIIB,negative
162819.0,"Stifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, Overvaluation",2015-03-23 08:46:00-04:00,BIIB,negative
162820.0,Benzinga's Top #PreMarket Losers,2015-03-23 08:15:00-04:00,BIIB,negative
162821.0,Stifel Nicolaus Downgrades Biogen Idec to Hold,2015-03-23 06:25:00-04:00,BIIB,neutral
162822.0,UPDATE: Biogen Idec Becomes Biogen,2015-03-23 06:05:00-04:00,BIIB,neutral
162823.0,"Biogen Idec to be Become Biogen; CEO Says Co to Expand Drug Pipeline to Include Alzheimer's, ALS Treatments -Reuters",2015-03-23 04:38:00-04:00,BIIB,positive
162824.0,These 4 Stocks Finished The Week At All-Time Highs,2015-03-22 16:40:00-04:00,BIIB,neutral
162825.0,Major Profit-Taking In Biogen As It Bolts To New All-Time Highs,2015-03-20 10:51:00-04:00,BIIB,neutral
162826.0,Benzinga's Volume Movers,2015-03-20 10:18:00-04:00,BIIB,neutral
162827.0,Morning Market Gainers,2015-03-20 09:37:00-04:00,BIIB,neutral
162828.0,Biotech Stocks Soar Amid Positive News,2015-03-20 08:54:00-04:00,BIIB,positive
162829.0,Benzinga's Top #PreMarket Gainers,2015-03-20 08:14:00-04:00,BIIB,positive
162830.0,US Stock Futures Signal Higher Start On Wall Street,2015-03-20 07:39:00-04:00,BIIB,neutral
162831.0,UPDATE: Biogen Shares +5% Premarket on Positive Alzheimer's Study Results,2015-03-20 06:37:00-04:00,BIIB,positive
162832.0,Biogen Shares Rise ~2% Premarket on Light Trading Following Alzheimer's Study Results,2015-03-20 05:48:00-04:00,BIIB,positive
162833.0,"UPDATE: Biogen Says Alzheimer's Drug Shows Significant Reduction in Amyloid Brain Plaque, Slows Cognitive Decline vs Placebo in Phase I Study; Enrollment in Phase III Trial to Begin Later This Year",2015-03-20 05:40:00-04:00,BIIB,positive
162834.0,Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD Conference,2015-03-20 05:37:00-04:00,BIIB,positive
162835.0,Analysts See Biogen Catalyst Coming On Friday,2015-03-17 13:18:00-04:00,BIIB,neutral
162836.0,Analyst Sees Upside To Outlook At 4 Biotechs,2015-03-13 14:44:00-04:00,BIIB,neutral
162837.0,The 4 Biggest Biotech Stocks In The Market,2015-03-11 13:49:00-04:00,BIIB,neutral
162838.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,BIIB,neutral
162839.0,"Biogen, Sobi Announce Positive Top-Line Efficacy and Safety Results from Phase 3 ALPROLIX Pediatric Study",2015-02-27 07:11:00-05:00,BIIB,positive
162840.0,The Catalysts Biogen Idec Investors Should Watch,2015-02-24 18:32:00-05:00,BIIB,neutral
162841.0,Evercore ISI Technical Analysis: The 'Single Best Idea',2015-02-23 07:34:00-05:00,BIIB,positive
162842.0,4 Stocks Wall Street Loves This Year...And 4 It Doesn't,2015-02-16 20:59:00-05:00,BIIB,positive
162843.0,UPDATE: Isis Pharmaceuticals Earns $5M Milestone Payment from Biogen Idec,2015-02-10 08:35:00-05:00,BIIB,neutral
162844.0,"After A Blockbuster 2014, What Will 2015 Hold For Pharmaceutical M&A?",2015-02-06 15:28:00-05:00,BIIB,positive
162845.0,Should You Stick With Biogen Stock?,2015-02-04 14:44:00-05:00,BIIB,neutral
162846.0,iShares NASDAQ Biotech ETF Pulls Back Off All-Time Highs,2015-02-02 14:26:00-05:00,BIIB,neutral
162847.0,"Biotech Breakdown: Market Breaks...Gilead, Kite Pharma & Biogen Idec Worth Watching",2015-02-01 21:14:00-05:00,BIIB,positive
162848.0,Stocks Hitting 52-Week Highs,2015-01-30 10:33:00-05:00,BIIB,neutral
162849.0,Morning Market Gainers,2015-01-30 09:51:00-05:00,BIIB,neutral
162850.0,"Friday Morning Movers: Amazon Pops, Deckers Outdoor Plummets Following Earnings Results",2015-01-30 09:27:00-05:00,BIIB,positive
162851.0,Biogen Idec Q4 Net Nearly Doubles; Beats Views,2015-01-29 17:03:00-05:00,BIIB,neutral
162852.0,"Biogen Reports Q4 Adj. EPS $4.09 vs $3.78 Est., Sales $2.64B vs $2.64B Est.; Sees FY Adj. EPS $16.60-$17",2015-01-29 16:02:00-05:00,BIIB,neutral
162853.0,"Notable Earnings After The Close: AMZN, GOOG, V, BIIB",2015-01-29 15:50:00-05:00,BIIB,neutral
162854.0,"Credit Suisse Previews Biogen, Says 'Consensus Tecfidera Downgrades = Pipeline Buying Opportunity'",2015-01-29 10:23:00-05:00,BIIB,positive
162855.0,"Earnings Scheduled For January 29, 2015",2015-01-29 04:45:00-05:00,BIIB,neutral
162856.0,"Biogen Idec, Fondazione Telethon, Ospedale San Raffaele to Collaboration to Develop Gene Therapies for Hemophilia",2015-01-29 04:45:00-05:00,BIIB,neutral
162857.0,"Earnings Scheduled For January 28, 2015",2015-01-28 05:02:00-05:00,BIIB,neutral
162858.0,"Must Watch Stocks for January 28, 2015",2015-01-28 04:02:00-05:00,BIIB,neutral
162859.0,"Biogen Idec to Report Q4 And Year End 2014 Financial Results on January 29, 2015 Instead Of Wednesday January 28, 2015",2015-01-26 17:32:00-05:00,BIIB,neutral
162860.0,5 Big Biotech Earnings Releases To Watch This Week,2015-01-26 14:34:00-05:00,BIIB,neutral
162861.0,The 5 Biggest Biotech Stocks,2015-01-20 16:43:00-05:00,BIIB,neutral
162862.0,Jefferies 'Encouraged' By Biogen Idec's New Data,2015-01-20 12:28:00-05:00,BIIB,neutral
162863.0,Nomura's Takeways From Biogen Idec's Analyst Meeting,2015-01-16 11:06:00-05:00,BIIB,neutral
162864.0,Biogen Idec To Acquire Convergence Pharmaceuticals In Deal Worth $675 Million,2015-01-14 12:50:00-05:00,BIIB,positive
162865.0,"UPDATE: Biogen Idec Acquisition of Convergence Pharmaceuticals was Announced on January 11,  International Biotechnology Trust Mentioned the Acquisition on Wednesday",2015-01-14 11:15:00-05:00,BIIB,positive
162866.0,A Look At 3 Biotech Stocks With Upside Potential,2015-01-12 16:25:00-05:00,BIIB,neutral
162867.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,BIIB,neutral
162868.0,"UPDATE: Biogen to Pay Convergence Shareholders Upfront Payment of $200M, Plus Up to Additional $475M Contingent on Future Milestones",2015-01-11 20:07:00-05:00,BIIB,negative
162869.0,Biogen Idec to Acquire Convergence Pharmaceuticals,2015-01-11 20:04:00-05:00,BIIB,neutral
162870.0,These Stocks Are Trending On Social Media This Thursday,2015-01-08 12:37:00-05:00,BIIB,neutral
162871.0,"Biogen Reports anti-LINGO Treatment Shows Evidence of Primary Endpoint Improvement, No Effect on Secondary Endpoint",2015-01-08 07:31:00-05:00,BIIB,positive
162872.0,J.P Morgan Just Chimed In With Ratings On Biotech Stocks,2015-01-06 16:34:00-05:00,BIIB,neutral
162873.0,What Investors Are Looking For In NPS Pharmaceuticals Ahead Of A Potential Sale,2015-01-06 12:34:00-05:00,BIIB,neutral
162874.0,UPDATE: Barclays Capital Initiates Coverage On Biogen On Tecfidera Upside,2015-01-06 10:00:00-05:00,BIIB,neutral
162875.0,Benzinga's Top Initiations,2015-01-06 09:30:00-05:00,BIIB,positive
162876.0,Barclays Initiates Biogen Idec At Overweight,2015-01-06 08:23:00-05:00,BIIB,negative
162877.0,"Barclays Initiates Coverage on Biogen Idec at Overweight, Announces $425.00 PT",2015-01-06 06:16:00-05:00,BIIB,negative
162878.0,"CORRECTION: Nomura Downgrades Biogen Idec to Neutral, Lowers PT to $378.00",2015-01-05 06:42:00-05:00,BIIB,negative
162879.0,"Nomura Downgrades Biogen Idec to Neutral, Lowers PT to $378.00",2015-01-05 06:41:00-05:00,BIIB,negative
162880.0,Are There Any Winners Left In The Biotech Space?,2014-12-24 13:01:00-05:00,BIIB,positive
162881.0,How Gilead And Johnson & Johnson's Tumble Could've Burned These Hedge Funds,2014-12-24 11:27:00-05:00,BIIB,neutral
162882.0,Morning Market Losers,2014-12-22 10:01:00-05:00,BIIB,negative
162883.0,Benzinga's Top #PreMarket Losers,2014-12-22 08:18:00-05:00,BIIB,negative
162884.0,Is Illumina Worth Adding To Your Portfolio?,2014-12-17 08:34:00-05:00,BIIB,positive
162885.0,"The Biotech Stock With The Most Upside In 2015, According To Morgan Stanley",2014-12-11 13:02:00-05:00,BIIB,neutral
162886.0,3 Biotech ETFs Rally On Merger News,2014-12-08 17:43:00-05:00,BIIB,neutral
162887.0,"Great News For Biogen, But What's Next For The Stock?",2014-12-03 12:36:00-05:00,BIIB,positive
162888.0,A Technical Look At Biogen's Huge Rally,2014-12-03 12:14:00-05:00,BIIB,positive
162889.0,"Biogen Announces Expanded Data from Phase 3 Studies Further Define the Safety, Efficacy of ELOCTATE, ALPROLIX",2014-12-03 07:19:00-05:00,BIIB,positive
162890.0,Markets Close Higher Following Strong November Auto Sales,2014-12-02 16:46:00-05:00,BIIB,positive
162891.0,Deutsche Bank Sees More Upside For Biogen,2014-12-02 13:15:00-05:00,BIIB,neutral
162892.0,Why Biogen Shares Soared Today,2014-12-02 11:34:00-05:00,BIIB,positive
162893.0,Biogen Up Sharply On Promising Alzheimer's Results,2014-12-02 10:02:00-05:00,BIIB,positive
162894.0,"CNBC's Meg Tirrell Tweets: '$BIIB up 5% pre-market as Alzheimer's drug BIIB037 shows promise in ph 1b study, co outlines plans to move to ph 3'",2014-12-02 08:41:00-05:00,BIIB,positive
162895.0,"Biogen Shares Spiking Higher, Now Up More Than 15 Points",2014-12-02 08:37:00-05:00,BIIB,positive
162896.0,FDA Orders New Label For Biogen Idec's MS Drug,2014-11-25 14:05:00-05:00,BIIB,neutral
162897.0,Biogen Shares Now Down 0.6% Following FDA Warning,2014-11-25 11:09:00-05:00,BIIB,negative
162898.0,UPDDATE: FDA Says Information Describing Case of PML Being Added to Tecfidera Label,2014-11-25 11:09:00-05:00,BIIB,neutral
162899.0,"UPDATE: FDA Says MS Patient Treated With Biogen's Tecfidera Developed Serious Brain Infection, Later Died",2014-11-25 11:06:00-05:00,BIIB,negative
162900.0,FDA Warns About Case Of Rare Brain Infection With Biogen's MS Drug,2014-11-25 11:04:00-05:00,BIIB,negative
162901.0,UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS Risk,2014-11-19 09:58:00-05:00,BIIB,positive
162902.0,"Credit Suisse Maintains Outperform on Biogen Idec Inc., Lowers PT to $400.00",2014-11-19 08:15:00-05:00,BIIB,positive
162903.0,The Bull/Bear Breakdown On Biogen Idec,2014-11-13 14:41:00-05:00,BIIB,neutral
162904.0,"Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings",2014-10-23 11:25:00-04:00,BIIB,neutral
162905.0,"US Stock Futures Rise Ahead Of Earnings, Economic Data",2014-10-23 07:41:00-04:00,BIIB,neutral
162906.0,Leading Researchers Join Biogen Idec To Advance Drug Discovery For Neurodegenerative Diseases,2014-10-23 07:31:00-04:00,BIIB,positive
162907.0,Markets Reverse Early Morning Gains Following Canadian Shooting,2014-10-22 16:43:00-04:00,BIIB,positive
162908.0,CORRECTION: Baird Upgrades Biogen Idec Inc. to Outperform,2014-10-22 12:26:00-04:00,BIIB,neutral
162909.0,Baird Upgrades Biogen Idec Inc. to Outperform,2014-10-22 12:25:00-04:00,BIIB,neutral
162910.0,Hearing Biogen Idec Upgrade at Baird,2014-10-22 12:23:00-04:00,BIIB,neutral
162911.0,Morning Market Losers ,2014-10-22 09:55:00-04:00,BIIB,negative
162912.0,Biogen Idec Shares Fall 5% Premarket on Report of Patient Death; Patient was Taking MS Drug Tecfidera and Died of Pneumonia,2014-10-22 09:23:00-04:00,BIIB,negative
162913.0,Benzinga's Top #PreMarket Losers,2014-10-22 08:43:00-04:00,BIIB,negative
162914.0,"UPDATE: Biogen Idec Posts Upbeat Q3 Results, Raises Earnings Forecast",2014-10-22 07:30:00-04:00,BIIB,neutral
162915.0,Biogen Idec Inc. Reports Q3 EPS of $3.80 vs $3.46 Est; Revenue of $2.50B vs $2.48B Est,2014-10-22 07:04:00-04:00,BIIB,neutral
162916.0,"Earnings Scheduled For October 22, 2014",2014-10-22 05:16:00-04:00,BIIB,neutral
162917.0,Which Fund Has The Most To Gain From Biogen Idec?,2014-10-13 10:05:00-04:00,BIIB,positive
162918.0,Biogen Idec Inc's Stock Is Set To Drop,2014-10-09 07:26:00-04:00,BIIB,negative
162919.0,#Premarket Prep Technical Update - Biogen Trading Higher,2014-10-03 14:56:00-04:00,BIIB,neutral
162920.0,Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech Peers,2014-09-30 15:17:00-04:00,BIIB,negative
162921.0,2 Columbia Growth Funds Notch Impressive Three-Month Performance,2014-09-18 10:52:00-04:00,BIIB,positive
162922.0,Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA ,2014-09-12 07:31:00-04:00,BIIB,positive
162923.0,"Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses",2014-09-11 08:17:00-04:00,BIIB,negative
162924.0,"Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients",2014-09-11 07:32:00-04:00,BIIB,positive
162925.0,"Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA Provides Strong, Sustained Efficacy for RRMS",2014-09-11 07:31:00-04:00,BIIB,positive
162926.0,Have We Seen The Market's Top?,2014-09-09 14:40:00-04:00,BIIB,positive
162927.0,"Allianz's Analyst Likes Biogen Idec Inc, Celgene Corporation & Gilead",2014-09-06 17:28:00-04:00,BIIB,positive
162928.0,Biogen Announces Health Canada Has Okayed Eloctate,2014-08-26 08:07:00-04:00,BIIB,neutral
162929.0,"Isis Pharmaceuticals Says on August 21, 2014, First Infant Received  First Dose of Isis-SMNRXx In Phase 3 Study; Isis Earned $18M Milestone Payment from Biogen",2014-08-21 16:52:00-04:00,BIIB,neutral
162930.0,8-K from Isis Pharma Shows Co. Earned $18M Milestone Payment from Biogen Related to ISIS-SMNRx Phase 3 Study,2014-08-21 16:19:00-04:00,BIIB,neutral
162931.0,UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval,2014-08-18 07:50:00-04:00,BIIB,positive
162932.0,Biogen Idec's PLEGRIDY Approved by FDA for Treatment of MS,2014-08-16 08:36:00-04:00,BIIB,positive
162933.0,"#PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq",2014-08-08 07:00:00-04:00,BIIB,neutral
162934.0,Top 4 Stocks In The Biotechnology Industry With The Highest Revenue,2014-08-07 04:24:00-04:00,BIIB,positive
162935.0,Why Investors Should Closely Watch Celgene,2014-08-06 16:53:00-04:00,BIIB,neutral
162936.0,Regulus Enters New Collaboration Agreement with Biogen; Regulus to Receive $2M Upfront with Potential Future Milestone Payments,2014-08-05 08:12:00-04:00,BIIB,positive
162937.0,Vertex Is Poised For An Earnings Breakout,2014-07-23 15:56:00-04:00,BIIB,positive
162938.0,Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout Target,2014-07-23 15:46:00-04:00,BIIB,positive
162939.0,Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip,2014-07-23 14:19:00-04:00,BIIB,positive
162940.0,Biogen Announces PLEGRIDY Approved in EU for Treatment of MS,2014-07-23 11:44:00-04:00,BIIB,positive
162941.0,Markets Mixed; PepsiCo Q2 Earnings Beat Street View,2014-07-23 11:19:00-04:00,BIIB,neutral
162942.0,Morning Market Movers ,2014-07-23 09:41:00-04:00,BIIB,neutral
162943.0,"UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, Shares Surge",2014-07-23 09:13:00-04:00,BIIB,positive
162944.0,Biogen Conference Call Starts,2014-07-23 09:03:00-04:00,BIIB,neutral
162945.0,Benzinga's Top #PreMarket Gainers,2014-07-23 08:13:00-04:00,BIIB,positive
162946.0,Biogen Idec Reports Q2 Adjusted EPS of $3.49 vs $2.80 Est; Revenue of $2.40B vs $2.14B Est,2014-07-23 06:52:00-04:00,BIIB,neutral
162947.0,"Earnings Scheduled For July 23, 2014",2014-07-23 05:26:00-04:00,BIIB,neutral
162948.0,Biotech Enters Reporting Season With Large Caps Central To Sector Performance,2014-07-18 15:40:00-04:00,BIIB,neutral
162949.0,Deutsche Bank Analyst Talks Up Biogen On CNBC; Stock Responds Slightly,2014-07-09 12:32:00-04:00,BIIB,neutral
162950.0,Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector,2014-07-03 12:26:00-04:00,BIIB,neutral
162951.0,Top 4 Stocks In The Biotechnology Industry With The Highest EPS,2014-06-25 04:54:00-04:00,BIIB,positive
162952.0,#Premarket Prep Technical Update - Biogen Trading Lower,2014-06-23 14:01:00-04:00,BIIB,negative
162953.0,ISIS Pharma Trades Up Premarket; NYT Says Has Potential Heart Attack Drug,2014-06-19 10:27:00-04:00,BIIB,negative
162954.0,Isis Pharmaceuticals Announces $10M Milestone Payment from Biogen,2014-06-17 07:02:00-04:00,BIIB,neutral
162955.0,"Benzinga's M&A Chatter for Monday June 16, 2014",2014-06-16 20:53:00-04:00,BIIB,neutral
162956.0,"Biogen, AbbVie Report Positive Top-Line Results from Phase 3 Trial of Daclizumaba for MS",2014-06-16 07:32:00-04:00,BIIB,positive
162957.0,UPDATE: Morgan Stanley Reiterates On Biogen Idec As Positive RPC1063 Data Poses Threat To Tecfidera,2014-06-10 09:16:00-04:00,BIIB,positive
162958.0,UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Good News On Eloctate,2014-06-09 10:00:00-04:00,BIIB,positive
162959.0,US Stock Futures Slightly Lower Ahead Of McDonald's Sales Report,2014-06-09 07:27:00-04:00,BIIB,negative
162960.0,"Isis Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1, Earns $15M Milestone from Biogen ",2014-06-09 07:17:00-04:00,BIIB,positive
162961.0,"FDA Has Approved Biogen's Eloctate for Use in Adults, Children with Hemophilia A",2014-06-06 16:21:00-04:00,BIIB,positive
162962.0,ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica & Targeted Therapy,2014-06-04 10:32:00-04:00,BIIB,neutral
162963.0,Market Wrap For May 29: Investors Welcome Another Record High For The S&P 500,2014-05-29 16:41:00-04:00,BIIB,positive
162964.0,JP Morgan Ratings Imply Pharma Pair Trade,2014-05-29 14:19:00-04:00,BIIB,positive
162965.0,#Premarket Technical Update - Biogen Trading Higher,2014-05-29 11:39:00-04:00,BIIB,neutral
162966.0,"UPDATE: JP Morgan Upgrades Biogen, Seeing Upside To Shares",2014-05-29 08:48:00-04:00,BIIB,positive
162967.0,Benzinga's Top Upgrades,2014-05-29 07:48:00-04:00,BIIB,positive
162968.0,"JP Morgan Upgrades Biogen Idec Inc. to Overweight, Raises PT to $375.00",2014-05-29 06:24:00-04:00,BIIB,neutral
162969.0,Array Announces Drug Discovery Deal with Biogen,2014-05-28 09:00:00-04:00,BIIB,neutral
162970.0,"Biogen Reports Adoption of Positive Opinion for Plegridy, Expecting EC Decision on MAA in 2H of This Year",2014-05-23 08:00:00-04:00,BIIB,positive
162971.0,Five Star Biotech Stock Watch: Biogen Idec,2014-05-21 13:40:00-04:00,BIIB,neutral
162972.0,"Richard Rudick Named VP Of Development Sciences, Value Based Medicine at Biogen",2014-05-12 07:20:00-04:00,BIIB,positive
162973.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS,2014-05-09 04:48:00-04:00,BIIB,positive
162974.0,UPDATE: Biogen Reports TYSABRI Improved Walking Speed in Significant Number of MS Patients,2014-05-01 07:48:00-04:00,BIIB,positive
162975.0,Biogen Says Tysabri Shows Improved Walking Speed in MS Patients,2014-05-01 07:46:00-04:00,BIIB,positive
162976.0,Biogen to Present Plegridy Data from Phase 3 Study at AAN Annual Meeting,2014-04-29 07:31:00-04:00,BIIB,neutral
162977.0,Market Wrap For April 28: Apple Hits New 52-Week Highs In a Volatile Start To the Trading Week,2014-04-28 16:34:00-04:00,BIIB,neutral
162978.0,#Premarket Technical Update - Biogen Continues Lower,2014-04-28 12:24:00-04:00,BIIB,negative
162979.0,Biotech Stocks Hedge Funds Are Betting On,2014-04-25 17:18:00-04:00,BIIB,neutral
162980.0,U.S.-Russia Tensions Over Ukraine Could Make This An Interesting Weekend,2014-04-25 15:37:00-04:00,BIIB,neutral
162981.0,"Biogen Raises Full-Year Earnings, But Is That The Entire Picture?",2014-04-24 17:03:00-04:00,BIIB,neutral
162982.0,Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine Concerns,2014-04-24 16:41:00-04:00,BIIB,neutral
162983.0,"Quintiles, Biogen Idec Announce Comprehensive Clinical Development Partnership",2014-04-24 08:01:00-04:00,BIIB,positive
162984.0,"Nomura Maintains Buy on Biogen Idec Inc., Raises PT to $415.00",2014-04-24 07:33:00-04:00,BIIB,neutral
162985.0,"Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple Announces 7-for-1 Stock Split",2014-04-23 16:46:00-04:00,BIIB,positive
162986.0,#Premarket Technical Update - Biogen Trading Lower After Earnings,2014-04-23 14:39:00-04:00,BIIB,negative
162987.0,"Biogen in 10Q Reports State, Federal Authorities Investigating Sales and Promotional Practices",2014-04-23 13:43:00-04:00,BIIB,positive
162988.0,Biogen Idec Inc. Sees FY2014 EPS $11.35-11.45 vs $11.32 Est,2014-04-23 07:13:00-04:00,BIIB,neutral
162989.0,Biogen Idec Inc. Reports Q1 EPS of $2.47 vs $2.57 Est; Revenue of $2.13B vs $2.0B Est,2014-04-23 07:01:00-04:00,BIIB,neutral
162990.0,"Earnings Scheduled For April 23, 2014",2014-04-23 05:15:00-04:00,BIIB,neutral
162991.0,Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII; Amunix Could Recieve up to $39M,2014-04-21 08:02:00-04:00,BIIB,positive
162992.0,Citigroup Saves The Market ,2014-04-14 13:31:00-04:00,BIIB,neutral
162993.0,Biogen to Present Clinical Data from Neurology Portfolio at AAN Annual Meeting,2014-04-14 07:31:00-04:00,BIIB,neutral
162994.0,Market Wrap For April 10: Wednesday's Rally Completely Forgotten,2014-04-10 16:33:00-04:00,BIIB,negative
162995.0,"Biogen Announces Naming of Adam Koppel as Senior VP, Chief Strategy Officer",2014-04-10 07:30:00-04:00,BIIB,neutral
162996.0,Biogen Idec And Sobi Announce Positive Top-Line Efficacy And Safety Results From Phase 3 Pediatric Study Of Investigational Therapy Eloctate For Hemophilia A ,2014-04-10 07:10:00-04:00,BIIB,positive
162997.0,Biotechs Struggling To Find A Bottom,2014-04-08 10:24:00-04:00,BIIB,negative
162998.0,"Sobi, Biogren Announce FDA Approves Alprolix) ",2014-03-31 05:42:00-04:00,BIIB,positive
162999.0,FDA Says Biogen's Alprolix for Hemophilia B Patients Approved,2014-03-28 16:39:00-04:00,BIIB,positive
163000.0,Market Wrap For March 27: Markets Lower Following Mixed Economic Data,2014-03-27 17:39:00-04:00,BIIB,negative
163001.0,Biotech ETFs Come Back Down To Earth,2014-03-27 16:29:00-04:00,BIIB,neutral
163002.0,Morgan Stanley's Top Biotech Pick is Biogen,2014-03-27 15:57:00-04:00,BIIB,positive
163003.0,"Morgan Stanley Initiates Coverage on Biogen Idec Inc. at Overweight, Announces $395.00 PT",2014-03-27 07:04:00-04:00,BIIB,negative
163004.0,Morgan Stanley Starts Biogen Idec With Overweight; $395 PT,2014-03-26 16:20:00-04:00,BIIB,negative
163005.0,Adding Downside Protection To Biogen,2014-03-25 18:46:00-04:00,BIIB,negative
163006.0,Have We Seen The Top Of The Market?,2014-03-24 14:32:00-04:00,BIIB,positive
163007.0,Health Canada Approves Biogen's Long-Acting ALPROLIX Therapy,2014-03-21 08:00:00-04:00,BIIB,positive
163008.0,"AVEO Announces Deal with Biogen, Regains Global Rights to AV-203",2014-03-20 16:31:00-04:00,BIIB,neutral
163009.0,Market Wrap For March 19: Yellen Hints of Higher Rates & Sooner Than Expected End To Taper,2014-03-19 18:03:00-04:00,BIIB,neutral
163010.0,UPDATE: Stifel Reiterates on Biogen Idec Following Hemophilia Survey,2014-03-19 08:12:00-04:00,BIIB,neutral
163011.0,"Stifel Nicolaus Maintains Buy on Biogen Idec Inc., Raises PT to $376.00",2014-03-19 06:47:00-04:00,BIIB,neutral
163012.0,Market Wrap For March 18: Markets Positive Despite Crimea Concerns,2014-03-18 16:35:00-04:00,BIIB,positive
163013.0,"Biogen Announces Received Notice of PDUFA Date Extension for Plegridy, Extended by Three Months",2014-03-18 07:31:00-04:00,BIIB,neutral
163014.0,"Keurig Green Mountain, Biogen Shares Rally Following Additions to S&P Indices‏",2014-03-17 13:06:00-04:00,BIIB,positive
163015.0,"BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, BMRN, MDVN)",2014-03-12 10:01:00-04:00,BIIB,positive
163016.0,Market Wrap For March 7: Markets Cap Off Positive Week With Small Gains,2014-03-07 16:31:00-05:00,BIIB,positive
163017.0,Biogen Shares Down 4%; Seeing Mixed Analyst Sentiment on IMS Tracking on Tecfidera,2014-03-07 12:54:00-05:00,BIIB,positive
163018.0,Benzinga's Top Upgrades,2014-03-06 08:22:00-05:00,BIIB,positive
163019.0,"BMO Capital Upgrades Biogen Idec Inc. to Outperform, Raises PT to $422.00",2014-03-06 07:44:00-05:00,BIIB,neutral
163020.0,Market Wrap For March 5: Markets Calm Following Tuesday's Massive Rally,2014-03-05 16:40:00-05:00,BIIB,positive
163021.0,US Stock Futures Flat Ahead Of ADP Jobs Report,2014-03-05 07:32:00-05:00,BIIB,neutral
163022.0,"Eisai, Biogen Enter Collaboration to Develop and Commercialize Alzheimer's Disease Treatments ",2014-03-05 05:36:00-05:00,BIIB,neutral
163023.0,Biotechs vs. Pharmaceuticals: What's the Difference?,2014-03-04 10:30:00-05:00,BIIB,neutral
163024.0,"Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, BMRN)",2014-02-27 12:26:00-05:00,BIIB,positive
163025.0,Moody's Upgrades Biogen Idec To Baa1; Outlook Stable,2014-02-26 13:14:00-05:00,BIIB,positive
163026.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2014-02-26 04:18:00-05:00,BIIB,negative
163027.0,Biogen Idec's Chairman William D. Young to Retire From Board of Directors ,2014-02-15 19:36:00-05:00,BIIB,neutral
163028.0,"Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to $400.00",2014-02-14 06:38:00-05:00,BIIB,positive
163029.0,UPDATE: Isis to Receive $2M Milestone Payment from Biogen Idec,2014-02-13 07:10:00-05:00,BIIB,neutral
163030.0,"Three ETFs To Buy On The Pullback (PJP, SKYY, SPY)",2014-02-10 09:13:00-05:00,BIIB,neutral
163031.0,Index Investing Is A Raw Deal: Here's A Better Approach,2014-02-07 10:42:00-05:00,BIIB,positive
163032.0,First Step to a Winning Investment Strategy,2014-02-03 10:54:00-05:00,BIIB,positive
163033.0,"Biogen Announces TECFIDERA Approved in EU as First-Line Oral Treatment for MS, Will Introduce TECFIDERA in EU in Coming Weeks",2014-02-03 08:56:00-05:00,BIIB,positive
163034.0,"Biogen, UCB Annouince Agreements to Commercialize MS, Hemophilia Therapies in Asia ",2014-01-30 05:45:00-05:00,BIIB,positive
163035.0,"New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)",2014-01-29 11:44:00-05:00,BIIB,positive
163036.0,Top Trending Tickers On StockTwits For January 29,2014-01-29 09:51:00-05:00,BIIB,positive
163037.0,US Stock Futures Flat; All Eyes On Fed Decision,2014-01-29 07:14:00-05:00,BIIB,neutral
163038.0,UPDATE: Biogen Idec Posts Higher Q4 Profit,2014-01-29 07:01:00-05:00,BIIB,positive
163039.0,Biogen Idec Reports Q4 Adjusted EPS of $2.34 vs $2.28 Est; Revenue of $1.97B vs $1.93B Est,2014-01-29 06:35:00-05:00,BIIB,neutral
163040.0,"Earnings Scheduled For January 29, 2014",2014-01-29 04:45:00-05:00,BIIB,neutral
163041.0,"Deutsche Bank Boosts Target on Gilead to $132, on Celgene to $190, on Biogen to $415, Says We Would Be Buyers on Weakness",2014-01-28 08:07:00-05:00,BIIB,negative
163042.0,CNBC's Brian Sullivan Just Finished Talking with Biogen CEO Scangos at JP Morgan Healthcare Conference: Says Co. In Talks for Acquisitions,2014-01-13 14:17:00-05:00,BIIB,positive
163043.0,Market Wrap For January 9: All Eyes on Tomorrow's Job Report,2014-01-09 16:43:00-05:00,BIIB,neutral
163044.0,Mid-Day Market Update: U.S. Stocks Turn Red; Bed Bath & Beyond Shares Decline On Weak Q3 Earnings,2014-01-09 12:46:00-05:00,BIIB,negative
163045.0,Benzinga's Volume Movers,2014-01-09 10:28:00-05:00,BIIB,neutral
163046.0,Stocks Hitting 52-Week Highs,2014-01-09 10:23:00-05:00,BIIB,neutral
163047.0,Morning Market Movers ,2014-01-09 10:05:00-05:00,BIIB,neutral
163048.0,Benzinga's Top #PreMarket Gainers,2014-01-09 08:14:00-05:00,BIIB,positive
163049.0,"Sangamo BioSciences, Biogen Partnership to Develop Novel Therapies for Sickle Cell Disease, Beta-Thalassemia",2014-01-09 07:11:00-05:00,BIIB,positive
163050.0,Sunesis Pharmaceuticals Announces Global Licenses for Two Kinase Inhibitor Programs ,2014-01-09 07:06:00-05:00,BIIB,negative
163051.0,Benzinga's Top Initiations,2014-01-08 08:05:00-05:00,BIIB,positive
163052.0,"Nomura Initiates Coverage on Biogen Idec Inc. at Buy, Announces $368.00 PT",2014-01-08 07:47:00-05:00,BIIB,neutral
163053.0,UPDATE: Biogen Idec's Scangos Sees Tecfidera Offer to a Great Start in the US,2014-01-07 16:31:00-05:00,BIIB,positive
163054.0,"Biogen Idec CEO Scangos Currently Speaking at Goldman Healthcare Conference: Expecting Tecfidera Uptake in Europe Slower Than US, Will Roll Out One Country at a Time",2014-01-07 16:29:00-05:00,BIIB,neutral
163055.0,Slideshow: The Top 10 'Highs & Dives' Of S&P 500 Stocks In 2013,2013-12-17 09:38:00-05:00,BIIB,positive
163056.0,"Biogen Idec, Samsung Bioepis to Market Anti-TNF Biosimilar Product Candidates in Europe ",2013-12-17 05:44:00-05:00,BIIB,neutral
163057.0,"Biogen Idec, Pharmacyclics See Surges In Short Interest (BIIB, CELG, PCYC)",2013-12-11 13:47:00-05:00,BIIB,positive
163058.0,"Biogen, Orphan Biovitrum  Announce Positive ALPROLIX, ELOCTATE  Phase 3 Data Across Multiple Hemophilia Populations at ASH",2013-12-09 11:32:00-05:00,BIIB,positive
163059.0,"Biogen, Sobi Announce Publication of Phase 3 ALPROLIXTM Haemophilia B Study Data in NEJM",2013-12-05 05:59:00-05:00,BIIB,neutral
163060.0,"Biogen to Present New Data from Hemphilia Clinical Development, Research Programs",2013-12-03 07:33:00-05:00,BIIB,neutral
163061.0,Biogen Idec Receives PDUFA Date Extension for ALPROLIX from FDA,2013-12-02 07:33:00-05:00,BIIB,neutral
163062.0,Deutsche Bank Comments on How Biogen Idec May be Affected by Tecfidera IMS Data,2013-11-29 10:58:00-05:00,BIIB,negative
163063.0,UPDATE: Piper Jaffray Resumes Coverage on Biogen Idec as 2014 Biotech Sector Outlook Remains Strong,2013-11-27 11:05:00-05:00,BIIB,positive
163064.0,Piper Jaffray Reinstates Overweight on Biogen Idec Inc.,2013-11-26 16:21:00-05:00,BIIB,negative
163065.0,"ETF Outlook for Tuesday, November 26, 2013",2013-11-26 08:16:00-05:00,BIIB,neutral
163066.0,Market Wrap For November 22: Markets Finish The Week On a Positive Note,2013-11-22 16:57:00-05:00,BIIB,positive
163067.0,"Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to $340.00",2013-11-22 11:35:00-05:00,BIIB,neutral
163068.0,"Citi Lifts Target on Biogen from $260 to $320, Maintains Buy",2013-11-22 11:29:00-05:00,BIIB,neutral
163069.0,Credit Suisse Reiterates on Biogen Idec on Positive RDP Decision,2013-11-22 10:31:00-05:00,BIIB,positive
163070.0, Journal Publishes Pivotal Data Demonstrating Efficacy and Safety of ELOCTATE for Hemophilia A ,2013-11-13 10:11:00-05:00,BIIB,positive
163071.0,Gilead Sciences Leads In Rising Short Interest Among Biotechs ,2013-11-12 16:41:00-05:00,BIIB,positive
163072.0,UPDATE: Biogen's Kingsley Says Co. Planning Mid-2014 Launch of Eloctate in US,2013-11-12 10:37:00-05:00,BIIB,neutral
163073.0,"Biogen Exec VP Global Commercial Operations Tony Kingsley Speaking at Credit Suisse Conference, Says 35K Patients Are on Tecfidera After First Six Months",2013-11-12 10:36:00-05:00,BIIB,positive
163074.0,Isis Pharmaceuticals Announces $1.5M Milestone Payment from Biogen Related to Phase 2 study of  ISIS-SMNRx ,2013-11-12 07:04:00-05:00,BIIB,neutral
163075.0,"#PreMarket Primer: Tuesday, October 29: Fed Meeting Likely Uneventful",2013-10-29 06:47:00-04:00,BIIB,neutral
163076.0,Benzinga's Volume Movers,2013-10-28 10:32:00-04:00,BIIB,neutral
163077.0,From Biogen Call: Eloctate Could Be Facing Potential Approval Delay,2013-10-28 09:21:00-04:00,BIIB,positive
163078.0,"UPDATE: Biogen Idec Posts 22% Rise In Q3 Profit, Lifts Full-Year Outlook",2013-10-28 08:40:00-04:00,BIIB,positive
163079.0,"Biogen Idec Inc. Raises FY2013 EPS Guidance from $8.25-8.50 to $8.65-8.85 vs $8.59 Est, Sales Growth 23-25%",2013-10-28 07:16:00-04:00,BIIB,positive
163080.0,Biogen Idec Inc. Reports Q3 EPS of $2.35 vs $2.10 Est; Revenue of $1.83B vs $1.78B Est,2013-10-28 07:15:00-04:00,BIIB,neutral
163081.0,"#PreMarket Primer: Monday, October 28: All Eyes On Apple",2013-10-28 06:51:00-04:00,BIIB,neutral
163082.0,"Earnings Scheduled For October 28, 2013",2013-10-28 05:31:00-04:00,BIIB,neutral
163083.0,"Earnings Expectations For The Week Of October 28: Apple, Facebook, GM and More",2013-10-27 19:10:00-04:00,BIIB,neutral
163084.0,Benzinga Weekly Preview: FOMC Meeting Closely Watched,2013-10-25 16:18:00-04:00,BIIB,neutral
163085.0,"Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)",2013-10-25 15:36:00-04:00,BIIB,positive
163086.0,"Stocks to Watch for October 21, 2013",2013-10-21 11:00:00-04:00,BIIB,neutral
163087.0,"Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)",2013-10-11 14:33:00-04:00,BIIB,neutral
163088.0,"Biotech ETFs Plummeting (XBI, IBB, BBH)",2013-10-08 12:42:00-04:00,BIIB,neutral
163089.0,Biogen TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in MS Patients ,2013-10-04 05:51:00-04:00,BIIB,positive
163090.0,US Stock Futures Down Ahead Of Jobless Claims Data,2013-10-03 07:05:00-04:00,BIIB,neutral
163091.0,Biogen Reports TYSABRI Data Show Significant Reductions in MS Disease Activity ,2013-10-03 06:00:00-04:00,BIIB,positive
163092.0,5 Healthcare Stocks With The Highest EPS Estimates For The Next Quarter,2013-10-02 10:35:00-04:00,BIIB,neutral
163093.0,UPDATE: Credit Suisse Raises PT on Biogen Idec on Higher Tecfidera and Hemophilia Sales Estimates,2013-10-02 09:04:00-04:00,BIIB,positive
163094.0,"FBR Capital Maintains Outperform on Biogen Idec Inc., Raises PT to $290.00",2013-10-02 06:25:00-04:00,BIIB,neutral
163095.0,US Stock Futures Up Ahead of Economic Data,2013-10-01 07:05:00-04:00,BIIB,neutral
163096.0,Biogen Announces Data from Phase 3 ADVANCE Study of PLEGRIDY Show Significant Clinical and MRI Improvements with,2013-10-01 06:03:00-04:00,BIIB,positive
163097.0,"BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)",2013-09-25 12:52:00-04:00,BIIB,positive
163098.0,BofA Merrill Added Biogen to 'US 1' List,2013-09-18 08:25:00-04:00,BIIB,neutral
163099.0,"Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)",2013-09-14 11:47:00-04:00,BIIB,positive
163100.0,"Amicus, Biogen Announce Deal for Discovery, Development, Commercialization of Parkinson's Treatment",2013-09-10 07:32:00-04:00,BIIB,neutral
163101.0,"Market Wrap for Monday, September 9: Nasdaq Bounces To 13 Year High",2013-09-09 16:14:00-04:00,BIIB,neutral
163102.0,Mid-Afternoon Market Update: Markets Lead by the NASDAQ as Various Health Names Drop,2013-09-09 15:55:00-04:00,BIIB,negative
163103.0,Mid-Day Market Update: Dow Rises Over 100 Points; Apple Shares Gain,2013-09-09 13:38:00-04:00,BIIB,positive
163104.0,Hearing Piper Cautious on Isis Pharmaceuticals,2013-09-09 10:49:00-04:00,BIIB,negative
163105.0,Benzinga's Volume Movers,2013-09-09 10:31:00-04:00,BIIB,neutral
163106.0,Mid-Morning Market Update: Markets Open Higher; Koch Industries To Acquire Molex For $38.50/Share,2013-09-09 10:22:00-04:00,BIIB,neutral
163107.0,Benzinga's Top Pre-Market Gainers,2013-09-09 08:11:00-04:00,BIIB,positive
163108.0,US Stock Futures Up Ahead Of Consumer Credit Data,2013-09-09 07:15:00-04:00,BIIB,positive
163109.0,"Biogen, Isis Pharmaceuticals Announce Strategic Collaboration ",2013-09-09 07:02:00-04:00,BIIB,neutral
163110.0,Biotech Breakout Highlights Flawed ETF Thinking,2013-09-05 14:31:00-04:00,BIIB,neutral
163111.0,"Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, VRTX)",2013-08-27 13:29:00-04:00,BIIB,positive
163112.0,"Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)",2013-07-26 10:46:00-04:00,BIIB,positive
163113.0,"BMO Capital Maintains Market Perform on Biogen Idec Inc., Raises PT to $237.00",2013-07-26 09:08:00-04:00,BIIB,neutral
163114.0,"Benzinga Market Primer: Friday, July 26: Futures Flat On Mixed Global Stocks Overnight",2013-07-26 06:41:00-04:00,BIIB,neutral
163115.0,Biogen Idec Inc. Sees FY2013 EPS $8.25-8.50,2013-07-25 07:01:00-04:00,BIIB,neutral
163116.0,Biogen Idec Inc. Reports Q2 EPS of $2.30 vs $1.93 Est; Revenue of $1.70B vs $1.62B Est,2013-07-25 07:01:00-04:00,BIIB,neutral
163117.0,"Benzinga Market Primer: Thursday, July 25: Futures Lower After Technical Breakdown",2013-07-25 06:31:00-04:00,BIIB,negative
163118.0,"Bloomberg Reporting Biogen Spokesperson Has Said Female Patient Previously Treated with Tecfidera Died of Bilateral Pneumonia, Not Dehydration",2013-07-22 17:16:00-04:00,BIIB,negative
163119.0,"Analyst at ISI Said Death from Biogen's Tecfidera Related to Dehydration, Not Linked to Tecfidera",2013-07-22 14:18:00-04:00,BIIB,negative
163120.0,Biogen Responds to Reports of Patient Death from Tecfidera,2013-07-22 14:17:00-04:00,BIIB,negative
163121.0,Biogen Sells Off; May be Attrinuted to Report of Tecfidera Death,2013-07-22 13:52:00-04:00,BIIB,negative
163122.0,US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review ,2013-07-19 07:30:00-04:00,BIIB,positive
163123.0,Health Care ETFs Looking Healthy Ahead of Earnings,2013-07-15 15:43:00-04:00,BIIB,positive
163124.0,"Short Interest Rises in Gilead Sciences, Onyx Pharmaceuticals (BIIB, GILD, ONXX)",2013-07-11 12:47:00-04:00,BIIB,positive
163125.0,"Biogen, Sobi Offer New Data from Phase 3 Trial of ALPROLIX",2013-07-02 11:06:00-04:00,BIIB,neutral
163126.0,UPDATE: Piper Jaffray Raises PT on Biogen Idec on Multiple Positive Factors,2013-07-01 11:34:00-04:00,BIIB,positive
163127.0,Benzinga's Top Upgrades,2013-07-01 07:26:00-04:00,BIIB,positive
163128.0,"Citigroup Upgrades Biogen Idec Inc. to Buy, Maintains $236.00 PT",2013-07-01 06:26:00-04:00,BIIB,neutral
163129.0,UPDATE: Biogen in Pact with Adaptive Biotech for Immune Test,2013-06-27 11:16:00-04:00,BIIB,positive
163130.0,"Adaptive Biotech., Biogen Idec in Pact for Immunological Services",2013-06-27 11:10:00-04:00,BIIB,neutral
163131.0,"Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, VRTX)",2013-06-26 13:17:00-04:00,BIIB,positive
163132.0,"Market Wrap for Wednesday, June 12: Stock and Bond Markets Fall Mid-Week; Liquidity Concerns Remain a Focus ",2013-06-12 16:45:00-04:00,BIIB,neutral
163133.0,Afternoon Market Losers,2013-06-12 14:10:00-04:00,BIIB,negative
163134.0,"Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)",2013-06-12 13:29:00-04:00,BIIB,positive
163135.0,Benzinga's Top Pre-Market Losers,2013-06-12 08:18:00-04:00,BIIB,negative
163136.0,Benzinga's Top Downgrades,2013-06-12 07:55:00-04:00,BIIB,positive
163137.0,"Citigroup Downgrades Biogen Idec Inc. to Neutral, Raises PT to $236.00",2013-06-12 06:35:00-04:00,BIIB,neutral
163138.0,"Deutsche Bank Reiterates Buy Rating on Biogen, PT $240.00 On Upside From Quick-Start Program and Inventory",2013-06-05 14:21:00-04:00,BIIB,neutral
163139.0,Hearing Defense of Biogen Coming Out of Deutsche Bank,2013-06-05 14:08:00-04:00,BIIB,positive
163140.0,UPDATE: Biogen Shares Sink as Cowen Warns of 'Double-Counting' on Tecifera Prescriptions,2013-06-04 12:10:00-04:00,BIIB,positive
163141.0,Shares of Biogen Lower as Cowen Note Warns of Double Counting for Tecfidera Prescriptions in IMS Health's Weekly NRx Data,2013-06-04 09:16:00-04:00,BIIB,negative
163142.0,Benzinga's Top Pre-Market Losers,2013-06-04 08:18:00-04:00,BIIB,negative
163143.0,"Short Interest in Vertex Rises, in Biogen Idec Falls",2013-05-29 13:19:00-04:00,BIIB,positive
163144.0,Biogen Idec Submits BLA to FDA for Approval of PLEGRIDY for Multiple Sclerosis ,2013-05-21 05:55:00-04:00,BIIB,positive
163145.0,Leerink Swann Highlights Big Gains in Prescriptions for Biogen's MS Treatment,2013-05-20 13:30:00-04:00,BIIB,positive
163146.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter ,2013-05-15 04:13:00-04:00,BIIB,positive
163147.0,FDA Accepts Biogen's Biologics License App for Eloctate,2013-05-13 07:31:00-04:00,BIIB,positive
163148.0,"Short Interest in Vertex Rises, in Celgene Falls",2013-05-11 10:45:00-04:00,BIIB,positive
163149.0,S&P Highlights Biotech ETFs,2013-05-10 07:39:00-04:00,BIIB,neutral
163150.0,Isis Pharmaceuticals Earns $3.5M from Biogen Idec,2013-05-09 16:35:00-04:00,BIIB,neutral
163151.0,Morgan Stanley Reiterates Overweight on Biogen Idec Following AlphaWise Survey,2013-05-03 09:14:00-04:00,BIIB,negative
163152.0,Three Sector ETFs Up 20% or More YTD,2013-05-03 08:09:00-04:00,BIIB,neutral
163153.0,Illumina and Other Bargain Biotech Stocks Worth a Look Now,2013-05-01 12:57:00-04:00,BIIB,positive
163154.0,Equal-Weight ETF Trounces Traditional S&P 500 Peers,2013-04-30 11:15:00-04:00,BIIB,neutral
163155.0,"Short Sellers Move into Celgene, Regeneron",2013-04-26 13:25:00-04:00,BIIB,neutral
163156.0,"Benzinga Market Primer: Friday, April 26",2013-04-26 06:33:00-04:00,BIIB,neutral
163157.0,"Benzinga Market Primer: Thursday, April 25",2013-04-25 06:42:00-04:00,BIIB,neutral
163158.0,Biogen Idec Inc. Reports Q1 EPS of $1.97 vs $1.59 Est; Revenue of $1.40B vs $1.41B Est,2013-04-25 06:31:00-04:00,BIIB,neutral
163159.0,"Biogen Near Lows, May be Attributed to Cautious JMP Note",2013-04-24 13:19:00-04:00,BIIB,negative
163160.0,UPDATE: Deutsche Bank Raises PT on Biogen Idec on Tecfidera Launch Confidence,2013-04-23 13:46:00-04:00,BIIB,positive
163161.0,"Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to $240.00",2013-04-22 16:37:00-04:00,BIIB,neutral
163162.0,Market Wrap for April 22: Stocks Rise Moderately to Begin Week ,2013-04-22 16:16:00-04:00,BIIB,neutral
163163.0,Biotech Mutual Funds Show ETFs Are The Place to Be,2013-04-22 12:41:00-04:00,BIIB,neutral
163164.0,Stocks Hitting 52-Week Highs,2013-04-22 10:34:00-04:00,BIIB,neutral
163165.0,A Look Ahead: This Week's ETFs to Watch,2013-04-21 18:22:00-04:00,BIIB,neutral
163166.0,"Citigroup Maintains Buy on Biogen Idec Inc., Raises PT to $235.00",2013-04-19 06:36:00-04:00,BIIB,neutral
163167.0,S&P Upgrades Biogen from BBB+ to A-,2013-04-17 13:42:00-04:00,BIIB,neutral
163168.0,Biogen Loses Appeal in Arzerra Patent Case Against Glaxo,2013-04-16 11:40:00-04:00,BIIB,negative
163169.0,"UBS Maintains Neutral on Biogen Idec Inc., Raises PT to $208.00",2013-04-12 10:19:00-04:00,BIIB,neutral
163170.0,Benzinga's Top Pre-Market Gainers ,2013-04-12 09:44:00-04:00,BIIB,positive
163171.0,"Bank of America Upgrades Biogen Idec Inc. to Buy, Raises PT to $246.00",2013-04-12 09:00:00-04:00,BIIB,neutral
163172.0,ETF Showdown: A Pharma Fight,2013-04-11 16:21:00-04:00,BIIB,negative
163173.0,Under The Hood: An Unheralded Biotech ETF,2013-04-11 13:53:00-04:00,BIIB,neutral
163174.0,Biogen Crosses Above $200,2013-04-11 10:25:00-04:00,BIIB,neutral
163175.0,"Short Sellers Move Out of Amgen, Celgene, Pharmacyclics",2013-04-10 13:30:00-04:00,BIIB,neutral
163176.0,"RBC Capital Boosts Target on Biogen from $180 to $215, Maintains Outperform",2013-04-09 08:48:00-04:00,BIIB,positive
163177.0,"Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to $225.00",2013-04-04 11:48:00-04:00,BIIB,positive
163178.0,"Lancet Publishes SELECT Study of Biogen's Daclizumab HYP, Biogen Says 150MG, 300MG DAC HYP Injections Met Endpoint",2013-04-04 08:22:00-04:00,BIIB,neutral
163179.0,UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Price Announcement,2013-04-01 11:17:00-04:00,BIIB,neutral
163180.0,"Canaccord Genuity maintains Buy on Biogen Idec Inc., Raises PT to $206.00",2013-04-01 09:40:00-04:00,BIIB,neutral
163181.0,Biotech Breakout Boosting ETFs,2013-03-28 15:21:00-04:00,BIIB,positive
163182.0,UPDATE: Bank of America Raises PT on Biogen Idec Following Tecfidera Approval,2013-03-28 15:02:00-04:00,BIIB,positive
163183.0,UPDATE: Goldman Sachs Raises PT on Biogen Idec on Tecfidera Approval,2013-03-28 14:55:00-04:00,BIIB,positive
163184.0,UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval,2013-03-28 14:30:00-04:00,BIIB,positive
163185.0,UPDATE: Jefferies Raises PT on Biogen Idec on FDA Tecfidera Approval,2013-03-28 10:26:00-04:00,BIIB,positive
163186.0,"Bank of America Maintains Neutral on Biogen Idec Inc., Raises PO to $187.00",2013-03-28 09:20:00-04:00,BIIB,negative
163187.0,"Goldman Sachs Maintains Conviction Buy on Biogen Idec Inc., Raises PT to $211.00",2013-03-28 09:19:00-04:00,BIIB,neutral
163188.0,"Canaccord Genuity Maintains Buy on Biogen Idec Inc., Raises PT to $200.00",2013-03-28 08:56:00-04:00,BIIB,neutral
163189.0,Benzinga's Top Pre-Market Gainers,2013-03-28 08:51:00-04:00,BIIB,positive
163190.0,"Short Sellers Dump Amgen, Focus on Celgene, Gilead Sciences",2013-03-28 08:18:00-04:00,BIIB,negative
163191.0,"Stifel Nicolaus Maintains Buy on Biogen Idec Inc., Raises PT to $202.00",2013-03-28 08:09:00-04:00,BIIB,neutral
163192.0,"Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to $215.00",2013-03-28 06:37:00-04:00,BIIB,neutral
163193.0,Biogen Confirms US Approval for TECFIDERA,2013-03-27 16:12:00-04:00,BIIB,positive
163194.0,Biogen Shares Now Up Nearly 2% Following News of FDA Approval for MS Pill Tecfidera,2013-03-27 15:36:00-04:00,BIIB,positive
163195.0,Biogen Wins FDA Approval for MS Pill,2013-03-27 15:34:00-04:00,BIIB,positive
163196.0,13 Drugs Pending FDA Approval in 2013,2013-03-26 13:19:00-04:00,BIIB,positive
163197.0,Moving Averages Indicate These Sector ETFs Could be Stretched,2013-03-25 17:33:00-04:00,BIIB,neutral
163198.0,UPDATE: Morgan Stanley Raises PT on Biogen Idec on Long-Term Potential,2013-03-25 13:18:00-04:00,BIIB,neutral
163199.0,"Morgan Stanley Maintains Overweight on Biogen Idec Inc., Raises PT to $188.00",2013-03-25 07:45:00-04:00,BIIB,negative
163200.0,UPDATE: Bank of America Raises PO On Biogen Idec; Promising New Product Expected,2013-03-22 11:12:00-04:00,BIIB,negative
163201.0,"Bank of America Maintains Neutral on Biogen Idec Inc., Raises PT to $182.00",2013-03-22 08:41:00-04:00,BIIB,neutral
163202.0,Bloomberg Reporting Biogen's Tecfidera Wins Positive Opinion from EMA,2013-03-22 08:19:00-04:00,BIIB,positive
163203.0,XenoPort May Be Beneficiary of Biogen Patent Filings,2013-03-20 09:11:00-04:00,BIIB,positive
163204.0,Positive Year One Results from Biogen Idec Phase 3 ADVANCE Trial of PLEGRIDY Presented at AAN Meeting ,2013-03-20 07:32:00-04:00,BIIB,positive
163205.0,US Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate) ,2013-03-19 16:00:00-04:00,BIIB,positive
163206.0,"Biogen, Elan Reaffirm Substantial Efficacy from New TYSABRI Data for Treatment of Patients with MS",2013-03-18 07:48:00-04:00,BIIB,positive
163207.0,"Three Top Performing BRIC Stocks (CBPO, GSH, VIPS)",2013-03-17 15:13:00-04:00,BIIB,positive
163208.0,Biogen Enters $750M Credit Pact,2013-03-14 16:50:00-04:00,BIIB,positive
163209.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, PCYC)",2013-03-12 13:19:00-04:00,BIIB,positive
163210.0,Biogen Idec Submits BLA to FDA for Recombinant  Factor VIII Therapy for Hemophilia A ,2013-03-12 07:35:00-04:00,BIIB,neutral
163211.0,Biogen Announces FDA Acceptance for Biologics License Application for First Long-Lasting Factor IX Therapy,2013-03-04 07:31:00-05:00,BIIB,positive
163212.0,"Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to $200.00",2013-03-04 06:39:00-05:00,BIIB,positive
163213.0,"Benzinga's M&A Chatter for Friday March 1, 2013",2013-03-02 10:36:00-05:00,BIIB,neutral
163214.0,"Biogen Heads Up To Test $169 Resistance Level, Breakout In Play ",2013-03-01 14:41:00-05:00,BIIB,positive
163215.0,Bristol Meyers Squibb Reportedly Considered Large Acquisitions of Biogen and Shire,2013-03-01 14:38:00-05:00,BIIB,neutral
163216.0,Biogen Spikes Higher,2013-03-01 14:35:00-05:00,BIIB,neutral
163217.0,"Short Interest Swings in Biotech Stocks (ALXN, AMGN, CELG)",2013-02-28 15:13:00-05:00,BIIB,positive
163218.0,Here are the 20 Stocks with the Highest Share Price,2013-02-27 13:30:00-05:00,BIIB,positive
163219.0,UPDATE: Canaccord Genuity Upgrades Biogen Idec to Buy on BG-12 Early Launch,2013-02-27 07:12:00-05:00,BIIB,neutral
163220.0,"Canaccord Genuity Upgrades Biogen Idec Inc. to Buy, Raises PT to $187.00",2013-02-27 06:02:00-05:00,BIIB,neutral
163221.0,Elan Provides Update on Tysabri Collaboration with Biogen Idec,2013-02-22 05:58:00-05:00,BIIB,neutral
163222.0,"Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)",2013-02-12 13:29:00-05:00,BIIB,positive
163223.0,UPDATE: Credit Suisse Raises PT to $185 on Biogen Idec on Tysabri Restructuring,2013-02-08 11:07:00-05:00,BIIB,positive
163224.0,"Credit Suisse Maintains Outperform on Biogen Idec Inc., Raises PT to $185.00",2013-02-08 07:42:00-05:00,BIIB,positive
163225.0,UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals,2013-02-08 07:39:00-05:00,BIIB,positive
163226.0,"Citigroup Upgrades Biogen Idec Inc. to Buy, Raises PT to $187.00",2013-02-08 06:44:00-05:00,BIIB,neutral
163227.0,"Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to $201.00",2013-02-07 08:31:00-05:00,BIIB,neutral
163228.0,"Market Wrap for Wednesday, February 6: Major Averages Close Near Unchanged; Euro Falls",2013-02-06 16:21:00-05:00,BIIB,neutral
163229.0,"Deutsche Bank Maintains Buy on Biogen Idec Inc., Raises PT to $170.00",2013-02-06 15:37:00-05:00,BIIB,neutral
163230.0,"Biogen Expecting to Open $500-750M Credit Line; Sees Tysabri Deal Adding $0.50-0.60 to EPS in 2013, $0.65-0.80 in 2014",2013-02-06 08:00:00-05:00,BIIB,positive
163231.0,Elan Agrees to Restructure Tysabri Collaboration with Biogen Idec ,2013-02-06 05:56:00-05:00,BIIB,positive
163232.0,Acorda Therapeutics Could Be a Stock to Watch in 2013,2013-02-04 15:21:00-05:00,BIIB,neutral
163233.0,"Jefferies Maintains Buy on Biogen Idec Inc., Raises PT to $187.00",2013-01-29 08:03:00-05:00,BIIB,neutral
163234.0,"UPDATE: Biogen Idec Posts Downbeat Q4 Profit, Issues Weak 2013 Profit Forecast",2013-01-28 07:37:00-05:00,BIIB,positive
163235.0,"Biogen Idec Inc. Sees FY2013 EPS $7.15-7.25 vs $7.25 Est, Sees Sales Growth ~10%",2013-01-28 07:17:00-05:00,BIIB,positive
163236.0,"Benzinga Market Primer: Monday, January 28",2013-01-28 06:46:00-05:00,BIIB,neutral
163237.0,Biogen Idec Inc. Reports Q4 EPS of $1.40 vs $1.46 Est; Revenue of $1.42B vs $1.38B Est,2013-01-28 06:41:00-05:00,BIIB,neutral
163238.0,US Stock Futures Flat Ahead Of Caterpillar Earnings,2013-01-28 05:56:00-05:00,BIIB,neutral
163239.0,"Earnings Scheduled For January 28, 2013",2013-01-28 01:08:00-05:00,BIIB,neutral
163240.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2013-01-26 12:17:00-05:00,BIIB,positive
163241.0,Biogen Idec Announces Positive Top-Line Results from Phase 3 Study of Peginterferon Beta-1a in Multiple Sclerosis ,2013-01-24 07:35:00-05:00,BIIB,positive
163242.0,"Morgan Stanley Sees Possible Near-Term Increase in M&A, Unveils 'Acquisition Likelihood Estimate Ranking Tool'",2013-01-22 10:07:00-05:00,BIIB,positive
163243.0,Biogen Submits Biologics License Application to FDA for First Long-Lasting Factor IX Therapy for Hemophilia B ,2013-01-04 07:34:00-05:00,BIIB,neutral
163244.0,"Canaccord Genuity Maintains Hold on Biogen Idec Inc., Lowers PT to $139.00",2013-01-03 10:00:00-05:00,BIIB,negative
163245.0,"Bank of America Maintains Buy on Biogen Idec Inc., Lowers PO to $164.00",2013-01-03 09:53:00-05:00,BIIB,negative
163246.0,"Oppenheimer Maintains Perform on Biogen Idec Inc., Lowers PT to $141.00",2013-01-03 09:53:00-05:00,BIIB,negative
163247.0,UPDATE: Piper Jaffray Downgrades Biogen Idec to Neutral on Valuation  ,2013-01-03 09:31:00-05:00,BIIB,neutral
163248.0,Benzinga's Top Pre-Market Losers,2013-01-03 08:23:00-05:00,BIIB,negative
163249.0,Biogen Idec Reports Top-Line Results from Phase 3 Trial of Dexpramipexole in People with ALS Did Not Meet Primary Endpoint,2013-01-03 07:32:00-05:00,BIIB,neutral
163250.0,"Piper Jaffray Downgrades Biogen Idec Inc. to Neutral, Lowers PT to $166.00",2013-01-03 07:01:00-05:00,BIIB,negative
163251.0,"Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)",2012-12-28 11:10:00-05:00,BIIB,positive
163252.0,"Canaccord Genuity Initiates Coverage on Biogen Idec Inc. at Hold, Announces $144.00 PT",2012-12-17 17:05:00-05:00,BIIB,neutral
163253.0,"Goldman Sachs Reinstates CL-Buy on Biogen Idec Inc., Announces $178.00 PT",2012-12-13 06:17:00-05:00,BIIB,neutral
163254.0,These ETFs Are Awash in 2013 Takeover Targets,2012-12-12 13:01:00-05:00,BIIB,neutral
163255.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)",2012-12-12 12:57:00-05:00,BIIB,positive
163256.0,"Biogen, Eisai Announce Manufacturing Alliance at Research Triangle Park Plants",2012-12-12 08:06:00-05:00,BIIB,neutral
163257.0,"Biogen, Isis Pharma Announce Collaboration for Antisense Programs",2012-12-10 08:03:00-05:00,BIIB,neutral
163258.0,"Brean Murray Initiates Coverage on Biogen Idec at Buy, Announces PT of $184",2012-11-21 11:00:00-05:00,BIIB,neutral
163259.0,"Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)",2012-11-12 13:24:00-05:00,BIIB,positive
163260.0,Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study,2012-10-31 08:11:00-04:00,BIIB,positive
163261.0,"BMO Capital Markets Maintains Biogen Idec at Market Perform, Raises PT from $136 to $147",2012-10-26 08:25:00-04:00,BIIB,neutral
163262.0,"Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)",2012-10-25 14:09:00-04:00,BIIB,positive
163263.0,"Piper Jaffray Maintains Biogen Idec at Overweight, Raises PT from $159 to $179",2012-10-18 12:19:00-04:00,BIIB,negative
163264.0,Biogen IDEC Says FDA Extends its Drug Review Date by 3 Months,2012-10-18 08:08:00-04:00,BIIB,positive
163265.0,"Barclays Maintains Biogen Idec at Overweight, Raises PT from $140 to $150",2012-10-15 12:10:00-04:00,BIIB,negative
163266.0,"Short Interest Swings in Biotech Stocks (BIIB, CELG, GILD)",2012-10-15 06:59:00-04:00,BIIB,positive
163267.0,Biogen's Sandrock Says Very Confident BG-12 Shows No Cancer Risk; Stacks Up Well vs Other MS Drugs on Safety,2012-10-12 08:05:00-04:00,BIIB,negative
163268.0,A Peek Into The Market Before The Trading Starts,2012-10-12 07:16:00-04:00,BIIB,neutral
163269.0,Biogen Announces New Data from Phase 3 Studies for Oral BG-12 Treatment for Multiple Sclerosis ,2012-10-12 06:11:00-04:00,BIIB,neutral
163270.0,"Acorda Therapeutics Names Jane Wasman President, International ",2012-10-09 06:39:00-04:00,BIIB,neutral
163271.0,"UPDATE: Credit Suisse Reiterates Outperform Rating, Raises PT on Biogen Idec",2012-10-08 12:12:00-04:00,BIIB,positive
163272.0,"Credit Suisse Maintains Biogen Idec at Outperform, Raises PT from $165 to $175",2012-10-08 07:01:00-04:00,BIIB,positive
163273.0,Oppenheimer Downgrades Biogen Idec from Outperform to Perform,2012-10-04 16:24:00-04:00,BIIB,neutral
163274.0,UPDATE: Stifel Nicolaus Increases PT to $168 on Biogen Idec on Hemophilia Trial  ,2012-09-27 10:50:00-04:00,BIIB,neutral
163275.0,"Stifel Nicolaus Maintains Biogen Idec at Buy, Raises PT from $167 to $168",2012-09-27 07:57:00-04:00,BIIB,neutral
163276.0,"Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from $164 to $176",2012-09-27 06:20:00-04:00,BIIB,neutral
163277.0,UPDATE: Bank of America Raises PO to $173 on Biogen Idec on Strong Hemophilia Data  ,2012-09-26 13:58:00-04:00,BIIB,negative
163278.0,"Short Interest in Biotech Firms Resumes (BIIB, GILD, ILMN, REGN)",2012-09-26 13:22:00-04:00,BIIB,positive
163279.0,"Bank of America Maintains Biogen Idec at Buy, Raises PO from $157 to $173",2012-09-26 13:20:00-04:00,BIIB,negative
163280.0,Benzinga's Top Pre-Market Gainers,2012-09-26 08:16:00-04:00,BIIB,positive
163281.0,Biogen and Sobi Announce Positive Top-Line results from Phase 3 Study,2012-09-26 07:32:00-04:00,BIIB,positive
163282.0,Biogen Says Data Shows Potential for BG-12 as an MS Treatment,2012-09-19 17:04:00-04:00,BIIB,neutral
163283.0,Short Sellers Shy Away from Biotech Firms,2012-09-13 13:34:00-04:00,BIIB,negative
163284.0,Biogen Idec Foundation Awards $1M to Museum of Science in MA,2012-09-12 08:01:00-04:00,BIIB,positive
163285.0,"UBS Downgrades Biogen Idec from Buy to Neutral, Maintains PT at $156",2012-09-10 11:32:00-04:00,BIIB,neutral
163286.0,"Deutsche Bank Maintains Biogen Idec at Buy, Raises PT from $150 to $160",2012-09-06 06:17:00-04:00,BIIB,neutral
163287.0,Joule Elects Caroline Dorsa to Board of Directors  ,2012-09-04 10:05:00-04:00,BIIB,neutral
163288.0,Short Interest in Biotech Firms on the Rise,2012-08-27 15:21:00-04:00,BIIB,positive
163289.0,"Benzinga'a M&A Chatter for Wednesday August 15, 2012",2012-08-15 17:17:00-04:00,BIIB,neutral
163290.0,Hearing DealReporter Saying Biogen Could Make Bid for Elan,2012-08-15 13:23:00-04:00,BIIB,neutral
163291.0,Short Sellers Shy Away from Biotech Firms,2012-08-13 06:18:00-04:00,BIIB,negative
163292.0,"Benzinga'a M&A Chatter for  Monday July 30, 2012",2012-07-30 17:37:00-04:00,BIIB,neutral
163293.0,Elan Spokesperson Declines Comment on Bloomberg Report of Possible Takeover by Biogen,2012-07-30 06:18:00-04:00,BIIB,neutral
163294.0,"UBS Maintains Biogen Idec at Buy, Raises PT from $148 to $156",2012-07-25 12:17:00-04:00,BIIB,neutral
163295.0,"Morgan Stanley Maintains Biogen Idec at Overweight, Raises PT from $140 to $150",2012-07-25 06:53:00-04:00,BIIB,negative
163296.0,"Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from $154 to $164",2012-07-25 06:02:00-04:00,BIIB,neutral
163297.0,"Citigroup Maintains Biogen Idec at Neutral, Raises PT from $144 to $147",2012-07-24 15:32:00-04:00,BIIB,neutral
163298.0,"Social Media Outlook for Tuesday July 24 (GWR, BIIB, DV, UPS)",2012-07-24 11:04:00-04:00,BIIB,neutral
163299.0,"Financial Breakfast: Morning News Summary for July 24, 2012",2012-07-24 07:25:00-04:00,BIIB,neutral
163300.0,Biogen Idec Reports Q2 EPS $1.82 vs $1.56 Est; Revenues $1.4B vs $1.33B Est,2012-07-24 07:01:00-04:00,BIIB,neutral
163301.0,"Benzinga Market Primer, Tuesday July 24",2012-07-24 06:58:00-04:00,BIIB,neutral
163302.0,Leerink Swann Resumes Coverage on Biogen Idec at Outperform,2012-07-23 08:23:00-04:00,BIIB,neutral
163303.0,"Biogen, Bayer Ms Drugs Fail To Slow Disability, Study Finds - Bloomberg",2012-07-17 16:00:00-04:00,BIIB,negative
163304.0,"3 Unheralded ETFs Up More Than 10% in the Past 90 Days (PBE, TAGS)",2012-07-16 16:00:00-04:00,BIIB,neutral
163305.0,"Stifel Nicolaus Maintains Biogen Idec at Buy, Raises PT from $144 to $167",2012-07-09 07:52:00-04:00,BIIB,neutral
163306.0,BioMarin Pharmaceutical Hits New 52-Week High on Continued Takeover Chatter,2012-06-29 12:03:00-04:00,BIIB,neutral
163307.0,"Biogen Idec, Isis To Develop Antisense Drug For Treatment Of Myotonic Dystrophy Type 1; Biogen Idec Says Isis Will Receive Upfront Payment Of $12M",2012-06-29 08:06:00-04:00,BIIB,neutral
163308.0,"Benzinga's M&A Chatter for Thursday June 28, 2012",2012-06-28 18:20:00-04:00,BIIB,neutral
163309.0,Spokesperson for BioMarin Pharmaceutical Won't Comment on Guardian Report on Takeover Bids,2012-06-28 13:45:00-04:00,BIIB,neutral
163310.0,Editor of Little Bear Blog is Long BioMarin Pharmaceutical on Takeover Chatter,2012-06-28 12:26:00-04:00,BIIB,neutral
163311.0,"UPDATE: BioMarin Spikes Higher on Report GlaxoSmithKline, Sanofi, Biogen Could Bid $60/Share -Guardian",2012-06-28 12:10:00-04:00,BIIB,neutral
163312.0,Biogen Idec to Highlight Innovative Pipeline and Commercial Strategy   ,2012-06-12 08:31:00-04:00,BIIB,positive
163313.0,"Deutsche Bank Reiterates Buy Rating, $150 PT for Biogen Idec",2012-06-06 11:51:00-04:00,BIIB,neutral
163314.0,"Disney, Raytheon and Other Avenger Picks for a Heroic Portfolio",2012-05-18 06:40:00-04:00,BIIB,positive
163315.0, Biogen Idec Announces US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review  ,2012-05-09 16:08:00-04:00,BIIB,positive
163316.0,"UBS Maintains Biogen Idec at Buy, Raises PT from $135 to $148",2012-05-09 11:03:00-04:00,BIIB,neutral
163317.0,UPDATE: Jefferies Raises PT to $154 on Biogen Idec; Strong MS Dynamics  ,2012-05-02 07:52:00-04:00,BIIB,positive
163318.0,"Jefferies & Company Maintains Biogen Idec at Buy, Raises PT from $137 to $154",2012-05-02 07:04:00-04:00,BIIB,neutral
163319.0,"Citigroup Maintains Biogen Idec at Neutral, Raises PT from $130 to $143",2012-05-01 14:54:00-04:00,BIIB,neutral
163320.0,"Piper Jaffray Maintains Biogen Idec at Overweight, Raises PT from $140 to $159",2012-05-01 14:17:00-04:00,BIIB,negative
163321.0,"Oppenheimer Maintains Biogen Idec at Outperform, Raises PT from $136 to $139",2012-05-01 12:06:00-04:00,BIIB,neutral
163322.0,"Financial Breakfast: Morning News Summary for May 1, 2012",2012-05-01 07:29:00-04:00,BIIB,neutral
163323.0,Biogen Idec Reports Q1 EPS $1.40 vs $1.48 Est; Revenues $1.3B vs $1.31B Est,2012-05-01 07:09:00-04:00,BIIB,neutral
163324.0,"Oppenheimer Maintains Biogen Idec at Outperform, Raises PT from $127 to $136",2012-04-25 07:53:00-04:00,BIIB,neutral
163325.0,Biogen Idec Announces Positive Results from Phase 3 CONFIRM Clinical Trial Show Efficacy and Safety of Oral BG-12 in Multiple Sclerosis  ,2012-04-24 07:33:00-04:00,BIIB,positive
163326.0,Benzinga's Top Upgrades,2012-04-04 08:01:00-04:00,BIIB,positive
163327.0,UPDATE: Goldman Sachs Upgrades Biogen Idec; Raises PT,2012-04-04 07:38:00-04:00,BIIB,neutral
163328.0,"Financial Breakfast: Morning News Summary for April 4, 2012",2012-04-04 07:24:00-04:00,BIIB,neutral
163329.0,"Goldman Sachs Upgrades Biogen Idec from Neutral to Buy, Raises PT from $120 to $150",2012-04-04 06:01:00-04:00,BIIB,neutral
163330.0,"UPDATE: Stifel Nicolaus Resumes Buy, $144 PT on Biogen Idec",2012-03-15 11:35:00-04:00,BIIB,neutral
163331.0,Biogen Idec Takes Option to MAKScientific MS Program ,2012-03-14 10:19:00-04:00,BIIB,neutral
163332.0,Biogen Idec Spiking Higher on Heavy Volume; Currently at $121,2012-03-09 14:24:00-05:00,BIIB,neutral
163333.0,Biogen Idec Trading 2.7% Higher on Heavy Volume; Currently at $120.16,2012-03-08 15:07:00-05:00,BIIB,neutral
163334.0,Biogen Idec Spokesperson Refutes Claims of Biopharm Insight Article,2012-03-08 14:24:00-05:00,BIIB,neutral
163335.0,Update: Biogen Spikes Lower on Negative Biopharm Insight Report,2012-03-08 14:05:00-05:00,BIIB,negative
163336.0,Biogen Spikes Lower on Negative Biopharm Insight Report,2012-03-08 14:04:00-05:00,BIIB,negative
163337.0,Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis   ,2012-02-28 08:02:00-05:00,BIIB,positive
163338.0,Biogen Says FDA Approves Avonex Pen & Dose Titration Regiment,2012-02-28 07:50:00-05:00,BIIB,positive
163339.0,A Peek Into The Market Before The Trading Starts,2012-02-28 07:48:00-05:00,BIIB,neutral
163340.0,Biogen Idec Announces FDA Approves AVONEX PEN and Dose Titration Regimen   ,2012-02-28 07:33:00-05:00,BIIB,positive
163341.0,Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis,2012-02-28 07:17:00-05:00,BIIB,neutral
163342.0,"Benzinga's M&A Chatter for Tuesday February 14, 2012",2012-02-14 18:32:00-05:00,BIIB,neutral
163343.0,Biogen Idec to Acquire Stromedix,2012-02-14 08:31:00-05:00,BIIB,neutral
163344.0,"Morgan Stanley Initiates Coverage on Biogen Idec at Overweight, Announces PT of $140",2012-02-10 06:39:00-05:00,BIIB,negative
163345.0,Biogen Idec Hits 52-Week High of $122.84,2012-02-02 10:56:00-05:00,BIIB,neutral
163346.0,Biogen Idec Trading 2.5% Higher on Heavy Volume; Currently at $120.93,2012-02-01 11:17:00-05:00,BIIB,neutral
163347.0,Biogen Idec Hits 52-Week High of $120.69,2012-02-01 11:17:00-05:00,BIIB,neutral
163348.0,Benzinga's Top Pre-Market Losers,2012-01-31 08:24:00-05:00,BIIB,negative
163349.0,Biogen Guides FY2012 EPS $6.10-6.20 vs $6.31 Est,2012-01-31 07:06:00-05:00,BIIB,neutral
163350.0,Biogen Idec Reports Q4 EPS $1.51 vs $1.49 Est; Revenues $1.30B vs $1.29B Est	 			,2012-01-31 07:02:00-05:00,BIIB,neutral
163351.0,Biogen Idec Receives Positive Mad Money/Jim Cramer Mention -CNBC,2012-01-26 18:27:00-05:00,BIIB,positive
163352.0,From Earlier:  Biogen Idec and Elan Corporation Announce ASCEND Study to Evaluate the Effectiveness of TYSABRI as a Treatment for Secondary-Progressive Multiple Sclerosis  ,2012-01-26 08:53:00-05:00,BIIB,neutral
163353.0,Biogen Spiking Lower on Heavy volume,2012-01-23 10:47:00-05:00,BIIB,negative
163354.0,Oppenheimer Releases Biogen Idec Company Update,2012-01-23 09:43:00-05:00,BIIB,neutral
163355.0,Quest Diagnostics STRATIFY JCV First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients ,2012-01-20 16:00:00-05:00,BIIB,positive
163356.0,"Elan, Biogen Win FDA Approval to Market Test for Tysabri Risks",2012-01-20 15:29:00-05:00,BIIB,positive
163357.0,Deutsche Bank Maintains Buy on Biogen Idec After European Medical Agency Announcement,2012-01-20 07:11:00-05:00,BIIB,neutral
163358.0,Citigroup Maintains Neutral on Biogen Idec After Analyst Meeting,2012-01-11 14:12:00-05:00,BIIB,neutral
163359.0,"Biogen Idec Block Trade of 398,913 Shares at $116.1, 34.3% of total volume ",2012-01-11 11:55:00-05:00,BIIB,negative
163360.0,Just What The Doctor Ordered: 4 ETFs For Biotech M&A,2012-01-09 15:49:00-05:00,BIIB,neutral
163361.0,Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy,2012-01-04 08:31:00-05:00,BIIB,neutral
163362.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest Operating Margin,2011-12-29 03:21:00-05:00,BIIB,positive
163363.0,Best Biotech Stocks of 2011,2011-12-27 10:39:00-05:00,BIIB,positive
163364.0,"Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec",2011-12-20 11:18:00-05:00,BIIB,neutral
163365.0,J.P. Morgan Reiterates Neutral On Biogen Idec,2011-12-06 13:28:00-05:00,BIIB,neutral
163366.0,"ISI Reiterates Buy, $120 PT On Biogen ",2011-12-05 13:18:00-05:00,BIIB,neutral
163367.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Highest EPS,2011-12-02 09:37:00-05:00,BIIB,positive
163368.0,Idenix and Spectrum Pharmaceuticals to Open Near 52-Week Highs,2011-11-22 06:49:00-05:00,BIIB,neutral
163369.0,Deutsche Bank Maintains Buy Rating and $129 PT on Biogen Idec ,2011-11-14 07:44:00-05:00,BIIB,neutral
163370.0,JP Morgan Maintains Neutral for Biogen Idec on Positive Lemtrada Data  ,2011-11-14 07:43:00-05:00,BIIB,positive
163371.0,"Biogen Spiking to New 52-Week Highs, $120.66",2011-10-28 10:23:00-04:00,BIIB,neutral
163372.0,Biogen IDEC Inc's Profit Up,2011-10-28 09:27:00-04:00,BIIB,positive
163373.0,"Financial Breakfast: Morning News Summary for October 28, 2011",2011-10-28 07:45:00-04:00,BIIB,neutral
163374.0,Biogen Idec Reports Q3 EPS $1.43 vs $1.53 Est; Revenues $1.31B vs $1.27B Est			,2011-10-28 07:00:00-04:00,BIIB,neutral
163375.0,Biogen Idec and Portola Pharmaceuticals Announce Global Collaboration for Oral Syk Inhibitor Program Targeting Autoimmune and Inflammatory Diseases  ,2011-10-27 08:35:00-04:00,BIIB,negative
163376.0,"Oppenheimer Raises PT on Biogen Idec to $127 from $109, Maintains Outperform",2011-10-26 13:21:00-04:00,BIIB,neutral
163377.0,Biogen Hits New 52-Week High; $117.54,2011-10-26 11:23:00-04:00,BIIB,neutral
163378.0,UPDATE: Piper Jaffray Raises PT on Biogen Idec to $135,2011-10-26 11:20:00-04:00,BIIB,neutral
163379.0,Piper Jaffray Raises PT on Biogen Idec to $135,2011-10-26 11:12:00-04:00,BIIB,neutral
163380.0,Biogen Idec Announces Positive Top-Line Results from Second Phase 3 Trial Investigating Oral BG-12  in Multiple Sclerosis   ,2011-10-26 07:00:00-04:00,BIIB,positive
163381.0,"Biogen Idec Earnings Preview: Analysts Expect Higher EPS, Revenue",2011-10-25 11:48:00-04:00,BIIB,neutral
163382.0,Jefferies Maintains Buy on Biogen Idec,2011-10-24 07:59:00-04:00,BIIB,neutral
163383.0,Jefferies Maintains Buy on Biogen Idec,2011-10-24 07:59:00-04:00,BIIB,neutral
163384.0,Earnings Expectations for the Week of October 24,2011-10-23 13:40:00-04:00,BIIB,neutral
163385.0,J.P. Morgan Maintains Neutral on Biogen Idec,2011-10-21 07:59:00-04:00,BIIB,neutral
163386.0,"From Earlier, Biogen Idec and Elan Receive Notification of PDUFA Date Extension   ",2011-10-20 08:56:00-04:00,BIIB,neutral
163387.0,Deutsche Bank Maintains Buy Rating and $129 PT on Biogen Idec ,2011-10-19 07:16:00-04:00,BIIB,neutral
163388.0, Biogen Idec and Elan Announce Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS  ,2011-10-19 06:23:00-04:00,BIIB,positive
163389.0,Earnings Season Kicks Off  10-17-2011,2011-10-17 15:09:00-04:00,BIIB,neutral
163390.0,Deutsche Bank Comments on Amgen's Restructuring Rumors,2011-10-13 12:21:00-04:00,BIIB,neutral
163391.0,J.P. Morgan Maintains Neutral on Biogen Idec,2011-10-13 09:23:00-04:00,BIIB,neutral
163392.0,No New Safety Issues Seen in Biogen Idec's MS Drug BG-12,2011-10-05 07:35:00-04:00,BIIB,positive
163393.0,Deutsche Bank Releases Company Update on BIIB,2011-10-04 09:04:00-04:00,BIIB,neutral
163394.0,Oppenheimer Outperform on Biogen Idec ,2011-10-03 07:56:00-04:00,BIIB,neutral
163395.0,Notable Put Options Activity in Biogen Idec,2011-09-29 10:37:00-04:00,BIIB,neutral
163396.0,Top 4 Large-Cap Stocks In The Biotechnology Industry With The Lowest PEG Ratio,2011-09-26 04:42:00-04:00,BIIB,negative
163397.0,Notable Put Options Activity in Biogen Idec,2011-09-16 11:21:00-04:00,BIIB,neutral
163398.0,"UBS Upgrades Biogen, Raises PT",2011-09-09 10:50:00-04:00,BIIB,neutral
163399.0,Biogen Idec Fully Acquires Biogen Dompé Joint Ventures   ,2011-09-06 08:15:00-04:00,BIIB,neutral
163400.0,UPDATE: Oppenheimer Upgrades Biogen Idec from Perform to Outperform,2011-08-18 08:59:00-04:00,BIIB,neutral
163401.0,"Oppenheimer Upgrades Biogen Idec To Outperform, $100 PT",2011-08-18 08:44:00-04:00,BIIB,neutral
163402.0,Oppenheimer Upgrading Biogen Idec ,2011-08-18 08:41:00-04:00,BIIB,neutral
163403.0,Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis   ,2011-08-09 08:01:00-04:00,BIIB,positive
163404.0,UPDATE: Citadel Securities Initiates Coverage on Biogen Idec,2011-08-08 07:58:00-04:00,BIIB,positive
163405.0,"Citadel Initiates Biogen Idec With Add Rating, $130 PT",2011-08-08 06:01:00-04:00,BIIB,neutral
163406.0,Check Out The Chart: An Unhealthy Biotech ETF?,2011-07-27 13:52:00-04:00,BIIB,negative
163407.0,"Amgen Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter",2011-07-26 12:29:00-04:00,BIIB,negative
163408.0,Biogen IDEC Inc Earnings: Net Income Drops,2011-07-26 08:40:00-04:00,BIIB,neutral
163409.0,Biogen Idex Guides Year EPS Above $5.70 vs $5.86 Est,2011-07-26 07:17:00-04:00,BIIB,neutral
163410.0,Biogen Idec Reports Q2 EPS of $1.36 vs. $1.40 Est; Revenues $1.21B vs. $ 1.19B Est ,2011-07-26 07:16:00-04:00,BIIB,neutral
163411.0,Earnings Scheduled For July 26,2011-07-26 04:47:00-04:00,BIIB,neutral
163412.0,Biogen Idec Receives Conditional Approval in the European Union for FAMPYRA® to Improve Walking in Adults with Multiple Sclerosis ,2011-07-25 09:13:00-04:00,BIIB,positive
163413.0,Fifteen Health Care ETFs Trading Near 52-Week Highs,2011-07-21 13:57:00-04:00,BIIB,positive
163414.0,Biogen IDEC Earnings Preview: Analysts Expect Falling Revenue Over Last Quarter,2011-07-21 13:43:00-04:00,BIIB,negative
163415.0,Five Health Care ETFs Your Broker Forget To Mention,2011-07-20 13:23:00-04:00,BIIB,positive
163416.0,Citi Updates On BIIB ,2011-07-19 09:12:00-04:00,BIIB,neutral
163417.0,ISI Provides Color on Novartis,2011-07-19 08:12:00-04:00,BIIB,neutral
163419.0,Twelve Health Care ETFs Trading Near 52-Week Highs,2011-07-13 07:38:00-04:00,BIIB,positive
163420.0,Morgan Stanley Provides Color on Baxter,2011-07-13 06:30:00-04:00,BIIB,neutral
163421.0,ISI Provides Color on Biogen Idec,2011-07-13 03:29:00-04:00,BIIB,neutral
163422.0,J.P. Morgan Maintains Neutral On Biogen Idec Following MS Data,2011-07-11 13:12:00-04:00,BIIB,neutral
163423.0,Hottest and Coldest Sectors for Friday 7/8/11,2011-07-08 17:24:00-04:00,BIIB,neutral
163424.0,Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows,2011-06-29 04:11:00-04:00,BIIB,positive
163425.0,Carl Icahn Discloses a 3.4% Stake in Biogen Idec,2011-06-22 16:29:00-04:00,BIIB,neutral
163426.0,"Jefferies Maintains Rating, PT On BIIB ",2011-06-22 08:12:00-04:00,BIIB,neutral
163427.0,Biogen Idec Trading Nearly 2% Higher on Deutsche Bank Upgrade ,2011-06-21 10:47:00-04:00,BIIB,neutral
163428.0,Benzinga's Top Pre-Market NASDAQ Gainers,2011-06-21 08:17:00-04:00,BIIB,positive
163429.0,Benzinga's Top Upgrades,2011-06-21 08:03:00-04:00,BIIB,positive
163430.0,UPDATE: Deutsche Bank Upgrades Biogen Idec to Buy,2011-06-21 07:51:00-04:00,BIIB,neutral
163431.0,Deutsche Bank Updates 6/21,2011-06-21 07:03:00-04:00,BIIB,neutral
163432.0,"Deutsche Bank Upgrades Biogen To Buy, Raises PT To $129",2011-06-21 05:47:00-04:00,BIIB,neutral
